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1.1 The problem of heterogeneity in cancer
Cancer is a heterogeneous disease. This heterogeneity is fueled by evolution
and eventually leads to resistance to chemo and targeted therapies [139]. Although
the recent success of immunotherapy has brought us closer to a cure, a large fraction
of patients still fail to receive durable clinical benefit [216]. In order to stay one step
ahead in this evolutionary arms race, it has become clear that one needs to design
rational treatment combinations. Key to designing such combinations is our ability
to characterize the extent of tumor heterogeneity, both among and within patients,
and identify the underlying evolutionary mechanisms driving it.
Projects like The Cancer Genome Atlas [1], vastly improved our knowledge
on the extent of tumor heterogeneity among patients by doing a comprehensive
multi-”omic” profiling of thousands of patient tumors (inter-tumor heterogeneity).
This revealed novel tumor subtypes and their underlying driver mutations. With
recent advances in next generation sequencing technologies, it is now possible to
further sequence tumors at a single cell resolution, thereby allowing one to assess
the heterogeneity of tumors within patients (intra-tumor heterogeneity).
While single cell data ideally represents the state-of-the-art in terms of char-
acterizing tumor heterogeneity, in this thesis we predominantly focus on developing
1
computational methods to characterize tumor heterogeneity from bulk sequencing
data and demonstrate their clinical impact; something which is currently not pos-
sible using single cell technologies alone due to their limited scalability to large
cohorts.
1.2 Fantastic sources of tumor heterogeneity and ways to character-
ize them
There exist multiple sources of tumor heterogeneity. However, they can be
broadly categorized into the following three groups:
1.2.1 Genetic Heterogeneity
Cancer is, in essence, a genetic disease [237]. Errors in the DNA replication or
repair machinery result in accumulation of somatic mutations in cells, and in specific
contexts, these mutations can drive multiple clonal expansions [144]. This gives rise
to heterogeneous tumor cell populations. In addition, a vast majority of tumors have
chromosomal instability, which results in large-scale structural changes (such as the
gain or loss of entire chromosomes), that are often associated with poor clinical
outcomes[22, 226, 56]. In chapter 3, we show how computational methods can be
applied to characterize intra-tumor genetic heterogeneity from bulk sequencing data
and study its effects on the host immune response while controlling for differences
in overall mutation burden. In addition, in chapter 4, we investigate chromosome
arm imbalances across solid tumors from different tissues of origin to uncover factors
2
explaining their observed tissue-specific heterogeneity.
1.2.2 Epigenetic Heterogeneity
Tumor cells can also exhibit phenotypic plasticity by dynamically modulating
gene expression via epigenetic mechanisms or cellular signalling events. This is
often said to lead to acquired resistance to many targeted therapies as opposed
to hardwired resistance that arises from genetic heterogeneity [139]. In chapter 2,
utilizing bulk transcriptomic data of breast cancer patients from the TCGA, we
explore how such dynamic changes in gene expression in cancer can potentially lead
to a ”functional re-wiring” of genes. Such functional re-wiring could explain why
a vast majority genetic interactions are context specific, making the translation of
these interactions into clinically effective targeted therapies a challenge [11]. In
addition we also developed new mixed integer linear programming frameworks to
impute functional effects of protein-protein interactions from genetic perturbation
data, thereby bringing us one step closer to building accurate computational models
of cellular signaling [157].
1.2.3 Microenvironmental Heterogeneity
Tumor cells also constantly interact with other cell types in their micro-
environment in order to facilitate their growth and suppress the host immune re-
sponse. These interactions can further fuel tumor evolution and lead to their ob-
served genetic and epigenetic heterogeneity. It has become increasingly evident that
3
the interactions between cell types in the tumor microenvironemt play a critical
role in facilitating a response or resistance to treatment with the establishment of
immunotherapy as the third major arm of cancer treatment (besides surgery and
chemo therapies) [216]. In chapter 5, we develop a new computational method to
characterize the cellular heterogeneity of each patient’s tumor microenvironment
from bulk transcriptomic data. Using our method one can aim to not only infer
the cellular abundance of each cell type in the tumor micro-environment but also
investigate their transcriptional states and infer clinically relevant cellular crosstalk.
Applying our method to the TCGA, we generate a large resource of deconvolved
transcriptomes of each patient’s tumor tumor sample, thereby enabling the analysis
of the TCGA at a cell type specific resolution. In addition, we uncover a shared
repertoire of cell-cell interactions that specifically occur in the TME of mismatch-
repair-deficient solid tumors and explain their universally high response rates to
immune checkpoint blockade treatment. These results point to specific T-cell co-
stimulating interactions that can enhance immunotherapy responses in tumors in-
dependent of tumor mutation burden levels. Finally, using machine learning, we
demonstrate how one can exploit the large deconvolved data resource we gener-
ated to identify key cell-cell interactions in the TME predicting patient responses
to immune checkpoint blockade therapy in melanoma.
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Chapter 2
Algorithms for context-specific functional annotation of genes and
the imputation of functional effects of protein-protein interactions
?? This work was done in collaboration with Dr. Sridhar Hannenhalli and Dr.
Roded Sharan and appears in PLoS Computational Biology [171] and Bioinformatics
[172]
2.1 Overview
Cellular functions are carried out by networks of interacting proteins [17].
In particular, empirical data suggest that proteins that participate in the same
biological process or a pathway tend to interact with one another, and more broadly,
tend to inhabit the same neighborhood in the protein interaction network (PIN).
This guilt-by-association principle has been successfully applied to predict protein
function, outperforming alternative methods that do not take the PIN into account
[5, 123, 138, 206, 207, 223].
Given that a gene’s function is informed by its PIN neighborhood, it is plausi-
ble that a an organism may dynamically adapt its genes’ functions across different
contexts, such as developmental stages, tissues, diseases and evolution, by altering
the PIN structure. For example, during Drosophila development, a key regulatory
transcription factor fushi tarazu (FTZ) changes function from an ancestral homeotic
5
gene (those that regulate development of specific body parts) to a pair-rule segmen-
tation gene (regulating initial formation of the segments in a developing embryo).
Notably, this functional switch involves changes in FTZ’s interaction partners; while
in the ancestral species FTZ interacted with homeotic proteins, in drosophila it in-
teracts with protein involved in segmentation, and thus it got co-opted into segmen-
tation function [134]. Furthermore, many genetic interactions exhibit context speci-
ficity [96]. Based on these premises, we describe a network diffusion-based algorithm
to predict how a gene’s function might change due to shifts in its protein-protein
interaction neighborhood during malignant transformation. This approach uniquely
reveals several functions that are significantly lost or gained in breast cancer and
modulate patient survival.
Furthermore, another aspect important for the characterization epigenetic tu-
mor heterogeneity is modeling how cells respond to different genetic alterations or
environmental perturbations. Key to building such models is having well annotated
biological pathways representing how biological signals flow affect the activity of
different proteins and transcription of genes. However, such annotations are sparse.
So we additionally developed an optimization framework to impute missing func-
tional annotations describing how biological signals are propagated over the joint
protein-protein interaction and regulatory network of a cell given transcriptional
data before and after genetic perturbations. This imputation problem was previ-
ously shown to be non-deterministic polynomial time (NP)-hard for general networks
[25]. In this work, we overcome the limitation of network coverage of previous meth-
ods by developing new mixed integer linear programming formulations and utilizing
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state-of-the-art SAT solvers. Overall, our imputation method outperforms previous
work by a considerable margin.
2.2 Methods
2.2.1 Inference of gain or loss of function via ”guilt-by-association”
Let G(V,E) be the weighted un-directed network with V representing the set
of nodes and E the set of weighted interactions. Let W be the weighted adjacency
matrix corresponding to G and let D be the diagonal degree matrix (with diagonal
entries corresponding to the weighted degree of each node in the graph). For a bio-
logical function f (which represents any biological process or pathway in a publicly
available database), let Af be the set of genes annotated with that function. For a
RNA-seq sample s, let Gs(Vs, Es) be the sample-specific sub-network of G consist-
ing of all genes with an expression ≥ 1 RPKM in that sample, let Ys be the prior
knowledge vector such that Ys,g = 1,∀g ∈ Af∩Vs. The guilt-by-association principle
implies that the involvement of any gene g in a function f is likely to be influenced
by the involvement of the genes in its neighborhood (Figure 2.1). Additionally, the
involvement should be consistent with our prior knowledge of functional member-
ships. This can be mathematically modelled by the following diffusion equation:
Fs = (1− α)(D−1/2s WsD−1/2s )Fs + αYs (2.1)
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Here Fs is a vector of raw involvement scores of every gene in Gs.α ∈ (0, 1) is a
parameter that weighs the importance of prior knowledge in the model. Notice that
the adjacency matrix Ws is symmetrically normalized by the square root of the
product of node degrees. This step controls for biases that may arise from diffusing
information through high degree nodes (hubs) in the network. As shown in previous
work, the raw scores are fairly robust for the choice of α, and we adopt the choice




s lie in [−1, 1], it can
be shown that I− (1−α)D−1/2s WsD−1/2s is positive definite and we get the following
solution:
Fs = α(I − (1− α)D−1/2s WsD−1/2s )−1Ys (2.2)
There are several ways to compute the above solution, the simplest being the iter-
ative matrix multiplication algorithm first proposed by Zhou [34]. To circumvent
the overhead costs of multiplying large matrices, we proceed by solving the system
using the conjugate gradient (CG) method. The above procedure assigns a raw
involvement score to each gene in Gs for each diffused function. This raw score
however depends on|Af ∩ Vs| as well as the sample-specific PIN topology. To ap-
propriately calibrate it, we can estimate a significance p-value for the score, in a
function-specific manner. This is done by comparing a gene’s raw score against a
null distribution of scores generated by diffusing random prior knowledge vectors
in Gs annotating |Af ∩ Vs| genes. Hence each null distribution is parameterized
by |Af ∩ Vs| which we call the seed size. Note that this technique requires us to
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run a large number of bootstrap instances on separately for each sample-specific
PIN (1157 samples in total analyzed in our study) for each function (1184 functions
evaluated in this study). To tackle such an enormous computational task, we follow
a memoization procedure in which for each sample, we pre-compute a smaller set
of null distributions from pre-determined seed sizes (40 to 500 with an increment of
10) and estimate p-values of diffused raw scores by simply comparing them to a null
distribution closest in seed size to the true null distribution for that sample. The
null distributions are based on 100 bootstrap samples. Finally, we say that a gene
is assigned a function f in a given sample if the p-value associated with its raw score
in that sample < 0.01.
Figure 2.1: The reference gene is depicted by black circle. The initial static global PIN
is projected onto normal and cancer samples based on gene expression, and each function
(red and green) are diffused through each PIN. In this case, the reference gene is assigned
green function in normal and red function in cancer, i.e., the gene gained red and lost the
green function in cancer.
Given a cohort of samples under two conditions (normal and breast cancer in
our application) and a gene-function pair (g, f), we determine the number of sam-
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ples where g was gained function f by diffusion (see above). Having determined
this separately for normal and breast cancer samples, we perform a Fisher’s exact
test to assess whether the gain of f by g is significantly enriched in either one of
the conditions. We say a gene g gains a function f in cancer if the gain of f by
g is significantly enriched among cancer samples when compared to normal. The
enrichment p value is determined by Fisher exact test. Unless stated otherwise, we
use the default p-value significance threshold of 0.05. We also estimated the False
Discovery Rate (FDR) for each pair of g and f . The FDR criterion however yields
substantially fewer genes resulting in decreased power for various downstream anal-
yses. Therefore by default we used the p-value criterion, and provide the results
based on FDR criterion in the supplementary material of the publication. In ad-
dition to the significance criteria, we also consider the effect size of the functional
gain or loss. Let θ be the odds ratio derived from the Fisher contingency table. To
reduce chances of false discovery, we require the effect size to be large. Hence, for
downstream analyses we looked at a range of θ from θ = 2 to 10, and unless oth-
erwise mentioned, the default is highly stringent θ = 10, while the results for other
values of θ are provided in the supplementary material of the publication. Note that
if a gene is not expressed in a sample then it is not present in the sample-specific
PIN and therefore cannot be assigned a function. Thus if g is un-annotated by a
function, biases may arise in the determination of its gain or loss via guilt by as-
sociation if there are significant differences in the expression of g in sample-specific
networks generated within a cohort or between two cohorts. To control for such a
bias, we take two filtering measures. First, we check if g is expressed significantly
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more in samples corresponding to one condition relative to the other by building
a contingency table for expressed versus not expressed among normal and cancer
samples and performing a Fisher exact test. We exclude g if its p-value ≤ 0.05.
Second, in estimating loss and gain for g relative to a function we only consider
samples where g was expressed. This results in downstream analyses of 12599 genes
out of a total of 16562 from the original network. To quantify the degree of gain (or
loss) of a function in cancer relative to normal due to guilt by association, we only
consider the genes that are not annotated to have that function. This ensures that
our estimated change in functional activity is informed primarily by the changes
in PIN topology and not by the differential expression of the genes annotated to
perform a certain function. We Define
Φ(f, g) =

1 if g is un-annotated and gains f with θ ≥ 10





g Φ(f, g) be the difference between the number of un-annotated genes
gaining and losing f . The higher the |∆f | value, the greater the change in activity
of f between normal and cancer. The direction of change is determined by the sign:
“+” represents increase in activity from normal to cancer due to a greater number
of un-annotated genes potentially acquiring that function in cancer; we refer to
such a function as cancer-associated gained function. Likewise, “-” represents an
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overall decrease in functional activity due to a greater number of un-annotated
genes potentially losing that function in cancer; we refer to such a function as
cancer-associated lost function.
2.2.2 A mixed integer linear programming (ILP) framework for im-
putation of functional effects of protein-protein interactions
In this section we describe algorithms for inferring signs and direction of sig-
nal flow over the protein-protein/protein-DNA interaction network. The sign rep-
resents the functional effect on the target gene/protein carrying the signal along
the network. This depends on the type of the physical interaction being consid-
ered. For protein-DNA interactions (PDIs), a +/− sign describes a regulatory
effect; for protein-protein interactions (such as phosphorylation/de-phosphorylation
interactions between kinases and phosphatases), it represents a functional activa-
tion/repression effect. Currently, such direction and sign information is available for
only a few well-studied pathways (see Figure 2.2 for an example), although a large
fraction (40-70%) of the PPIs are expected to admit such an annotation [213]. The
inference of such annotation information is a precondition to any logical model of
a system under study (see, e.g., [157]). We start by formally defining the problem
and sketching the previous approach of [97]. Then, we study three variants of the
original problem (each describing a signaling model) and develop novel integer linear
programming formulations to solve them to optimality on current networks. We as-
sume we are given a (potentially partially signed) physical interaction network along
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with a collection of cause-effect gene pairs, such as commonly obtained from knock-
out experiments. The Maximum sign assignment (MSA) problem is to assign signs
to the unsigned edges of the network in a way that best explains the given pairs.
We say that a cause-effect pair (s, t) with sign δst (+ encoding down-regulation of t
in response to the knockout of s, − encoding up-regulation of t in response to the
knockout of s) is explained or satisfied by a sign assignment, if there exists a path
in the network from s to t whose aggregate sign (the product of the signs along its
edges) is δst. Formally, MSA is defined as follows:
Input. A partially signed network G(V,E) and a set of k cause-effect pairs (s1, t1), . . . , (sk, tk)
with signs δs1t1 , . . . , δsk,tk ∈ {+,−}
Goal. A sign assignment to the unsigned edges of the network such that a maximum
number of input pairs are satisfied by the assignment.
Figure 2.2: Yeast signaling pathways from KEGG in one network depicting the organiza-
tion of different types of physical interactions with their respective experimentally-derived
annotations of signal flow.
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This problem focuses on the A-path signaling model of [253]. [97] showed
that due to the nature of the model, any unsigned edge that lies on a cycle in
the network cannot be uniquely signed. They generalized this notion to any 2-
connected component (or block) by determining if these components are strongly
signed. They then proposed an approach to reduce the input network to an acyclic
one by contracting all edges in these strongly signed components without affecting
the maximum number of pairs that could be satisfied. In the reduced network,
every pair is connected by a unique path, facilitating the formulation of an ILP to
assign signs to the unsigned edges of this path such that the number of satisfied
pairs is maximized. A key drawback of this approach is that reducing the network
to an acyclic one severely restricts the number of edges participating in the ILP
(coverage) and, hence, restricts the number of interactions that can be uniquely
signed. In subsequent paragraphs, we discuss three variants of MSA, each describing
a different plausible signaling model, where edges lying on cycles may have unique
signs and, hence, may no longer be contracted.
The first variant we consider, A-shortest-path (ASP), considers a signaling
model where the length of a satisfying path is always assumed to be the shortest
possible. The shortest path assumption is motivated from the observation that
signaling pathways tend to be of short length [214]. For each edge (u, v) ∈ E, let
xuv = 1 denote whether its sign is − (0 if +). Similarly, we re-write the signs
δst ∈ {+,−} as δst ∈ {0, 1}. Due to the nature of knockout experiments, there
are usually much fewer sources compared to targets. Hence, for each source s, we
construct a subnetwork Gs(Vs, Es) such that each edge in this subnetwork lies along
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a shortest path from s to one of its targets t. This is done by applying a breadth-
first-search starting from each source and target [214]. Furthermore, we denote by
Ns(v) the set of neighbors of v in Gs and by dsv the length of the shortest path from
s to v. Additionally, for each pair (s, v) in Gs, we define auxiliary variables csv, rsv
where csv = 0 implies that under the selected sign assignment there exists a shortest
path from s to v with aggregate sign rsv, i.e., the node pair (s, v) is satisfied under
the selected assignment. (Note, (s, s) is trivially assumed to be satisfied). We also
define E+, E− which represent subsets of edges in the ILP with known prior positive
and negative signs respectively. Then the following ILP formulation can be used to




s. t. 1 +
∑
u∈{Ns(v)|dsv=dsu+1}(csu − 1) ≤ csv ∀s, v ∈ Vs \ s
rsv = XOR(rsu, xuv|csv = 0) ∀s, (u, v) ∈ {Es : dsv = dsu + 1}
cst + yst ≤ 1 ∀(s, t)
rss = 0, css = 0, rst = δst ∀(s, t)
xuv = 0 ∀(u, v) ∈ E+
xuv = 1 ∀(u, v) ∈ E−
yst, xuv, rsv, csv ∈ {0, 1} ∀s, t, u, v
The XOR relation between rsv, rsu and xuv is conditioned on the value of csv.
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That is, rsv = rsu ⊕ xuv only if csv = 0.It is linearized as follows:
rsv − csv ≤ 2− xuv − rsu
rsv − csv ≤ xuv + rsu
rsv + csv ≥ xuv − rsu
rsv + csv ≥ rsu − xuv
Let l denote a layer of Gs such that all nodes belonging to this layer have
dsv = l. Given a feasible solution to the ILP, if yst = 1 we can show that there exists
a shortest path from s to t with aggregate sign δst. Indeed, if yst = 1 then cst = 0
by the third constraint. This implies that
∑
u∈Ns(t)|dst=dsu+1(csu − 1) < 0. Thus,
if t is in layer l of Gs, there must exist a neighbor u of t in layer l − 1 such that
csu = 0. Furthermore, if cst = 0, xut is bound by the XOR constraint to have a sign
whose product with rsu is δst. Similarly, if csu = 0, there must be a neighbor w in
layer l − 2 where csw = 0 and rsw ⊕ xwu ⊕ xut = δst. By carefully investigating the
constraints applicable to the subsequent layers of Gs (i.e., l− 3, . . . , 0) we find that
there must exist a shortest path from s to t such that the product of signs along its
edges is δst. The final two constraints incorporate prior knowledge of signs in the
ILP.
The second variant we study, ’A-directed-shortest-path’ (AdirSP), addition-
ally assumes each shortest path explaining a pair to be directed from the cause to
the effect. It is worth noting that one cannot adapt existing ILP solutions to the
orientation and sign assignment problems, as both rely on reducing the input graph
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into an acyclic one. This reduction does not work when simultaneously optimizing
both. Instead, we simply adapt the ASP formulation above to simultaneously find
sign and direction assignments to the network. Specifically, we consider a pair (s, t)
to be satisfied by a sign and direction assignment over the network if a directed
shortest path from s to t in this assignment has aggregate sign δst. We call this vari-
ant of MSA the ’A-directed-shortest-path’ (AdirSP). Let ouv = 1 denote whether
an edge (u, v) is directed from u to v (0 if from v to u) and let the flow variables
f suv indicate the existence of a flow from u to v. The flow variables allow computing










wu ∀s, (u, v) ∈ {Es :
dsv = dsu + 1, dsu ≥ 1}
f suv ≤ ouv ∀s, (u, v) ∈ Es





uv − 1) ≤ csv ∀s, v ∈ Vs \ s
rsv = XOR(rsu, xuv|csv = 0, f suv = 1) ∀s, (u, v) ∈ {Es : dsv = dsu + 1}
cst + yst ≤ 1 ∀(s, t)
rss = 0, css = 0, rst = δst ∀(s, t)
xuv = 0 ∀(u, v) ∈ E+
xuv = 1 ∀(u, v) ∈ E−
yst, xuv, ouv, a
s
uv, rsv, csv, f
s
uv ∈ {0, 1} ∀s, t, u, v
The first constraint ensures that each edge has a unique orientation. In some feasible
solution, if f suv = 1, then the second and third constraint ensure that a directed path
exists from s to v containing edge (u, v).
Note that the XOR relation that helps determine the sign of an edge now
additionally depends on the existence of a flow in that edge. The constraint is
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linearized as follows:
rsv − csv − 1 + f suv ≤ 2− xuv − rsu
rsv − csv − 1 + f suv ≤ xuv + rsu
rsv + csv + 1− f suv ≥ xuv − rsu
rsv + csv + 1− f suv ≥ rsu − xuv
Another change from the previous formulation is the definition of auxiliary variables
asuv for each edge participating the ILP. Their value depends on the flow in edge (u, v)
originating from s and on csu. The OR relation between these variables is linearized
as follows.
asuv ≤ (1− f suv) + csu
asuv ≥ 1− f suv
asuv ≥ csu
Given a feasible solution in which yst = 1, we show that there exists a shortest path
oriented from s to t such that its aggregate sign is δst. Let t be in layer l of the





ut−1) < 0 (by constraint 5), which implies that there exists
a neighbor u in layer l − 1 where asut = 0. This implies f sut = 1, csu = 0 (constraint
4) and δst must be the product of the signs given by xut and rsu (constraint 6).
Additionally, csu = 0 implies there exists a neighbor w in layer l − 2 where aswu = 0
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(constraint 5). This implies f swu = 1, csw = 0 and rsw ⊕ xwu ⊕ xut = δst. In this
manner after carefully investigating the constraints through subsequent layers of Gs
(i.e l − 3, l − 4, ..., 0) we can find a directed shortest path from s to t such that the
product of signs along its edges is δst. The last two constraints account for signs
that are already known.
The underlying assumption in both signaling models above is that a single path
is sufficient to force a predefined effect. However, due to the inherent stochasticity
in signaling, this might not always be the case [119]. Hence, we strengthen the pair
satisfaction assumption in the ASP model to require that a pair (s, t) is satisfied if
all shortest paths connecting s to t admit the same aggregate sign δst. We call this




s. t. csu ≤ csv ∀s, (u, v) ∈ {Es : dsv = dsu + 1}
rsv = XOR(rsu, xuv|csv = 0) ∀s, (u, v) ∈ {Es : dsv = dsu + 1}
cst + yst ≤ 1 ∀(s, t)
rss = 0, css = 0, rst = δst ∀(s, t)
xuv = 0 ∀(u, v) ∈ E+
xuv = 1 ∀(u, v) ∈ E−
yst, xuv, rsv, csv ∈ {0, 1} ∀s, t, u, v
As above, let t belong to layer l of Gs. Given a feasible solution to this new formula-
tion, if yst = 1, cst must be 0 (from third constraint). Hence, for every neighbor u of
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t that lies in layer l− 1 of Gs, csu = 0 (from 1st constraint). This in turn constrains
the sign assignment of the respective edges (i.e rsu⊕xut = δst, for all neighbors u in
layer l− 1). By carefully investigating the constraints through subsequent layers of
Gs (i.e l− 2, l− 3, ..., 0), it becomes apparent that for any node v in Gs, all shortest
paths from s to v must admit the same aggregate sign (rsv). Hence, all shortest
paths from s to t must have an aggregate sign δst.
Notably, the models discussed above permit mathematically efficient formula-
tions. Specifically, if p is the number of sources (p << k), then each formulation
contains O(k + p|V |+ |E|) variables and O(k + p(|V |+ |E|)) constraints.
Each of the above models may admit multiple sign assignments with optimal
or near optimal scores. Hence, it is necessary to quantify the robustness of a sign
assignment to an edge. To this end, we solve each ILP repeatedly n times; each
time adding a small Gaussian noise of mean 0 and variance 0.01 to the objective
function as shown below. This stochastic approach, motivated by [92], effectively
results in a random sampling of different likely solutions that exist nearby in the
optimum solution space, thereby allowing us to assess the robustness of the sign on
each edge. The procedure is as follows:
1: procedure GetScores(ILP ,n)
2: scoresuv ← 0, ∀(u, v) ∈ E that are in ILP
3: for i = 1:n
4: set objective:
∑
st(1 + εst)yst, where εst ∼ N (0,0.01)
5: x∗ ← solve(ILP )
6: scoresuv = scoresuv + x
∗
uv/n, ∀(u, v) ∈ E that are in ILP
7: return scores
An edge score close to 1 implies that the sign is negative with high confidence,
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a score close to 0 implies a positive sign with high confidence and a score close
to 0.5 implies that the sign on that edge cannot be uniquely determined (possibly
implicating the absence of an activation/repression effect). For efficiency, we use
n = 10 throughout. Our conclusions do not change for larger values of n.
2.3 Results
2.3.1 Guilt by association reveals functional heterogeneity in breast
cancer
Our overall strategy is to (1) project PIN onto each transcriptomic sample, (2)
diffuse functions across the sample-specific PIN to estimate sample-specific function
of each gene, and (3) analyze functional changes across conditions. Starting from a
previously curated PIN [205], with 16,562 genes and 262,780 edges, we project the
PIN on each sample-specific transcriptome, by removing the nodes corresponding to
unexpressed or lowly expressed genes (RPKM ¡ 1; see Methods), to obtain a sample-
specific PIN. This general approach to obtain a sample-specific network has been
used previously to obtain tissue-specific networks in human [19]. For each of the
1184 functional terms (1175 GO terms and 9 NetPath cancer-related pathways, see
Methods), in each of the 1157 sample-specific PINs (110 breast cancer samples and
1047 normal breast tissue samples from TCGA [1]), we diffuse the function across
the network starting from known annotated (and expressed) genes to yield a raw
score for each node. Such sample-specific diffusion-based functional inference across
normal and cancer samples allows us to identify specific genes that significantly gain
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or lose a particular function in cancer samples, and to assess whether a function has
significantly gained or lost genes performing the function in cancer.
After diffusing each of the 1184 functional terms f across 110 normal and 1047
breast cancer samples, we assessed for each gene g whether the fraction of samples in
which g is deemed to have the function is significantly different between the normal
and tumor tissues based on a Fisher exact test; a greater fraction in cancer is referred
to as functional gain and the opposite as functional loss. In addition to statistical
significance, we require that the ratio of the fractions of samples where the gene is
deemed to have the function in cancer versus normal ≥ θ (gain), or ≤ 1
θ
(loss). The
default value used in the main results is θ = 10 (our conclusions are robust for θ
from 2 to 10). We denote by ∆f the difference between the number of genes deemed
to have gained function f and the number of genes deemed to have lost it. Positive
values of ∆f indicate net gain and negative values indicate net loss of that function
in cancer relative to normal. In total, 732 functions are predicted to undergo a net
loss in cancer and 417 are predicted to have a net gain. Table 1 lists the top 10
functions gained and lost. Note that for a function if a majority of genes annotated
to have that function are differentially expressed between normal and tumor tissues
then ∆f will simply reflect this differential expression of the annotated genes and
not the effect of altered PIN. To ensure that our inference of functional loss and
gain is independent of differential expression of the genes annotated to have the
function, when calculating ∆f , we exclude the genes annotated with the function.
Consistently, as shown in Table 2.1, the functions inferred to have been lost or gained
based on ∆f exhibit modest log fold changes between normal and cancer in terms
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of average number of annotated genes expressed in each cohort, and therefore may
go undetected by standard differential expression analysis. Interestingly, overall,
we see a weak inverse correlation between ∆f and the log fold change based on
expressed annotated genes (Spearman correlation = -0.09). Thus our approach
uniquely reveals cancer-associated functions. For instance, we find mitotic spindle
organization to be lost in cancer consistent with previous reports associating spindle
misalignment with cancer [137]. Likewise, we find positive regulation of smooth
muscle cell proliferation to be gained in cancer, consistent with prior studies [44].
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Table 2.1: Top 10 gained (green) and lost (red) functions are shown, along with ∆f, ∆f
divided (normalized) by the number of genes annotated by the function, and the log fold
change, which is the log ratio of the average number of expressed genes annotated by f in
cancer and normal samples.




GO:0048661 positive regulation of smooth
muscle cell proliferation
893 15.13 -0.04
GO:0048010 vascular endothelial growth fac-
tor receptor signaling pathway
744 10.19 -0.01
GO:0051279 regulation of release of se-
questered calcium ion into
cytosol
740 13.21 -0.03
GO:1901983 regulation of protein acetylation 723 12.05 -0.04
GO:0000910 cytokinesis 527 6.84 -0.02
GO:0010676 positive regulation of cellular car-
bohydrate metabolic process
523 8.43 -0.05
GO:0051291 protein hetero oligomerization 508 5.90 -0.03
GO:0042552 myelination 394 6.67 -0.03
GO:2000756 regulation of peptidyl-lysine
acetylation
369 6.47 -0.03
GO:0016575 histone deacetylation 333 5.64 -0.01
GO:0006334 nucleosome assembly -310 -3.13 0.04
GO:0051148 negative regulation of muscle cell
differentiation
-127 -2.49 -0.06
GO:0007032 endosome organization -75 -1.27 -0.007
GO:0018022 peptidyl-lysine methylation -65 -0.91 0.002
GO:0007052 mitotic spindle organization -64 -1.054 0.005
GO:0019886 antigen processing and presenta-
tion of exogenous peptide antigen
via MHC class II
-56 -0.62 0.003
GO:0016236 macroautophagy -53 -0.71 -0.01
GO:2000117 negative regulation of cysteine-
type endopeptidase activity
-52 -0.61 0.005
GO:0051437 pos reg of ubiquitin-protein ligase






Our analysis above identifies functions with net loss in cancer induced by PIN
changes. For such a function f , if a gene g exhibits PIN-induced loss of function
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f , then it is likely that mutation-induced loss in activity of g may also be linked
to cancer. In other words, for lost functions (negative ∆f) we might expect to see
more frequent mutations among the genes contributing to the functional loss. We
assessed for each function (irrespective of net loss or gain) if it exhibits an elevated
mutation frequency among its lost genes (Methods); we explicitly excluded the genes
annotated with the specific function. We find that a much greater fraction of lost
functions exhibit elevated mutation frequency among their lost genes compared to
gained functions used as a control (Fisher p-value = 0.008, odds ratio = 2.36; Table 2;
Methods). We repeated this analysis for all values of θ from 2 to 10 and additionally
for θ = 2 combined with FDR < 0.1 to ascertain loss/gain of a gene relative to a
function. In 9 of the 10 tests, the odds ratio > 1, with an average odds ratio of
1.51. As an alternative, we directly quantified Spearman correlation between ∆f
and mean mutation rate of corresponding lost genes. Again, in 9 out of 10 cases,
consistent with our expectation, we found a weak but significant (all p-values <
0.005) inverse correlation. Likewise, instead of mutations when we use deletion
CNV rates to quantify loss in activity (Methods), we find that compared to gained
functions, a larger fraction of lost functions exhibited an elevated deletion CNV
rate (Table 2.2). While the Fisher test p-value was marginal (0.09), the odds ratio
was 2.15. After repeating the tests as above for other values of θ, in 8 of the 10
tests, the odds ratio > 1, with an average odds ratio of 1.59. As an alternative,
we directly quantified Spearman correlation between ∆f and deletion CNV rate
of corresponding lost genes across all functions. In all 10 test cases, consistent
with our expectation, we found a weak but significant (all p-values < 0.001) inverse
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correlation. These results suggest that a change in network neighborhood of a gene
may provide an alternative mechanism for functional loss, in addition to mutations
and deletion CNVs.
Table 2.2: The Fisher test contingency table showing the distribution of functions with
elevated mutation rates (columns 2 and 3) and deletion CNV rates (columns 4 and 5)
between lost and gained functions. Mut(f) = 1 denotes significantly higher mutation
rates among the genes contributing to functional loss. CNV(f) = 1 has an analogous
interpretation for deletion CNV.
Mut(f) = 1 Mut(f) = 0 CNV(f) = 1 CNV(f) = 0
∆f <0 48 684 26 706
∆f >0 12 405 7 410
We further assessed whether functions that exhibit cancer-associated gain or
loss also exhibit a consistent association with patient survival. For instance, for a
function with net loss in cancer relative to normal tissues, we expect that among
cancer patients the lower the activity of the function, the worst the patient survival
(and the converse for gained functions). To test this association, for each function
we estimate its sample-specific activity as the number of genes inferred to be per-
forming that function based on diffusion scaled across all samples. We then estimate
the association between patient survival risk and our diffusion-based sample-specific
activity of each function using a Cox proportional hazard regression model adjusted
for differences in age, and stratified by sex and race. A significant negative (re-
spectively, positive) regression coefficient β corresponds to negative (respectively,
positive) association with risk. Of the 1149 functions (732 net loss and 417 net
gain), 137 exhibited significant association with survival risk (p-value < 0.05). Of
these, 111 were negatively associated with risk, and interestingly, these were sig-
nificantly biased toward lost functions, consistent with our hypothesis (Table 2.3,
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columns 2 and 3; Fisher test p-value = 1.1E-3; odds ratio = 2.1). Only 26 of the
137 were positively associated with risk, but consistently, these were biased toward
gained functions (Table 2.3, columns 4 and 5; Fisher test p-value = 5.1E-5; odds
ratio = 5.7). As an alternative assessment, we found a significant positive correla-
tion between ∆f and β (Spearman correlation = 0.29; p-value < 2.2 E-16). These
results suggest that diffusion-based inference of cancer-associated functional change
may also be associated with the severity of the tumor among cancer patients. We
repeated the above analyses for all values of θ from 2 to 10 and additionally for θ =
2 combined with FDR < 0.1 to ascertain loss/gain of a gene relative to a function.
29 of the 30 tests are consistent with the results above.
Table 2.3: Fisher test contingency table to test for association between functional
loss/gain with associations with patient survival; β indicates the association of tumor-
specific functional activity with survival risk.
β<0 & p-value
≤ 0.05
p-value >0.05 β>0 & p-value
≤ 0.05
p-value >0.05
∆f <0 87 639 6 639
∆f >0 24 373 20 373
Encouraged by the results above, we directly assessed the power of our diffusion-
based sample-specific activity profile of a function in predicting patient survival. To
this end, we selected the top 1% and bottom 1% (=24) most cancer-associated
functions (ordered by ∆f), and for each function we estimated its diffusion-based
activity in each tumor sample, as defined above. Using the inferred activity levels of
these 24 functions as sample-specific features, we then computed the cross-validation
accuracy of patient survival prediction based on multivariate Cox regression. The
prediction accuracy was quantified using the standard concordance or C-index met-
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ric [173]. We find that cross-validation C-index is 0.567. We further included the
9 cancer-related pathways from the NetPath database [109], namely, EGFR1, FSH,
IL-1, IL-4, IL-5, Leptin, RANKL, TNF-alpha, and TSH. This extended feature set
of 33 functions yielded a cross-validation C-index of 0.62. As a control, we assessed
whether the standard alternative approach to quantify sample-specific functional
activity, based simply on expressed annotated genes could be equally effective. For
candidate features, we assessed the median number of expressed annotated genes in
each sample and identified 24 most differentially active functions based on the abso-
lute log ratio of the medians in cancer and normal samples. Adding the 9 NetPath
pathways to this list results in 33 features, as above. We then quantified sample-
specific activity of these 33 features based on the number expressed annotated genes
scaled across all samples and estimated the concordance in an identical fashion to
our diffusion-based approach above. This yielded a C-index of 0.51, which is sig-
nificantly lower than 0.62 (p-value = 0.01). We repeated the above analyses for all
values of θ from 2 to 10 and θ = 2; FDR < 0.1 to ascertain loss/gain of a gene rela-
tive to a function. In all cases the diffusion-based C-index is higher than the control,
and significantly so in 8 out of 10 cases. We further validated the survival predic-
tion accuracy of our diffusion-based functional activity profile in an independent
METABRIC breast cancer dataset [53]. We used the features derived from TCGA
dataset as above and used those to assess cross-validation prediction accuracy of
the diffusion-based and annotation-based methods in METABRIC. Again, we find
that C-index of the diffusion-based approach was 0.62 whereas the annotation-based
approach achieved an accuracy of 0.57 (difference p-value = 0.0004). These consis-
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tent results across datasets suggest that the diffusion-based approach to quantify
functional activity may provide additional information about the functional state of
a tumor, relevant to patient survival.
We further tested if our novel diffusion-based functional activity profile is
predictive of known clinical characteristics of breast tumors, specifcially, the can-
cer subtype (Basal, Her2, Luminal A, Luminal B, Normal), and its hormone re-
sponse status, Estrogen Receptor positive (ER+) and Progesterone Receptor pos-
itive (PR+). Based on clinical annotation of the METABRIC tumors, we trained
7 different Support Vector Machine (SVM) models, one per clinical indicator, us-
ing randomly selected 50% of the samples to train and the other half to assess the
prediction accuracy, quantified by ROC-AUC. We repeated the training and testing
2000 times to obtain mean and 95% confidence interval. Note that while the training
and testing of the model is done on METABRIC, the cancer-associated functions
used as features were inferred from TCGA data independently. We compared the
performance of our diffusion-based functional activity profile with annotation-based
activity profiles as above. Table 2.4 shows the AUC estimates of each model. We
found in all classification tasks, the diffusion-based model can predict each clinical
indicator more accurately than the alternative annotation-based approach.
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Table 2.4: The following table displays the AUC estimates of the 7 independent classifiers
trained with two different feature sets (diffusion-based functional activity and annotation-
based functional activity) for each clinical indicator
Clinical Indicator AUC - Diffusion AUC – Annotation (Control)
Basal 0.91 (95% CI = 0.887-0.928) 0.88 (95% CI = 0.842-0.893)
Her2 0.77 (95% CI = 0.737-0.808) 0.72 (95% CI = 0.672-0.747)
Luminal A 0.79 (95% CI = 0.763-0.806) 0.76 (95% CI = 0.745-0.788)
Luminal B 0.78 (95% CI = 0.752-0.8) 0.75 (95% CI = 0.735-0.786)
Normal 0.72 (95% CI = 0.685-0.761) 0.69 (95% CI = 0.64 -0.724)
ER+ 0.93 (95% CI = 0.916 – 0.949) 0.87 (95% CI = 0.857-0.899)
PR+ 0.77 (95% CI = 0.742-0.784) 0.75 (95% CI = 0.731-0.774)
Next, using our diffusion-based activity profiles of the 33 functions (24 GO
terms and 9 cancer-related NetPath pathways) used above, we clustered all METABRIC
samples using Nonnegative Matrix Factorization (NMF) [25], in an unsupervised
fashion, into 10 groups (Methods). Figure 2.3 panel A shows that the distribution
of the five known subtypes of breast cancer across the 10 clusters. Even though
the functional profile-based clustering are not associated with known subtypes, in-
terestingly, as seen in Figure 2.3 panel B, the diffusion-based unsupervised clusters
exhibit significant inter-cluster differences in patient survival (Log rank p-value =
3.2E-3). In contrast, when we use annotation-based functional activity profiles to
cluster the tumors following an identical procedure as above, the clusters did not
reveal a difference in survival across clusters (Log-rank p-value = 0.23). We fitted
a Cox proportional hazards model to the METABRIC survival data using cluster
membership as a feature while controlling for age, sex and race, as above. Cluster
memberships generated by diffusion-based functional activity profiles show a signif-
icant association with survival risk (β = 0.04, p-value = 8.5E-3) whereas cluster
memberships generated by annotation-based profiles had no significant effect (β =
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0.01, p-value = 0.32). These results suggest that in addition to expression based
changes, PIN-induced functional changes of genes in breast tumors may also play a

















Figure 2.3: (A) Distribution of five known subtypes across 10 clusters inferred from
diffusion-based activity profiles. (B) Kaplan-Meier survival curves of patients grouped in
the 10 clusters show significant survival differences.
Figure 2.4 shows, for each of 7 subtypes, the log-fold change in average functional
activity of the 33 functions (24 GO processes and 9 Netpath pathways) in sam-
ples corresponding to the subtype versus the rest. The most notable changes are
increase in activity of ovulation cycle process (GO:0022602), Epidermal Growth
Factor Receptor signalling pathway (EGFR1), and Receptor Activator of Nuclear
factor Kappa-B Ligand signalling pathway (RANKL) in ER+ breast tumors. Pre-
vious experimental and clinical studies have shown that increased level of EGFR in
ER+ breast tumors leads to resistance to hormone therapy [153, 70] through hor-
mone independent activation of estrogen receptors [28]. As seen in Figure 2.4, the
EGFR1 signalling pathway has a 0.23 log fold higher average functional activity in
ER+ breast cancer patients ( 70% of which were recorded to have taken hormone
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therapy). This suggests that PIN-induced increase in EGFR signalling activity in
ER+ tumors may lead to increased levels of EGFR thereby increasing the possibil-
ity of hormone therapy resistance. Our results also indicate a 0.24 log fold higher
functional activity in RANKL signaling in ER+ breast cancer. While RANK and
RANKL are normally expressed in mammary gland epithelial cells, they are also
expressed in many epithelial breast tumor cells. RANKL has been experimentally
shown to induce cell migration in epithelial tumor cells expressing RANK, and is
also an important osteoclast differentiation factor found highly expressed in the bone
marrow thereby creating a conducive environment for bone specific metastasis [107].
This is consistent with the observation that many tumors in breast that are known
to recur in bone tissue are ER+ [101]. Moreover, inhibition of RANKL expres-
sion in combination with hormone therapy has been shown to improve treatment
efficacy and prevention of bone metastasis in experimental mouse models of ER+
tumors [37]. These results suggest that the knowledge of PIN guided functional
changes in genes via guilt by association may provide important biological insights
into mechanisms of treatment resistance.
Figure 2.4: The following figure displays the log ratio between the average numbers
of genes assigned to each function by diffusion (represented by columns) across samples
annotated with a particular subtype (represented by rows) versus the rest of the samples.
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2.3.2 Imputing functional effects of protein-protein and protein DNA
interactions in Yeast
We focused our analysis on budding yeast (Saccharomyces cerevisiae). We
obtained 4095 protein-DNA interactions spanning 2079 proteins (conserved across
at least 2 other yeast species) from [136]. We additionally downloaded 2930 high-
quality experimentally verified protein-protein interactions from [254], 1361 kinase-
substrate/phosphatase-substrate interactions (KPIs) among 802 proteins from [31],
and 189 physical interactions from signaling pathways of yeast in KEGG. We merged
these sets into a unified yeast network of 8268 unique physical interactions among
3695 proteins.
We extracted all 110,487 knockout pairs spanning 6228 proteins from [182] and
additionally 699,771 pairs spanning 6110 proteins from [113]. A pair was assigned a
positive sign if the target gene was repressed in response to knockout of the source,
and a negative sign if the target gene was activated/up-regulated. We restricted
ourselves to knockout pairs such that the absolute log fold change in expression
of the target gene is > 2 and FDR < 0.001. This leaves us with 1756 significant
knockout pairs from [182], referred to here as the Reimand set, and 3524 significant
knockout pairs from [113], referred to here as the Kemmeren set. The above choice
of thresholds was made while taking into consideration the inherent computational
complexity of the problem.
For a systematic validation of our sign prediction models we collected sign
information as follows. 147 of 192 physical interactions in yeast had an exper-
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imentally confirmed sign from KEGG (See Figure 1).In addition, following[97],
we extracted GO molecular function annotations related to transcriptional acti-
vators (GO:0045893) and transcriptional repressors (GO:0045892). Protein-DNA
interactions originating from transcriptional activators were given a positive sign
whereas protein-DNA interactions originating from transcriptional repressors were
given a negative sign. Finally, we also extracted information on protein kinases
(GO:0004672) and protein phosphatases (GO:0004721). We reasoned that since
there are roughly 3 times as many confirmed functionally activating phophorylation
sites compared to repressive ones (PhosphoNET database, www.phosphonet.ca),
and that 71% of phosphorylation interactions of yeast in KEGG are annotated as
activating and 81% of de-phosphorylation interactions of yeast are annotated as
repressing, kinase-substrate interactions tend to be activating while phosphatase-
substrate interactions tend to be repressing. Thus, physical interactions linking a
GO annotated kinase and a substrate were given a positive sign whereas interactions
linking a GO annotated phosphatase to a substrate were given a negative sign. Any
interaction in the unified network that had conflicting signs was left unsigned (un-
less it had sign information from KEGG, in which case this latter information was
used). In summary, the validation set consists of three groups of signed interactions
in the network: (i) 2014 (1131 +, 883 −) signed protein-DNA interactions, (ii) 1044
(872 +, 172 −) signed kinase/phosphatase-substrate interactions, and (iii) 147 (96
+, 51 −) signed KEGG interactions.
We evaluated each of the four models presented above in a 5-fold cross-
validation setting on the unified yeast network, focusing on the interactions covered
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by each model, i.e., participating in the corresponding ILP. To this end, we randomly
divided all signed and covered interactions into 5 equal parts.Using each model, we
predicted the activation/repression potential of the interactions in each part while
constraining the signs of interactions in the remaining parts. Then we measured
the performance of the activation/repression scores of a given model across the five
parts for different subsets of signed interactions covered by the model. For each
subset, we denote its set of covered positive and negative interactions by E+ and
E−, respectively.
As a benchmark, we discuss the performance of the previous A-path model.
Recall that in this model we should contract all interactions that lie in a strongly
signed block of size ≥ 3. Since all blocks were strongly signed, this resulted in
an acyclic network with 77% of the interactions contracted. When working with
knockout pairs from the Reimand set, we observe that only 1% of all the network
interactions participate in the ILP constraints due to network reduction, and 25
of them belong to the validation set. Due to low coverage over the validation set,
we instead evaluated this framework using knockout pairs from the Kemmeren set.
Overall, 4% of network interactions are covered in this instance and 73 interac-
tions from the validation set were part of the ILP formulation, yielding an AUC of
0.66. Since there were only 73 interactions to validate our predictions, we could not
evaluate the performance on individual subsets.
Next, we evaluated the ASP, AdirSP and AllSP models over the unified net-
work. Tables 2.5 and 2.6 summarize the performance over the validation PDIs,
KPIs, and the KEGG interactions. We find that our new formulations lead to sign
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assignments on 35% of network interactions when working with the Reimand set
and 59% of network interactions when working with the Kemmeren set; ≈ 15-fold
coverage increase compared to previous work (A-path).
Table 2.5: Performance evaluation of different imputation models on the Reimand set
(coverage of 35%).
interaction |E+|, |E−| AUC AUC AUC
(ASP) (AdirSP) (AllSP)
PDI 435, 458 0.75 0.63 0.84
KPI 205, 20 0.83 0.56 0.72
KEGG 40, 27 0.56 0.52 0.65
Table 2.6: Performance evaluation of different imputation models on the Kemmeren set
(coverage of 59%).
interaction |E+|, |E−| AUC AUC AUC
(ASP) (AdirSP) (AllSP)
PDI 744, 653 0.63 0.59 0.83
KPI 522, 98 0.61 0.51 0.77
KEGG 46, 32 0.58 0.54 0.71
In order to directly compare the performance of the A-path model to our suggested
alternative models, we evaluated them on the restricted validation set of 73 in-
teractions covered by the A-path model.On this set (|E+| = 49, |E−| = 24) the
performance of AdirSP was lower to A-path (AUC of 0.64), while ASP and AllSP
had better performance (AUCs of 0.73 and 0.68, respectively)
Previous work as well as our models above vary in the assumptions they make
on the way a knockout effect is explained, going all they way from requiring a single
path of any length to requiring all paths of shortest length. Note that we adopt these
models partly because they are grounded in our very own observations of cellular
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signaling pathways and because they permit an efficient mathematical formulation.
These descriptions are not perfect. In turn, the solution of each model allows dif-
ferent degrees of freedom on the signs of underlying interactions. To make the best
inference possible for each physical interaction given the complex nature of cellular
signaling, we integrate the predictions of each model in an ensemble. That is, using
the sign scores from solutions to ASP, AdirSP and AllSP as features, we train a hy-
brid model, specifically a random forest classifier, that makes an overall prediction of
the sign of an interaction (A-path was excluded due to low coverage). The ensemble
model is evaluated via nested cross-validation. In detail, the validation set is divided
into the same 5 parts as above. Four of the parts are used for training the individual
models to score the fifth part. Next, we perform a 5-fold cross validation on the fifth
part to train and test the classifier. Finally, using the cross-validated predictions
across all parts, we report the mean classifier performance (AUC) against the signs
of different validation subsets. Tables 2.7 and 2.8 summarize the performance of the
random forest classifier on the different knockout sets and validation subsets.
Table 2.7: Performance evaluation of the random forest classifier using the Reimand set.
interaction |E+|, |E−| AUC
(classifier)
PDI 435, 458 0.86
KPI 205, 20 0.85
KEGG 40, 27 0.77
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Table 2.8: Performance evaluation of the random forest classifier using the Kemmeren
set.
interaction |E+|, |E−| AUC
(classifier)
PDI 744, 653 0.80
KPI 522, 98 0.67
KEGG 46, 32 0.81
Overall, we observe that the classifier outperforms all individual models on the set
of curated interactions from KEGG.It also outperforms the different models with
respect to PDIs and KPIs on the Reimand set. The lower performance of the
classifier on the KPI set (compared with the AllSP model) when working with the
Kemmeren set is likely an artefact resulting from the skewed distribution of class
labels. Such a skew may influence ensemble classifier performance on unseen data.
2.4 Discussion
This work demonstrates that tumors can exhibit transcriptional heterogeneity
to adapt and survive in harsh environments. This transcriptional heterogeneity can
potentially lead to gain or loss of function of genes via ”guilt-by-association” that
provide tumors with a fitness advantage. Using our diffusion based approach one
can uncover such events. However, this approach has a few notable limitations.
First, the guilt-by-association is a trend and there are several exceptions to the gen-
eral principle, as described previously [76], and second, the diffusion algorithm is
effective for relatively large functional groups. We have explicitly addressed these
limitations by restricting our analysis to those functional groups that yield a rea-
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sonable diffusion-based recall, suggesting that these functions are broadly clustered
in the PIN, and by only considering functional groups with at least 50 genes (and
at most 500 genes, as discussed in Methods). It is interesting to note that the num-
ber of genes implicated in a function can far exceed the number of genes currently
annotated by the function, consistent with substantive incompleteness of functional
annotations. However, it is difficult to verify these predicted functional implica-
tions, except indirectly through their predictive value in various tasks, as we have
done or via high throughput genetic interaction screens. Follow up investigations
will provide further insights and strengthen our conclusions. For instance, it will be
instructive to first experimentally test in model organisms such as yeast, the extent
to which context-specificity of genetic interactions can be explained by functional
re-wiring of the PIN.
In addition to the above, we developed novel mixed integer linear program-
ming models to infer the flow of biological signals over protein-protein interaction
networks. We discussed the underlying assumptions guiding the predictions of each
model and its advantages in terms of coverage relative to prior work by [97]. We
then measured the cross-validation accuracy of each in predicting signs across two
knockout datasets in yeast to find that our models lead to improvement in accuracy
and coverage over the previous state-of-the art method by [97]. We eventually train
a hybrid signaling model based classifier that learns to best combine predictions
of each model. This was partly motivated by the fact that the three models pre-
sented in this work, although mathematically efficient to represent, are insufficient
to capture the true complex nature of cell signaling.Furthermore, this warrants the
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exploration of other plausible models that could be potentially integrated into the




Intra-tumor genetic heterogeneity (ITH) and its impact on response
to immune checkpoint blockade therapy
?? This work was done in collaboration with Dr. Yardena Samuels and now
appears in Cell [249]
3.1 Overview
It has recently been shown that immunotherapy strategies that enhance anti-
tumor T-cell response, such as checkpoint inhibitors and adoptive T-cell therapy,
exhibit remarkable clinical effects in a wide range of tumor types [186, 248]. How-
ever, many tumors do not respond to checkpoint inhibitors and the determinants of
treatment efficacy remain largely unknown [208]. Neo-antigens that arise as a con-
sequence of somatic mutations within the tumor represent an attractive means to
promote immune recognition in cancer [87]. Indeed, high TMB and neo-antigen load
in tumors have been associated with an enhanced response to immune checkpoint
blockade therapy [73, 95, 204, 217, 233]. Cutaneous melanoma, which is among the
most highly mutated malignancies [4], has the highest objective response rates to
checkpoint blockade ( 60% upon combined CTLA4 and PD-1 blockade) [121]. There
is a growing appreciation of the key role of T-cell mediated responses against neo-
antigens in mediating responses to melanoma therapy [50, 83, 87, 222], as well as
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the characterization of T cell activation and dysfunctional states [45, 118, 127, 201].
While the leading hypothesis in the immunotherapy field is that tumors with
increased TMB present more neo-antigens and, thus, are more immunogenic [73, 85,
95, 192, 222, 233], tumors containing equally high TMB exhibit a variable immune
response [199], and some cancers with low TMB can respond to immunotherapy
[148], thus again questioning the association between TMB and response. Moreover,
predicted neoantigen load does not correlate with T cell infiltration in melanoma
[218], and TMB alone is not a sensitive or specific predictor of outcome to treat-
ment [99], suggesting that additional factors determine the development of T-cell
reactivity.
In parallel, it has recently been reported that ITH, manifested by the distri-
bution of clonal vs. sub-clonal mutations and neoantigens [144, 218], may influence
immune surveillance [142, 143, 184] and pan cancer analyses show better survival for
tumors with low ITH [7, 149, 150, 156]. Despite past attempts to model the effect of
increased TMB [239] or ITH [71], no attempts were made to study effects of TMB
and ITH on immune response in a comparative, causal manner. Here we evaluate
the contributions of different aspects of ITH and TMB in immune-mediated tumor
rejection in mouse models and study its parallels in patient data.
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3.2 Methods
3.2.1 Inference of ITH in melanomas from TCGA
From the TCGA data access portal (https://portal.gdc.cancer.gov/), we down-
loaded level 2 SNP array and germline + somatic variant call data for 432 skin cu-
taneous melanoma tumor and matched normal samples. Across all 432 patients, we
apply CHAT [126] under default package settings to estimate tumor purity followed
by estimation of cellular abundance of CNVs and somatic mutations from the SNP
array and variant call data respectively. We found that the average sample purity
estimated by CHAT is 74% with only 14 samples having purity less than 25%. How-
ever, we do not pre-filter any of these samples in our downstream survival analyses
as our final conclusions remain the same even after their removal. To estimate mu-
tation burden (TMB) per sample, we count the number of somatic variant calls that
were classified as missense or non-sense per sample. This data was obtained from
the cbioportal website (https://www.cbioportal.org). Since CHAT detects CNVs
using the circular binary segmentation algorithm [167], which essentially partitions
the genome into non-overlapping sections of same copy number, we estimate CNV
load per sample in a manner similar to [7]. To elaborate: for a tumor sample, let
Ls be the length of a segment s of the genome and let CNs be total copy number of
that segment inferred by CHAT while considering the tumor purity. Let Xs ∈ {0, 1}
be an indicator of deviation of CNs from normal diploid copy number of 2. Then,
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Given that tumor evolution is characterized by a series of clonal expansion events,
we often find that mutations and CNVs detected from a bulk tumor sample group
into clusters. The number of these clusters or clones is interpreted as the intra-tumor
heterogeneity. Using CHAT, we can derive two estimates of number of clones by
– clustering cellular abundances of somatic mutations (ITH1) or clustering cellular
abundances of CNVs (ITH2). Both estimates convey important information of the
underlying clonal structure at different resolutions. Hence, we set the overall intra-
tumor heterogeneity of a sample as:
ITH = max(ITH1, ITH2) (3.2)
Given the limitation of a single bulk tumor sample per patient for inference, the
above estimate is a lower bound and correlated with tumor purity (spearman’s rho
= 0.232, p value = 2.09E-5). However, we show that our downstream results still
hold after correcting for tumor purity, age and stage (see below).
To see if mutation burden, CNV load and ITH are associated with overall patient
survival, we stratified the TCGA patients into the following groups:
• Low mutation burden (≤median), high mutation burden (> median)
• Low cnv load (≤median), high cnv load (> median)
• Low ITH (≤median), High ITH (> median)
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Given a cohort of 402 patients with available clinical data, we then fit Kaplan-
Meier survival curves for each group and their combinations and test if there are
any significant survival differences between the groups using a Log-rank test. All
survival analyses were performed using the survival package readily available for
R. Due to potentially confounding effects of purity and other clinical factors, it is
necessary to ascertain whether the observed associations with survival still hold after
accounting for confounding factors. The three major potentially confounding factors
are tumor purity, patient age and clinical stage. We hence performed a multivariate
cox regression analysis in which patient age, tumor purity and clinical stage were
included as additional factors. Our original conclusions do not change after running
this analysis.
3.2.2 Quantifying host immune response from bulk RNA-seq data
Single-end RNA Seq data from the mouse cell-line derived tumors was trimmed
using Trimomatic (0.36) to filter out low quality and adaptor reads. The trimmed
data was then processed using Salmon (0.9.2) to directly quantify gene expression
levels (TPM). Furthermore, gene expression levels (RPKM) of the 432 melanoma
patients with corresponding survival information were downloaded from the TCGA
portal. Cytolytic activity (CYT) of TILs in the mouse cell-line derived tumors, and
likewise in patient tumors, was estimated from the geometric mean of expression
levels of GZMA and PRF1 [199].
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CYT = exp(
log(GZMA + 1) + log(PRF1 + 1)
2
) (3.3)
3.2.3 Phylogenetic analysis of mouse UVB and Sngle Cell Clones
Exome sequencing data for the UVB exposed sample (n = 1) and the individual
single cell clones (n = 20), were used for joint clustering to infer the subclones
present across this combined set of samples. MAF files (generated as described
above) and somatic copy number alteration logR scores by segment (generated using
CNVkit), were utilized as input to the SciClone clustering algorithm [151]. To
ensure high confidence clonal markers were used, the following variant filters were
applied: i) a minimum alternative read depth of > 5 was used, ii) indels and triallelic
sites were excluded, and iii) only variants present in ≥ 2 samples were retained
(i.e., private mutations only in one sample were excluded). This latter criteria of
filtering out private variants was implemented to minimize the impact of technical
artifacts, which are known to be a potential issue in ITH analyses [212], as well as
the fact that variants found only in one sample offered minimal utility in inferring
the overall cross-sample phylogeny. For completeness, the proportion of private
variants found in the experimental mixes used in Figure 6 is included in Table S7,
and further studies with high depth error corrected sequencing will be required
to accurately understand the biological role of private mutations. SciClone was
run with the following parameters: copyNumberMargins = 0.5, maximumClusters
= 30 and minimumDepth = -1 (variants were already pre-filtered for minimum
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depth of > 5 alternative reads during MAF file creation). The clustering solution
from SciClone was manually reviewed, and any obviously poor quality clusters were
removed (e.g., clusters defined by < 10 mutations, clusters present in every sample
but with low VAF values (< 25%), duplicated clusters). Phylogenetic trees, and
representative sample tumor diagrams were constructed using R package CloneEvol
[54]. Individual single cell clones were mapped to terminal clones/branches (from
the overall clustering solution), based on the closest fitting VAF frequency.
3.2.4 Analysis of human immune checkpoint blockade datasets
Four malignant melanoma cohorts were analyzed, from previously published
studies by Snyder et al. (anti-CTLA4 treated), Riaz et al. (anti-PD1 treated), Hugo
et al. (anti-PD1 treated) and Van Allen et al. (anti-CTLA4 treated). Pyclone clus-
tering results for the Riaz et al. cohort were obtained directly from the authors sup-
plemental data files (https://github.com/riazn/bms038 analysis/tree/master/data),
and clones defined by n ≥ 2 mutation were retained for further analysis. Pyclone
clustering results for the Snyder et al. (2014) [217] and Van Allen et al. (2015)
[233] cohorts were obtained from previously published work from McGranahan et
al. (2016) [143], with clones already having undergone quality control filtering. For
Hugo et al. (2016) [99], no previously published clustering results were available,
and instead we managed to successfully process raw WES data of a subset of 22 sam-
ples for which there is available survival information on 21 samples. The processing
pipeline used is as follows: we called variants for each cancer and paired normal sam-
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ples using the GATK (V. 3.6) ‘HaplotypeCaller’ [128, 145](Li et al., 2009, McKenna
et al., 2010) utility applying ‘-ERC GVCF’ mode to produce a comprehensive record
of genotype likelihoods for every position in the genome regardless of whether a vari-
ant was detected at that site or not. The goal of using the GVCF mode was to cap-
ture confidence score for every site represented in a paired normal and cancer cohort
for calling somatic mutation in cancer. Next, we combined the paired GVCFs from
each paired cohorts using GATK’s ‘GenotypeGVCFs’ utility yielding genotype likeli-
hood scores for every variant in cancer and the paired normal sample. Next, we used
GATK’s ‘VariantRecalibrator’ utility using dbSNP VCF (v146: ftp://ftp.ncbi.
nlm.nih.gov/snp/organisms/human_9606_b146_GRCh38p2/VCF) file by selecting
annotation criteria of QD;MQ;MQRankSum;ReadPosRankSum;FS;SOR, followed
by GATK’s ‘ApplyRecalibration’ utility with ‘SNP’ mode. Next, using GATK’s
‘VariantFiltration’ utility we selected the variants with VQSLOD ≥ 4.0. Finally,
somatic mutations were defined as the loci whose genotype (1/1, 0/1, or 0/0) with
‘PL’ (Phred-scaled likelihood of the genotype) score = 0, i.e., highest confidence)
in cancer is distinct from that in paired normal. The final somatic mutations were
mapped on an exonic site of a transcript by ‘bcftools’ tool (V. 1.3)[128] using BED
file of coding region. Clustering analysis was then completed using the CHAT algo-
rithm, as described above.
For each case, the count of mutations within each cluster (clone) as defined by
Pyclone/CHAT were computed, and Shannon diversity index (SDI) was calculated
using the entropy.empirical function in R package ‘Entropy’. Overall survival data
was obtained from the original author’s publications, and n = 3 cases from the Riaz
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et al. cohort with “NE” RECIST coding were excluded, on account of death having
occurred prior to disease assessment. In addition, the group of n = 10 cases from the
Van Allen et al. (2015) cohort with long-term survival but no clinical benefit from
anti-CTLA4 treatment were excluded, as per the original publication. All other cases
with available survival data and clustering results were used for survival analysis
(cases with available clustering results were those with data deposited in https://
github.com/riazn/bms038_analysis/tree/master/data (Riaz et al., 2017)[185]
and https://bitbucket.org/nmcgranahan/clonalneoantigenanaly-\sispipeline/
downloads/ (Van Allen et al., 2015 and Snyder et al., 2014 cohorts) [217, 233], ex-
tracted on date 14/05/2019, please refer to the original publications for further
details). Kaplan-Meier plots were drawn using the ggsurvplot function in R, with
the low/high diversity groups being defined by having a SDI value < or ≥ to the
median value in each cohort respectively. Significance values in Figure 7 were calcu-
lated using the coxph function in R, with SDI included in the model as a continuous
variable, and overall survival hazard ratios are reported per unit increase in SDI
score. To correct for purity, a multi-variable coxph model was used, with SDI and
purity included as variables, and the significance values of each variable in the model
were analyzed. Meta-analysis of significance across the two studies was calculated
using the Fisher method for combinig p values.
Statistical analyses on immune checkpoint blockade treated datasets were performed
using the Prism 8 software (GraphPad, San Diego, CA, USA) and the software
environment R, using RStudio. For all statistical analysis a p value of < 0.05 was
determined to be significant. All data is presented using standard error mean (SEM).
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P values are depicted in all figures, and selected p values with exceptional significance
to the paper are also briefly described in the main text. Samples sizes (n), means and
SEM are depicted in the figures and/or figure legends. Sample size values were either
depiction of number of mice used for experiments, or number of patients. For the
comparison of patient survival curves (Kaplan-Meier curves) the log rank test was
used. For samples with distribution other than normal, or with small sample size (n
¡ 6), the nonparametric Wilcoxon test, Mann-Whitney’s U test, and Kruskal-Wallis
test were used. For samples which approximate normal distribution, Student’s t test
or one-way ANOVA followed by Bonferoni’s post hoc test was used. For correlation
between CYT score and the number of clones depicted in Figure 3.1, the Spearman’s
Rho nonparametric test was used. For tumor growth curve, repeated-measures two-
way ANOVA was used, followed by Bonferoni’s post hoc test. For the analysis of
the Shannon diversity index (SDI), z-test from Cox proportional hazard mode was
used with SDI tested as a continuous variable. Proportions of genomic mutation
types of the different cell lines were analyzed using the Chi-Square test.
3.3 Results
3.3.1 Impact of ITH on patient survival in melanoma
We analyzed a cohort of 402 pre-treatment samples of TCGA [1] melanoma
patients with matched genomic and survival outcome information. Patients were
grouped based on their mutation burden, copy number variation (CNV), and ITH
(estimated as the number of clones), which were computed based on each sample’s
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somatic copy number alterations and somatic mutation data ( See section 3.1).
Neither mutation burden nor CNV load, as a single component, was significantly
associated with patient survival (Figure 3.1, panels A and B). However, patients
with low ITH had significantly better survival (Figure 3.1, panel C), consistent
with previous observations (Brown et al., 2014, Morris et al., 2016). Indeed, when
patients were segregated by number of clones, distinct survival curves could be seen;
patients with low ITH levels (2 clones) had the best survival rate, whereas those
with high ITH levels (6 clones) had the worst survival rate (Figure 3.1, panel D).
When combining all three factors, we found that patients with a high ITH and
a low mutational or CNV load had the worst survival rate (Figure 3.1, panels E
and F). These conclusions hold when controlling for potential confounding factors,
including age, tumor stage, and tumor purity (See Table 3.1). Finally, for each
patient we computed the “cytolytic score (CYT)” [199], which is associated with
the degree of anticancer immunity based on the geometric mean expression of two
key cytolytic effectors, Granzyme A and Perforin1, which are upregulated upon
CD8+ T cell activation and upon effective immunotherapy treatment. CYT scores
were significantly higher in patients with low ITH compared with those with high
ITH (Figure 3.1 panel G; Wilcoxon rank-sum test, p = 4.32 × 106). Notably, the
CYT scores were inversely correlated with the degree of number of clones throughout
the TCGA cohort (Figure 3.1 panel H; Spearman’s rho = −0.27, p = 4.3 × 106).
Together, our results suggest that ITH plays an important role in shaping melanoma
host immune response and patient survival.
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Figure 3.1: (A) Kaplan Meier survival curves (time is measured in days on the x axis)
of patients with high versus low mutation burden. Log rank statistics: 1.96, p = 0.16.
(B) Kaplan-Meier survival curves of patients with high versus low CNV load. Log rank
statistics: 0.31, p = 0.577. (C) Kaplan-Meier survival curves of patient with high versus
low ITH. Log rank statistics: 3.97, p = 0.046. (D) Kaplan-Meier survival curves for
patients segregated by their number of clones. (E) Kaplan Meier survival curves of patients
segregated based on the combination of mutation burden and ITH. Log rank statistics:
9.2, p = 0.0267. (F) Kaplan-Meier survival curves of patients segregated based on the
combination of CNV load and ITH. Log rank statistics: 4.57, p = 0.206. (G) CYT score
(in log scale) of patients with high versus low ITH. ? ? ?p < 0.001, Wilcoxon’s test.(H)
CYT score (in log scale) of patients segregated by their number of clones. Spearman’s
rho: −0.27, p < 0.001.
3.3.2 Tumors with lower ITH are swiftly rejected by immuno-competent
mice independent of tumor mutation burden levels
?? Experimental analyses done by the Yardena Samuels’ lab
Following these retrospective association results in human patients, we sought
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to establish an experimental in vivo mouse system that would enable us to uncou-
ple TMB and ITH and study their influence on tumor immunogenicity in a causal,
systematic manner. First, to assess the effect of increased mutational load and in-
creased concomitant heterogeneity on anti-tumor immunity, we exposed the mouse
melanoma B2905 cell line [170] to UVB irradiation (Figure 3.2, panel A), a key car-
cinogenic source driving melanoma initiation [57]. Because the literature regarding
UVB research in melanoma varies considerably with respect to the amount of radi-
ation exposure needed to induce melanoma genesis, we first titrated the amount of
radiation needed for an optimal UVB response without compromising cell longevity.
We found that a UVB dose of 600 J/m2 was sufficient to induce p53 elevation
[34] and cyclobutane pyrimidine dimer (CPD) formation [40] while maintaining the
longevity of the murine melanoma cell lines B2905 and B16F10.9
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Figure 3.2: (A) Scheme of experimental design for generating UVB-irradiated cells and
generating SCCs derived from UVB-irradiated cells. Cell lines are irradiated by UVB at
dosage of 600 J/m2; from these irradiated cells, SCCs are generated. (B) Distribution of
variant allele frequencies (VAFs) of parental B2905 cells (black), UVB-irradiated B2905
cells (red), SCC 1 (purple), and SCC 2 (green) in log2 space. VAF > 0.25(log2 = 2)
is considered clonal. (C) Tumors excised from mice inoculated with either parental or
UVB-irradiated cell lines on day 15 after inoculation.(D) In vivo tumor growth in mice
inoculated with parental B2905 cells (black) and UVB-irradiated cells (red). n = 3–4;
data are representative of three independent experiments. Data are mean ±SE. ?p <
0.05, ? ? ?p < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test.(E) Tumors
excised from UVB-irradiated B2905 cells versus SCC 2, day 19.(F) In vivo growth of
tumors in mice inoculated with UVB (red) or SCC 1 (purple) and SCC 2 (green). n
= 4–5; data are representative of two independent experiments. Data are mean ±SE.
? ? p < 0.01, ? ? ?p < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test. ?
refers to UVB and SSC 1 comparisons; # refers to UVB and SSC 2 comparisons.
In parallel with the increase in TMB upon UVB irradiation, we also detected an
increase in ITH from the distribution of the variant allele frequency (VAF; the fre-
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quency of a mutation within the population plotted against the probability density
function), which was skewed toward a more subclonal phenotype (VAF < 0.25) [245]
and exhibited a relatively small fraction of clonal single-nucleotide variants (SNVs):
0.063 compared with 0.079 in the parental cell line (Figure 3.2 panel B). UVB-
irradiated B2905 cells grew at a slower rate in vitro compared with non-irradiated
B2905 cells (Figure S2E), the irradiated cell line gave rise to tumors with an in-
creased growth rate when transplanted into immunocompetent syngeneic mice (Fig-
ure 3.2 panel C and D). This effect was not cell line specific because irradiated
B16F10.9 cells showed the same pattern of reduced growth in vitro and increased
tumorigenicity in vivo. We additionally assessed whether tumors derived from these
two lines, parental B2905 and UVB-irradiated B2905, had a differential response
to PD-1 blockade. We found that the response of mice with the UVB-irradiated
cell line to anti-PD-1 treatment was considerably milder than the response of those
with parental B2905 cells (Figure 3.3). Given that the UVB signature cannot predict
checkpoint blockade response in melanoma patients [149] and that excessive TMB
did not reduce tumor growth, we hypothesized that differences in heterogeneity may
play a role in mediating tumor growth in vivo.
3.3.3 Increasing ITH leads to reduced T-cell reactivity to neo-antigens
and T cell infiltration in-vivo
?? Experimental analyses done by the Yardena Samuels’ lab.
We next evaluated whether the growth rates of the tumors harboring dif-
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Figure 3.3: In vivo tumor growth in mice inoculated with parental B2905 (Black) or
UVB irradiated B2905 (red) lines, treated with anti-PD-1 or IgG control antibodies at
days 6, 9, and 12 post cells inoculation (n = 11-12). Data are mean ±SE. Comparisons
between parental B2905 tumors treated with IgG or anti-PD-1 treated are depicted by
asterisks, whereas comprisons between UVB B2905 tumors treated with IgG or anti-PD-1
are depcited by cross. ?p < 0.05, ? ? p < 0.01, ? ? ?p < 0.001, one-way ANOVA followed by
Tukey’s post hoc test
ferent degrees of heterogeneity are mirrored by the degree of T cell reactivity in
vivo. This was assessed by extracting total T cell receptor β+ (TCRβ+) TILs
(tumor-infiltrating lymphocytes) from non-irradiated parental B2905 tumors, UVB-
irradiated B2905-derived tumors, and B2905 SCC 2-derived tumors. To assess T
cell reactivity, we measured the fraction of TILs positive for the cytotoxic mediator
Granzyme B coupled with expression of CD107a, a degranulation marker [6, 198].
Although total Granzyme B+ fractions were similar in TILs derived from all tumors,
the Granzyme B+ CD107a+ fraction of TILs was significantly reduced in UVB-
irradiated B2905-derived tumors, whereas it remained similar in both the parental
and the SCC 2-derived tumors (Figure 3.4, panel A). In addition, SCC 2-resident
TILs contained a much higher interferon-+ fraction (Figure 3.4, panel B), indicating
stronger TIL activation and cytotoxicity. To substantiate these results, we sorted
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CD8+ TILs from UVB-derived and SCC 2-derived tumors 16 days after inoculation,
performed RNA sequencing (RNA-seq), and analyzed the TILs for their CYT score.
CD8+ TILs isolated from SCC 2-derived tumors had a higher CYT score, recapit-
ulating the high CYT scores of the low-ITH TCGA melanoma patients (Figure 3.4
panel G and H). Furthermore, this score significantly correlated with tumor weight
(Figure 3.4 panel C and D). Thus, the SCC 2-derived tumors, which had low ITH
and were ultimately rejected in vivo, were more immunogenic than their parental
heterogeneous UVB-irradiated, aggressive B2905-derived tumors, which had high
ITH.
In addition to the immune composition of the tumor microenvironment, the spatial
distribution of TILs within the malignant mass, in particularly immune infiltration
into the tumor core, correlates with better survival and treatment success [112, 117].
Immunohistochemistry (IHC) and immunofluorescence analyses of tumor sections
revealed that, although tumors derived from all three cell lines accumulated CD8+
TILs in the tumor margin, those derived from SCC 2 featured both higher penetra-
tion of CD8+ cells (Figure 3.4, panel E) and massive infiltration of TILs into the tu-
mor core (Figure 3.4 panel F and G). We recapitulated these data in three additional
SCCs that also formed tumors large enough for IHC analysis. We next quantified
the levels of regulatory T cells (Tregs), which are known to suppress anti-tumor im-
munity and promote tumor growth [66, 225] by CD3+ Foxp3+ immunofluorescence
(IF) staining of these tumors and found a direct correlation between ITH and Treg
levels (Figure 3.4 panel H and I). In conclusion, low-ITH tumors show enhanced
CD8+ T cell infiltration to the tumor core, a lower presence of immunosuppressive
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Figure 3.4: (A) Flow cytometry analysis of the Granzyme B and CD107a population
in total TCRβ+ TILs on day 19. n = 4–5; data are mean ±SE. ? ? p < 0.01 for
Granzyme B+ CD107a+ TILs, two-way ANOVA followed by Bonferroni’s post hoc test.(B)
Flow cytometry analysis of interferon-gamma (IFN−γ) in total TILs on day 19. n = 4–5,
?p < 0.05, Kruskal-Wallis test followed by Dunn’s multiple comparisons test. (C) CYT
score derived from RNA-seq data of sorted CD8+ TILs from UVB-irradiated B2905 and
SCC 2 tumors on day 15. ?p < 0.05, Mann-Whitney U test. (D) Pearson correlation
between CYT score and weights of tumors in Figure 3C. (E) Quantitation of total CD8+
TILs in the indicated tumors. Four sections from each tumor and three tumors derived
from each cell line were examined. A significant difference was observed between parental
cells and SSC 2 but not between parental cells and UVB. Data are mean ±SE. ?p < 0.05,
one-way ANOVA followed by Tukey’s post hoc test. (F) Relative quantitation of the
average percentage of CD8+ TILs in the tumor core versus the margin of the tumors
described in (E). Data are mean ±SE. (G) Representative immunohistochemical stain
for CD8 in slides taken from tumors derived by parental, UVB and SCC 2 on day 10 after
cell inoculation. The scale bars represent 100 µM. (H) Immunofluorescence stains of CD3
and Foxp3 in tumors derived from B2905 parental, UVB, and SCC 2, 16, and 11 on days
1011 after cell inoculation. 3–4 sections from each tumor and two tumors derived from
each cell line were examined. The scale bars represent 200 µM. (I) Relative quantitation of
the percentage of Foxp3+ of CD3+ TILs described in (H). Data are mean ±SE. ?p < 0.05,
one-way ANOVA followed by Tukey’s post hoc test.
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Tregs, and higher degranulation and cytotoxicity compared with high-ITH tumors.
This indicates that, indeed, low-ITH tumors elicit a strong anti-tumor response,
whereas high ITH tumors are relatively non-immunogenic.
3.3.4 Systematic clone mixing experiments show that both the num-
ber of clones and their genetic diversity affect host immune
rejection
?? Experimental analyses done by the Yardena Samuels’ lab
To further study the role of ITH in tumor rejection, we systematically gener-
ated tumors with defined states of heterogeneity using different combinations (mix-
tures) of the above-described 20 SCCs that were derived from the original, highly
heterogeneous UVB-irradiated cell line (3.2). The individual SCCs were mixed in
a controlled manner to dissect the functional ramifications of the two fundamen-
tal components of tumor heterogeneity: (1) the number of clones comprising the
tumor and (2) the genetic diversity between them. To choose relevant clones for
the mixing experiments, we performed a phylogenetic analysis of the heterogeneous
UVB cell line. This yielded a phylogenetic tree with six terminal branches (TBs),
numbered TB-4 to TB-10 (Figure 3.5 panel A). An almost identical clustering was
obtained using an orthogonal analytical methodology. We then placed the 20 SCCs
on the various terminal branches of the tree, based on their sequence similarity. To
study the role of tumor diversity in determining tumor growth, we inoculated four
different mixtures of 3 SCCs and monitored their growth, as shown in Figure 6B. To
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achieve genetically diverse mixes, each mix contained clones from 3 different TBs
of the UVB-irradiated phylogenetic tree (denoted as across branches [3AB]) (Figure
3.5 panel B and E). As seen in Figure 3.5, panel B, although diverse, none of the
3 clone mixes formed a large tumor, even 35 days after the mixes were inoculated.
However, increasing the number of branches included in the mix from 3 to 6 (one
clone from each TB [6AB]; Figure 3.5 panel E) results in significantly larger tumors
(Figure 3.5 panel B and C) (group factor p = 0.0238 when 6AB is compared with
the 3AB mixes by two-way ANOVA versus group factor p = 0.1614 when the 3AB
mixes are compared without 6AB). Doubling the number of clones included from
each of the six TBs (two clones from each TB [12AB]) further increased the sub-
clonal/clonal mutation ratio (Figure 3.5 panel D) and produced even more aggressive
tumors (Figure 3.5 panel C).
We next evaluated the functional effects of the tumor’s genetic diversity while con-
trolling for the overall mutational load. To this end, we compared the growth of
tumors generated from a mixture of clones originating from a single TB (6 SCCs
within TB-4 [6WB]) with that of those generated from the 6AB mix described above
(comprising clones from TB-4, TB-6, TB-7, TB-8, TB-9, and TB-10) (Figure 3.5
panel C and E). These two mixes have the same number of clones (six) and approx-
imately the same mutational loads (Figure 3.5 panel F) but vary in their genetic
diversity, as assessed by their clonal versus subclonal mutation ratios (Figure 3.5
panel D). Despite having similar mutational loads, we identified striking differences
in growth between 6AB and 6WB (Figure 3.5, panel C). Similarly, we next com-
pared the tumor growth curves of a mixture of 12 SCCs derived from one branch
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(12WB, derived from branch 5, which contains TB-4 and TB-7) with the growth of
the 12AB mix (two SCCs from TB-4, TB-6, TB-7, TB-8, TB-9, and TB-10) (Figure
3.5 panel C and E). Again, there were clear differences in tumor growth between
12AB and 12WB. Moreover, even though 12AB had a higher mutational load than
6AB (Figure 3.5 panel D), its growth surpassed that of 6AB. This indicates that an
increased mutational load is not sufficient to drive tumor rejection. The 12AB tu-
mors were still not as aggressive as the UVB irradiation-derived tumors (Figure 3.5
panel D), emphasizing that the latter tumors harbor a higher degree of ITH. Taken
together, these results testify that both the number of tumor subclones and their
genetic diversity play important roles in mediating tumor growth and rejection.
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Figure 3.5: (A) Phylogenetic tree representation of the UVB-irradiated B2905 cell line.
The tree depicts the results from mutation clustering analysis, which was used to define
the distinct subclones present within the UVB cell line. The phylogenetic relationship
between subclones is shown, and then each of the 20 UVB derived SCCs is mapped onto
the subclonal branch with the highest genetic similarity. Each of the 20 SCCs is depicted
as a ball of 100 tumor cells, with the color coding reflecting the percentage frequency of
each branch in each SCC sample. Shown in the top right box is a representation of the
UVB parental sample, again shown as a ball of 100 tumor cells, color-coded to match
the subclonal branches. (B) Top: Venn diagrams for the four 3AB mixes inoculated,
representing the number of protein-coding mutations and their intersections between the
SCC in each mix. Bottom: in vivo tumor growth curves of the four different 3AB mixes. n
= 5. Data are mean ±SE.(C) Left: in vivo tumor growth curves of the 6WB mix (within
TB-4) and 6AB mix (one SCC from each TB). n = 4–5. Right: in vivo tumor growth
curves of the 12WB mix (within TB-5) and 12AB mix (two SCC from each TB) and the
UVB-irradiated B2905 cell line. n = 5–6. Data are mean ±SE. (D) Percent clonal versus
sub-clonal mutations in the mixes described in (C). (E) The SCC included in each mix
described in (B) and (C). (F) The association between the 6AB, 6AB, 12AB, and 12WB
mix mutation number (unique) and the maximal tumor volume size (cubic centimeters)
within 40 days. Each dot represents an individual mouse. The graph shows statistical
significance between the 6 and 12 mixes but not between mutation number and tumor
volume (Wilcoxon rank-sum test)
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3.3.5 Tumor clonal diversity predicts responses to immune check-
point blockade therapy even after controlling for tumor muta-
tion burden
?? Analysis done in collaboration with Kevin Litchfield
To further evaluate the extent to which the number of clones and their genetic
diversity affect the anti-tumor immune response in human data, we analyzed four
previously published melanoma checkpoint inhibitor cohorts from Snyder et al.,
2014 [217], Riaz et al., 2017 [185], Hugo et al., 2016 [99], and Van Allen et al.
(2015) [233]. Given the results of the mixing experiment that show that both the
number of clones and their diversity are important determinants of tumor growth,
we analyzed patient data using the Shannon diversity index (SDI), a formal diversity
metric that quantitatively measures both the number of clones and the diversity of
the mutations across clones in one index. As an example, a tumor with a low SDI
would have nearly all of its mutations concentrated in just one clone (a large truncal
neoantigen burden). In contrast, a high-SDI tumor would have a high number of
clones with mutations spread evenly or diversely across each clone (a large branched
neoantigen burden) (Figure 3.6 panel A). The first cohort analyzed (Snyder et al.,
2014) comprised data from 54 patients treated with anti-CTLA-4 therapy. We
found its SDI index to significantly associate with overall survival (p = 0.0064, SDI
tested as a continuous variable, z-test from the Cox proportional hazard model;
Figures 3.6 panel B and F). Patients with a higher diversity tumor (as measured by
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SDI) had poorer survival, with a hazard ratio (HR) of 8.8 (95% confidence interval,
1.8–41.6) per unit increase in SDI (Figure 3.6 panel F). In the second cohort (Riaz
et al., 2017), containing 57 patients treated with anti-PD1 therapy, we observed
a comparable but non-significant pattern (p = 0.079, HR = 2.2 [0.9–5.5] per unit
increase in SDI (Figure 3.6 panel C and F). In the third cohort (Hugo et al., 2016),
composed of 21 patients treated with anti-PD1 therapy, again a comparable but
non-significant pattern was noted (p = 0.096, HR = 4.2 [0.8–23.8] per unit increase
in SDI; Figures 7D and 7E). In the final cohort, which had data available from 70
patients treated with anti-CTLA4 therapy, no significant association between SDI
and overall survival was detected (Figures 7E and 7F); it should be noted, however,
that this result is consistent with previous ITH analyses in this cohort (McGranahan
et al., 2016) and may be explained by the high level of pre-treatment in this cohort,
making biomarker analyses more challenging. Given that all four datasets are of
fairly limited size, we performed a meta-analysis across all four studies, which yielded
an overall significance value of Pmeta = 0.0105, testifying that clone number and
genetic diversity between clones are drivers of the immunotherapy response in human
cohorts. Importantly, this result remained significant after adjusting for tumor
purity in a multi-variable analysis for each cohort, with updated Pmeta = 0.012
for the SDI variable (across all four studies), and Pmeta = 0.15 for tumor purity,
suggesting that the latter is not a confounding variable in our analysis. Similarly,
we corrected for TMB in the multi-variable analysis for each cohort, which yielded
an updated Pmeta = 0.039 for the SDI variable and Pmeta = 0.33 for TMB.
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Figure 3.6: (A) The cartoon illustrates two examples of the SDI, top low SDI (the
tumor is predominantly composed of one major clone) and bottom high SDI (the tumor is
composed of multiple clones with higher evenness between clones). SDI is measured using
individual tumor subclones (from Pyclone clustering) as types and the somatic mutations
as entities so that a tumor with a low SDI would have nearly all mutations concentrated in
just one clone, and, in contrast, a tumor with a high SDI would have a higher number of
clones, with mutations spread evenly or diversely across each clone. (B) The SDI analysis
applied to the Snyder et al. (2014) anti-CTLA4 dataset [217]. Overall survival Kaplan-
Meier plots are shown for with patients with a high SDI in red (SDI above median value
in cohort) and a low SDI in green. The number of patients at risk by time point is shown
in the table below. (C–E) The same data format as in (B) for the Riaz et al. (2017)
anti-PD-1 dataset [185] (C), Hugo et al. (2016) anti-PD-1 dataset [99](D), and Van Allen
et al. (2015) anti-CTLA4 dataset [233] (D), respectively. (F) Forest plot showing the HR
for the SDI in each dataset, with the HR value corresponding to the survival risk per unit
increase (i.e., each +1 increment) in the SDI. For significance analysis, SDI is tested as a
continuous variable (to show a continuous association across the full range of data) using
a Cox proportional hazard model (other clinical predictors, e.g., stage, are not included).
3.4 Discussion
Here we have established a framework that enables one to tease apart and
study the effect of TMB and ITH on tumor aggressiveness, evaluating their influ-
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ence on anti-tumor immunity in a controlled manner. Our findings in mice sug-
gest that, in melanoma, an essential genetic determinant of anti-tumor immune
response is tumor heterogeneity. These results corroborate previous reports that
clonal neoantigens are associated with a more robust tumor infiltrate and clinical
outcome, with and without checkpoint inhibitor blockade [143]. By systematically
generating tumors composed of different SCC mixes in a designed, controlled man-
ner, we further dissected the two major components of a tumor’s ITH, finding that
both the number of distinct clones composing the tumor and the degree of their
genetic diversity influence tumor aggressiveness.
Our experimental mouse data are mirrored in TCGA melanoma patients,
where the overall survival rate is significantly higher in tumors with a fewer num-
ber of clones, and the combination of number of clones and diversity (their SDI)
is inversely associated with overall survival in immune checkpoint inhibitor-treated
cohorts. These findings, which tightly match our experimental findings in mice,
further support the detrimental influence of tumor heterogeneity on the anti-tumor
immune response in humans, in keeping with previous studies [143].
Alongside the effects on tumor growth and responsiveness, the complex mech-
anisms behind the modulation of anti-tumor immunity by tumor heterogeneity need
to be further addressed in future studies. We suggest that diminishing tumor het-
erogeneity exposes tumor cells by reducing their neoantigen landscape, bringing
reactive neoantigens to the “frontline,” thus better exposing them to immune de-
tection. This, in turn, leads to enhanced infiltration into the tumor core, elevated
effector cytokines, and heightened degranulation. When neoantigen-specific CD8+
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T cells are able to infiltrate and kill tumor cells, more tumor antigens are exposed
to the tumor microenvironment, further promoting neoantigen uptake and presen-
tation by tumor-associated DCs, enhancing the ability of the immune system to
reject the tumor. In contrast, in more heterogeneous tumor cell populations, tu-
mor cells could have a better chance of escaping immune surveillance because the
reactive neoantigens undergo “dilution” within the tumor relative to other neoanti-
gens. The total outcome is weaker anti-tumor immunity, manifested by reduced
immune infiltration into the tumor core and dampening of TIL degranulation, cyto-
toxicity, effector cytokine secretion, and proliferation. In addition to CD8+ T cells,
we found lower numbers of Tregs in tumors derived from SCCs (low ITH) than in
UVB-derived, more heterogeneous tumors, indicating a strong immunosuppressive
tumor microenvironment in high-ITH tumors that is resolved in single-cell-derived
tumors. Overall, our results are consistent with the recent hypothesis by Gejman et
al. (2018) [71] that, because of increased antigenic variability, the relative expression
of each neoantigen is lowered in tumors with increased ITH, diminishing the TILs’
ability to home to their target cells and mount a sufficient cytotoxic response.
In addition to the differential infiltration of CD8+ T cells and differential Treg
accumulation observed in the tumors, other immune mechanisms also likely play a
part in the reduced response to heterogeneous versus homogeneous tumors. These
may involve non-Treg CD4+ cells, which are important for priming of CD8+ T cells
[27] and recognition of MHC class II-borne tumor antigens [256]. Different CD4+ T
cells effector subsets can have direct or indirect anti-tumor immunity. These subsets
include CD4+ cytotoxic T cells that can directly eliminate MHC class II+ tumors
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[90] and CD4+ Th1 and Th17 cells that can mediate elimination of tumor cells
in an antigen-specific manner [158, 180]. Indeed, strong anti-tumor responses of
CD4+ cells against tumor MHC class II neoantigens in cancer patients have been
reported [130, 230, 236]. This suggests an additional level of complexity within the
tumor-immune interface and a significant clinical potential for future therapies.
Additional immune subsets other than T cells that may play a role in this
setting encompass M1 and M2 macrophage polarization [33], NK cells [88], DCs
[58], or neutrophils [49]. To fully elucidate the immune profiles of ITH-high versus
-low tumors, cutting-edge, high-dimensional techniques such as single-cell RNA-
seq [127, 201] and CyTOF [86] and state-of-the-art analysis algorithms such as
CIBERSORT [164] could be utilized in follow-up studies.
Although we show that high ITH impairs the immune system response, tu-
mors with impaired immune responses can likely still acquire high levels of ITH.
Thus, impaired immune response and ITH levels are tightly associated. However,
whether ITH is a cause or a consequence of tumor progression or both is not fully
elucidated. Interestingly, previous studies have shown that functional cooperation
between genetically distinct subclones can be essential for overcoming environmental
constraints and, thus, affect tumor maintenance and growth [48, 140] and metastatic
behavior [102]. Of note, it has been shown recently that the immune system as well
as checkpoint immunotherapy can select for low-ITH tumors [152]. Understanding
the complex interactions between tumor heterogeneity and the immune response
and how they change during tumor evolution still remains a challenge.
Despite the strengths, there are several shortcomings of our study. Specifically,
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the single-cell cloning process inherently involves in vitro selection of clones. This
may miss clones with a low survival capability in vitro, which does not necessarily
reflect their functional importance in vivo. Likewise, we acknowledge the limita-
tions of accurately assessing ITH from a single biopsy sample in the TCGA and
immune checkpoint blockade (ICB) datasets because of the narrow sampling frame
of taking just one sample from one spatial location. The sequencing depth, tumor
purity, choice of processing pipeline, and nature of the single biopsy (primary versus
metastatic) may also affect ITH assessment, making it challenging to derive a single
prognostic measure of ITH. We believe that additional studies that quantify ITH in
large-scale cohorts with multi-region biopsies are likely to shed further light on the
prognostic role of tumor ITH, providing a higher-resolution view of the fundamental
trends outlined in this study.
In summary, our findings show the value of evaluating ITH as an important de-
terminant of melanoma patients’ response to checkpoint therapy. They also support
the notion that clonal neoantigens are more likely to lead to better cancer vaccines
[143, 202]. On the flip side, our results cast doubt on the notion that excessive
mutagenesis, directed to enhance TMB, can enhance the efficacy of immunotherapy.
Indeed, it is conceivable that excessive neoantigen heterogeneity may actively im-
pair a productive anti-tumor immune response. In conclusion, our functional data
support recent findings that the clonality of a tumor can be used as a biomarker
for predicting better outcomes in melanoma and may improve patient matching to
current immunotherapy in a manner complementary to mutational load. We suggest
that ITH is a strong determinant of immune response and immunotherapy success
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in melanoma, highlighting the potential importance of assessing it in the clinic. The




Factors driving acquisition of cancer type-specific chromosomal
aneuploidies
?? This work was done in collaboration with Dr. Noam Auslander and cur-
rently under review at Genome Medicine.
4.1 Overview
In solid tumors of epithelial origin, i.e., carcinomas, and in certain other solid
tumors such as glioblastoma multiforme and malignant melanoma, aneuploidies of
specific chromosomes define the landscape of somatically acquired genetic changes
[116, 115, 161, 93, 187]. In fact, aneuploidy is present in about 90% of solid tumors
[21]. Remarkably, the distribution of ensuing genomic imbalances is cancer-type
specific [93, 188]. For instance, colorectal carcinomas are defined by extra copies
of chromosomes and chromosome arms 7, 8q, 13q and 20q, accompanied by losses
of 8p, 17p and 18q [190]. In contrast, cervical carcinomas invariably carry gains of
chromosome arms 1q and 3q. In other words, a gain of 3q is not observed in colorectal
cancer, and cervical carcinomas do not have copy number gains of, e.g., chromosomes
7 or 13q [93, 187, 188]. Furthermore, cancer-type specific chromosomal aneuploidies
emerge in dysplastic, i.e., not yet malignant, lesions, that are prone to progress to
invasive disease [190, 178, 22, 226, 55]. Numerous cancer-type specific aneuploidies
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originate at early stages of tumorigenesis, yet are retained in late stage tumors and
in metastases, as reflected in the TCGA database [178]. The cancer-type specific
distribution of genomic imbalances was recently confirmed in two comprehensive
pan-cancer analyses of several thousand tumors [22, 226]. Although some intra-
tissue differences can be observed for certain tumor subtypes arising from the same
tissue, different tumor types from the same tissue tend to cluster together (e.g.,
low-grade gliomas cluster with glioblastomas as do clear cell and papillary renal cell
carcinomas) . On one hand, it is possible that loss or gain of particular chromosomes
or their fragments during carcinogenesis target the gain of specific oncogenes or
the loss of tumor suppressors located on these chromosomes [21, 55, 15]. On the
other hand, it is well known that chromosome-wide alterations of gene expression
levels follow genomic copy number changes [232, 189], i.e., the transcripts of genes
that are located on gained chromosomes are more, and those on lost chromosomes
are less abundant. This correlation has been firmly established in primary human
carcinomas, in derived cell lines, and in experimental cancer models [232, 247, 231,
221, 62, 191]. Hence the gain or loss of specific chromosomes can potentially act
as a mechanism to maintain tissue specific gene dosage. Given this background,
we decided to explore how the frequencies of chromosomal arm gains and losses in
specific cancer types correlate with (i) mean chromosome arm gene expression levels
of their normal tissue of origin, and (ii) the chromosomal distribution of previously
identified or newly implicated tissue specific driver genes. Our exploratory analysis
unearths a complex picture of factors shaping the evolution of tumor karyotypes
in which recurrent chromosomal alterations can potentially “hardwire” expected
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chromosome-wide gene expression levels of their normal tissue of origin in addition
to targeting tissue-specific driver genes.
4.2 Methods
4.2.1 Tissue and tumor type inclusion
Initially, all 33 TCGA tumor types were considered for analysis. Chromosome
arm-wide gain and loss data data for 33 tumor types were obtained from Taylor
et al. [226], cancer gene expression data and normal gene expression was obtained
from TCGA (xenabrowser.net) and GTEx (GTEx analysis V6p), respectively, us-
ing Reads Per Kilobase of transcript, per Million mapped reads (RPKM) values with
no additional normalization. The RPKM values are already library size normalized,
through dividing by the total number of reads in a sample, therefore accounting
for whole genome doubling events. Moreover, because the GTEx samples are of
healthy individuals, it is unlikely that any of these samples harbor whole genome
doubling events. Processed methylation datasets of normal tissues were collected
from the Gene Expression Omnibus (GEO) database. For consistency, we restricted
our search to datasets where methylation was quantified using the same platform
(Illumina 450K). This approach resulted in the identification of 18 tissue specific
methylation datasets, which were analyzed together. For analysis comparing tu-
mor and normal tissues, tumor samples from 25 tumor types and 19 corresponding
normal GTEx tissues of origin were considered (See Table 4.1). Likewise, for com-
paring tissue specific methylation and expression levels, only 11 tissues which had
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a matching methylation dataset available were considered.
Table 4.1: Cancer type-normal tissue pairs evaluated




normal methylation data available


































4.2.2 Curation and pre-processing normal tissue specific methylation
datasets
We curated a list of 18 Illumina 450K methylation datasets covering 11 organ
tissues from GEO (See Table 4.2). These were datasets spanning different studies
comparing methylation levels of organ tissues between diseased and normal control
individuals. We only selected methylation profiles of normal control individuals for
further analysis. Moreover, multiple datasets containing samples coming from the
same organ tissue were merged to generate one methylation dataset per organ. The
methylation data of each dataset was pre-processed in the following steps:
• Filtering out probes within 15 base pairs of single nucleotide polymorphisms
[60].
• Re-normalizing the beta values between type 1 and type 2 probes using beta
mixture quantile normalization [228]. This minimizes biases that may arise
due to sensitivity differences between the two probe designs.
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Table 4.2: list of curated methylation datasets
Dataset ID Tissue
GSE32146 Colon
GSE40360 Brain, frontal lobe
















4.2.3 Computation of the chromosome arm imbalance score in can-
cerous tissues
We used the TCGA sample-wise chromosomal arm gain and loss data provided
by Taylor et al. [11], where the ploidy was determined via the ABSOLUTE algorithm
[38]. Independent chromosome arm copy number alterations were distinguished from
whole genome duplication events by comparing the absolute integer copy number of
chromosomal arm regions to the baseline tumor ploidy. Each segment was designated
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as gained, deleted, or neutral compared to the ploidy of each sample. The scores of
each arm are -1 if lost, +1 if gained, 0 if non-aneuploid, and “NA” otherwise. For
sake of consistency, all “NA” entries were re-set to 0 (i.e, we consider those samples
non-aneuploid for that arm). The discrete representation was used because it is
most fitting to describe arm-level changes, which may be either gained (1) or lost
(-1) by definition, rather than continuous GISTIC data, which is better suited for
studying targeted focal copy number alterations. For each of the 39 chromosomal
arms we define an arm imbalance score for a set of cancer types sharing the same
tissue of origin (or a singular cancer type), by computing the difference between the
frequency of gains and losses. Formally:
Arm Imbalance Score(Ai, Tj) =
∑
samples s ∈Tj IsG(Ai)−
∑
samples s ∈Tj IsL(Ai)
Number of samples in Tj
(4.1)
Where Ai is chromosomal arm i (of 1 to 39 chromosomal arms), Tj is the tissue of








1 if sample s has a loss of arm Ai
0 otherwise
Hence, arms that are more frequently gained are assigned positive scores, while
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arms that are more frequently lost are assigned negative scores. Arms that are nei-
ther gained nor lost, and arms where the frequency of gains and losses is comparable
are assigned neutral (≈zero) score. However, the latter is negligible since chromo-
some arms that are frequently gained are rarely lost in a specific tumor type and
vice versa. This score is hence equivalent to the mean value of gains/loss incidences
in set of tumor types considered and chromosomal arm.
4.2.4 Permutation tests to evaluate correlation significance
In this study, we compute correlations across cancer/tissue types, and across
chromosomal arms. To evaluate whether the magnitude of correlations is significant
compared to random, we employ a permutation test, to estimate a background null
distribution of the number of positive correlations. We therefore repeat 1000 itera-
tions of randomly shuffling the cancer/tissue pairing and 1000 iterations of randomly
shuffling the arm-level pairing. We compare the number of positive correlations P ,
achieved with the true pairings to this background (Ni,i = 1, 2, . . . , 1000), to com-





a similar manner, we test whether mean arm-wide gene expression levels of each of
the 39 chromosome arms in a sample are informative for predicting the sample’s
tissue of origin, compared to the background of any random aggregation of gene
expression into 39 groups. Therefore, we design a permutation test with 1000 itera-
tions. In each iteration, we quantify how accurately we can predict tissue of origin
based on randomly aggregating genes into 39 groups with similar sizes as that of
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chromosomal arm assignment. We evaluate the number of times (out of 1000) in
which the multiclass prediction accuracies of the shuffled predictor (Ni, with ran-
dom aggregation of genes into 39 groups) exceeded the original predictor (P , with
the aggregation of genes to 39 groups by chromosomal arm), to derive an empirical




4.2.5 Quantile normalization of gene expression and methylation val-
ues for cross tissue comparison and visualization
To enable side-by-side comparison and visualization of the arm imbalace scores
with mean chromosomal arm mean gene expression levels in different normal tissues
(and likewise in different cancers), the gene expression and arm-imbalance values
need to be on the same scale. Hence, we additionally quantile-normalized the mean
gene expression levels using the chromosomal arm imbalance distribution as ref-
erence, to enable visualization by generating similar expression distribution across
different tissues. We applied the same approach to quantile normalize chromosome
arm-wide mean methylation levels in normal tissues to visualize normal methylation
against normal gene expression in each tissue.
4.2.6 Curation of chromosome-wide distribution of relevant onco-
genes and tumor suppressors in each cancer type
We obtained a comprehensive list of known (or potential) oncogenes and
tumor-suppressors driving each cancer type from a recent pan-cancer study con-
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ducted by Bailey et al. [13]. This list was obtained from supervised machine learning
predictions based on features derived from mutation, copy number, gene expression
and mythylation changes observed in genes across different cancer types. Given a
cancer type, the oncogenes-tumor suppressor imbalance score for each arm in a given
cancer type (or collection of cancer types) is formally defined as follows: Oncogene-
tumor suppressor imbalance score = fraction of driver genes on the arm that are
oncogenes − the fraction of driver genes on the arm that are tumor-suppressors.
4.2.7 Normal and cancer tissue of origin classification and clustering
We classify normal (and likewise, cancer) samples using the chromosomal-arm
level expression of those samples. For each sample , we calculate the mean gene
expression level of the genes in each chromosomal arm. This results in 39 unique
features per sample (one per arm). We then perform K-Nearest-Neigbors (KNN,
with K=5, the value for which the best performance was observed for cancer type
classification from K=3,5,7) classification with a Leave-One-Out cross validation
(LOOCV), aiming to classify each sample based on the 39 arm level features, and
calculate the resulting accuracy (percentage of correctly classified samples in the
LOOCV). An analogous approach is taken for classification of tissue of origin based
on methylation data. Additionally, to rule out potential confounding batch effects
in gene expression data and the leave one out cross-validation procedure used, we
re-estimate overall KNN performance using 5-fold cross validation. For performing
hierarchical clustering of different tissue-types, each tissue-type is summarized as
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a vector of 39 features; one for each arm. 4 different hierarchical clustering anal-
yses are performed. For each one, a different set of 39 features is used. They are
systematically listed below:
• Chromosomal arm imbalance score computed across all cancer types originat-
ing from the same tissue
• Mean arm-wide normal gene expression across all genes and all normal samples
belonging to the same tissue.
• Mean arm-wide cancer gene expression across all genes and all samples origi-
nating from the same tissue
• Arm level oncogene-tumor suppressor imbalance score across all cancer types
originating from the same tissue
4.3 Results
4.3.1 Chromosome arm imbalance scores of cancer types and mean
chromosome arm-wide gene expression levels of their normal
tissue of origin
Taylor and colleagues [226] comprehensively recorded for each tumor sample
in the TCGA if a specific chromosome arm was gained or lost (while accounting
for the baseline tumor ploidy).We used this data to compute the mean chromosome
arm imbalance score of each arm in a given cancer type (or collection of cancer
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types) emerging from the same tissue of origin. In short, this score measures the
difference between the frequency of gains and losses of a specific chromosome arm.
As a first step, we validated previous observations by showing that the mean gene
expression levels over all genes and all samples from the same chromosome arms
and cancer type included in the TCGA database, respectively, positively correlate
with the corresponding arm imbalance scores (Figure 4.1, panel A). This analysis
confirmed that genomic copy number alterations in cancer genomes directly affect
gene expression levels. After having validated this correlation, we next computed the
mean expression levels over all genes and all samples from the same chromosome arm
and normal tissue, respectively, from the GTEx database. These values were then
correlated with the mean chromosome arm imbalance scores of respective cancer
types emerging from that tissue. Figure 4.1 panel B plots a heatmap with rows
indicating chromosome arms. The chromosome arm wide mean expression levels
in each normal tissue and corresponding arm imbalance scores in associated cancer
types are juxtaposed and quantile normalized to the same scale for visualization and
comparison.
In general, chromosome arms that are most frequently altered are either fre-
quently gained or lost in each cancer type, with some notable exceptions (See for
eg: chromosome 13q in gastrointestinal tumors). Nevertheless, the frequencies of
these gains and losses vary by tissue of origin and result in varying arm imbal-
ance scores across cancer types. Among the frequently altered chromosome arms,
we see that chromosome arms 13q, 18q, 10q and 2p have the strongest correla-
tions between their normal tissue specific mean expression levels and arm imbalance
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scores, and these correlations are positive. When looking at each tissue individually
(columns of Figure 4.1 panel B), we see the strongest correlations between the nor-
mal chromosome-wide mean expression levels and arm imbalance scores for brain,
colon and kidney tissues and these correlations are also positive. Although the sta-
tistical power to assess the significance of these individual correlations is limited, we
see that a majority of correlations (both at tissue and arm level) are positive. We
evaluate the overall probability of getting so many positive correlations (both at the
arm and tissue level), using a permutation test. To this end, we repeat 1000 times
of randomly shuffling the chromosomal arm assignments (rows of Figure 4.1 panel
B) and another 1000 for the tissue assignments (columns of Figure 4.1 panel B). We
find that similar or higher correlations were found for the shuffled data in less that
5% of the cases, yielding a permutation P < 0.05 for both arm-wise and tissue-wise
correlations. We additionally repeated this analysis for early stage tumors from
the TCGA database (defined as tumors with AJCC stage classification of 0 or 1).
Although the number of tumors available for analysis was further reduced, a similar
trend of weak, but predominantly positive correlations was observed.
If certain chromosome arm aneuploidies might “hard-wire” the chromosome
arm wide gene expression levels specific to their normal tissues, this suggests that
one should be able to classify tissue of origin of normal and cancer tissue samples
just based on the mean chromosome arm-wide gene expression levels of each of the
39 arms. To test this hypothesis, we obtained the mean gene expression levels for
each arm in each normal tissue sample in GTEx (and likewise for each cancer sam-













































































































































































































































































































































































Figure 4.1: Correlations of chromosome arm-wide gene expression levels and chromo-
some arm-wide aneuploidies (A) Spearmn correlation plot of chromosome arm-wide gene
expression levels in cancers and patterns of chromosome arm-wide gains and losses in can-
cers reported in the TCGA database. Bar plot represent the spearman rank correlations
for each cancer type independently. The height of the bar reflects the correlation coeffi-
cient, and the size of the circle the significance. Size of 2 indicates p-value < 0.01, size
of 1 indicates p-value < 0.1 and size of 0 indicates p-value < 1. (B) Spearmn correlation
of chromosome arm-wide gene expression levels based on the GTEx database (left col-
umn) with chromosome arm wide aneuploidies in associated cancer types based on data
reported in the TCGA database (right column), respectively, for 19 tissue entities. The
arm imbalance score is reflected in colors: Red indicates more frequent gains compared to
losses; blue indicates more frequent losses compared to gains. The hue of the colors indi-
cates the frequency of copy number changes and the quantile normalized levels of mean
chromosome arm-wide gene expression, respectively. Barplots shown beside each heatmap
are the spearman rank correlations (horizontal bars indicate comparisons for each arm
independently, vertical bars indicate comparisons for each tissue independently). A size
of 2 indicates p-value < 0.01, a size of 1 indicates p-value < 0.1 and size of 0 indicates
p-values < 1.
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multi-class classification was applied with leave-one-out cross validation. We find
that mean chromosome arm-wide gene expression can effectively classify the tissue of
origin of both normal and cancer samples from GTEx and TCGA, respectively, and
that the performance is generally better for normal tissues (Figure 4.2 panel A). The
resulting accuracy was better for tissues with higher case numbers, as expected for
KNN analyses. Furthermore, these results could never be obtained when the chro-
mosome assignment of genes was randomly shuffled (by repeating 1000 shuffling of
the chromosomal assignments of genes, empirical P-value < 0.001). A five-fold cross
validation analysis yielded similar results. To visualize these classifications, we used
t-distributed Stochastic Neighbor Embedding (t-SNE) dimensionality reduction of
the 39 dimensional feature space. We found that samples from the same normal
tissues cluster closely in most cases (Figure 4.2 panel B), but to a lesser extent,
for cancer entities (Figure 4.2 panel C). The separate sub-clusters within each tis-
sue correspond to the different anatomical regions of the tissues that were sampled
from GTEx. Overall, these results suggest that certain chromosomal aneuploidies
acquired by tumors might hardwire expected tissue-specific gene expression levels






































































































































































































































































































































































Figure 4.2: (A) K-Nearest-Neighbors (KNN) multi-class analysis: predictions made
in a leave one out fashion (i.e., the accuracy). Height of bars indicate the fraction of
correctly predicted cases. The numbers on top of each bar indicate the number of samples
available for each class. (B,C) t-Distributed Stochastic Neighbor Embedding (t-SNE)
dimensionality reduction analysis of chromosome arm-wide mean gene expression levels in
normal tissues (B) and in cancers (C).
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4.3.2 Chromosome arm imbalance scores of cancer types and the dis-
tribution of cancer type-specific driver genes over chromosome
arms
Recent studies have looked at the connection between specific chromosomal
gains and losses and driver genes located on these chromosomes for specific cancer
types [55, 243]. In this study, we revisit this connection. For each tissue analyzed
in this study, the correlation between the frequency of losses in associated cancer
types and the fraction of drivers that are tumor suppressors is consistently strong
and positive (Figure 4.3 panel A, permutation test with 1000 random shuffling of
arms and tissue pairing of the values in Figure 4.3 panel A, p-value < 0.05) The
strongest of these correlations are observed for chromosome arms 17p, 17q and 9p.
The direction of correlation between gains of chromosome arms and the location of
tissue specific oncogenes is however less clear (Figure 4.3 panel B, empirical p-value
after 1000 iterations of random shuffling is > 0.05, Supplementary Table 5). To
explore this further, we performed four hierarchical clustering analyses of tissues
based on i) chromosomal arm imbalance scores in associated cancer-types (Figure
4.4 panel A), (ii) mean chromosome arm-wide gene expression levels in associated
cancer types (Figure 4.4 panel B), (iii) mean chromosome arm-wide gene expression
levels in normal tissue (Figure 4.4 panel C), and (iv) chromosome arm-wide imbal-
ance in the fraction of oncogenes and tumor suppressor genes originating from each
tissue (Figure 4.4 panel D). For ease of visualization, the tissues are partitioned
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and coloured by 4 distinct clusters obtained from each hierarchical clustering sep-
arately. We find that the hierarchical clustering of tissues based on chromosomal
arm imbalance scores (Figure 4.4 panel A) and the hierarchical clustering based
on mean chromosome arm-wide normal gene expression levels (Figure 4.4 panel C)
are highly similar (spearman correlation of cophenetic distances = 0.61, p-value
< 2.2E-16). Likewise, a strong similarity is observed between hierarchical cluster-
ing of tissues based on arm imbalance scores (Figure 4.4 panel A) and hierarchical
clustering based on cancer gene expression levels (Figure 4.4 panel B) (spearman
correlation of cophenetic distances = 0.52, p-value = 1.57E-13). However, such a
similarity is not observed when looking at the arm imbalance scores (Figure 4.4
panel A) and distribution of tissue specific oncogenes and tumor suppressor genes
across arms (Figure 4.4 panel D) is (spearman correlation of cophenetic distances
= -0.09, p-value = 0.2067). While the list of tissue specific cancer driver genes is
still incomplete, these results suggest that copy number changes in resident driver
genes may not be sufficient to explain the observed tissue-specificity of chromosomal
aneuploidies in cancers.
4.3.3 Chromosome arm-wide methylation levels in normal tissues
A possible mechanism regulating chromosome-wide gene expression levels in
normal tissues is DNA methylation. Therefore, in a fashion similar to Figure 1B, we
explored whether mean chromosome arm-wide methylation levels correlate with the


































































































































































































































































































Figure 4.3: (Continued on the following page.)
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Figure 4.3: For each set of cancer types with shared tissue of origin, we plot: A) The
fraction of driver genes on each arm that are considered to be tumor suppressors (left
column) and the frequency of losses reported for the arm. The bluer the color, the higher
the tumor suppressor burden (and likewise for the frequency of losses). B) The fraction
of driver genes on each arm that are considered to be oncogenes (left column) and the
frequency of gains reported for the arm (right column). The redder the color, the higher
the oncogenic burden (and likewise for frequency of gains). Barplots shown beside each
heatmap are the spearman rank correlations (horizontal bars indicate coomparisons for
each arm independently, vertical bars indicate comparisons for each tissue independently).
The size of bubbles indicates the p-value. A size of 2 indicates p-value < 0.01, a size of 1
indicates p-value < 0.1 and size of 0 indicates p-values < 1. As seen at the tissue level,
correlation between tumor suppressor burden and frequency of losses is almost always
positive (permutation test p-value after randomly shuffling data < 0.05), whereas that is
not the case for gains.
(GEO) database provides genome-wide methylation levels for 11 different tissue
types, all obtained using the same Illumina 450K platform. Based on these data,
we analyzed chromosome arm-wide mean methylation patterns for 11 tissues from
765 samples (Materials and Methods, Supplementary Table 5). For each tissue, we
observe that differences in mean methylation levels across chromosomal arms within
a tissue are consistently negatively correlated with corresponding mean arm-wide
gene expression levels (permutation test with 1000 random shuffling of arms and
tissue pairing of the values, p-value < 0.05) (Figure 4.5 panel A). However, for a
single arm across tissues, the directionality of correlations are less consistent. This
could potentially be due to the small number of tissues analysed. Furthermore, an
individual sample-level classification analysis using the KNN algorithm reveals that
one can predict (in leave one out cross-validation) the normal tissue of origin of in-
dividual samples just based on chromosome arm-wide mean methylation levels. The
clustering of samples by tissue is visualized using t-SNE dimensionality reduction.
(Figure 4.5 panels B and C). Tissues with very few samples had poor classification
accuracy as expected from KNN. These results suggest that normal chromosome
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Figure 4.4: (A) cancer chromosome arm-wide gains and losses, (B) cancer mean chro-
mosome arm-wide gene expression, (C) mean chromosome arm-wide gene expression of
normal tissues, and (D) chromosome arm-wide imbalance of tumor suppressor genes and
oncogenes. Note that the clusters are similar in A-C, yet different in D.
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arm-wide methylation levels may play some part in regulating the transcriptional
output of each chromosome arm.
4.4 Discussion
Chromosomal aneuploidies are a defining feature of tumors of epithelial ori-
gin. These aneuploidies result in tumor type specific genomic imbalances [116, 93,
187, 21, 22]. As of yet, there is no sufficient explanation for this specificity [21].
In this work, we systematically compared the frequencies of chromosome arm gains
and losses in different cancer types to the mean chromosome arm wide gene ex-
pression leves in normal tissues of origin and distribution of known or implicated
tissue-specific oncogenes/tumor suppressors across chromosome arms. Our analysis
reveals a complex picture of factors driving frequent chromosome arm alterations in
specific cancer types. Specifically, we notice recurrent losses in chromosome arms
in cancer types where tissue-specific tumor suppressors reside, suggesting that these
losses broadly target these driver genes. However, the targets of recurrent tissue-
specific chromosomal gains are less clear. While it is possible that these chromosomal
gains are targeting yet unidentified oncogenes, our analysis of normal chromosome
wide gene expression and methylation data suggests an alternative paradigm in
which these alterations instead aim to hardwire expected gene expression levels of
normal tissue origin. This notion is further supported by recent observations across
multiple cancer types where oncogenes were found to be preferentially activated via











































































































































































































































































































Figure 4.5: (Continued on next page.
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Figure 4.5: (A) For each tissue with available normal methylation data, we plot the
mean arm-wide methylation levels of each arm (left column) and the mean arm-wide
expression levels of each arm (right column). The mean expression and methylation values
are quantile normalized to the same scale (See Methods) for comparison and visualization.
For left column: The redder the color, the higher the arm-wide methylation level, the
bluer the color the lower, the lower the arm-wide methylation level . For right column:
the redder the color, the higher the arm-wide expression level, the bluer the color the
lower the arm-wide expression levels. Bar plots besides the heatmap are spearman rank
correlations (horizontal bars indicate comparison for each arm independently, vertical bars
indicate comparison for each tissue independently). The size of bubbles indicates the p-
value. A size of 2 indicates p-value < 0.01, a size of 1 indicates p-value < 0.1 and size
of 0 indicates p-values < 1. As seen at the tissue level, correlation between arm-wide
methylation levels and expression levels is consistently negative (permutation test p-value
after random shuffling the data < 0.05). (B) Leave One Out Cross-Validation Accuracy of
predicting each tissue entity based on chromosome wide mean methylation levels of each
sample. The height of the bar indicates the accuracy quantified as fraction of samples
correctly classified. The numbers on top of each bar indicate the number of samples
from a given tissue. (C) tSNE plot depicting the clustering of different tissue samples by
chromosome arm wide mean methylation levels.
affected by these alterations remain incompletely understood. We previously showed
experimentally that the gain of chromosome 13 in colorectal cancer activates both
Notch and Wnt signaling [36], and that the acquisition of extra copies of chromosome
7 in normal colon cells results in upregulation of cancer-associated pathways [29],
which could imply that tissue-type specific chromosome arm-wide gene expression
levels promote cellular fitness. Of note, Sack et al. [200] have demonstrated that
the inclusion of tissue-specific growth promoting genes strengthens the correlation
between chromosome arm loss/gain ratios and the proliferation-driving capability
of each chromosome-arm in breast and pancreatic cancers. Graham and colleagues
reported a general role of copy number alterations and metabolic selection pressure
[81]. Despite the ubiquitous presence of chromosomal aneuploidies in most solid tu-
mors, there are also several publications pointing to a reduction of cellular fitness as
a consequence of general aneuploidy in model systems such as yeast, immortalized
murine embryonic fibroblasts and typically near-diploid cancer cells engineered to
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harbor specific trisomies [82, 244, 209], so the functional implications of these events
remains an open challenging question.
There are some limitations specific to the data analysis conducted in this study.
Firstly, our analyses comparing cancer types to normal tissues were restricted to tis-
sues where data was measured in a homogeneous fashion on the same platform and
publicly available (i.e., GTEx for gene expression and GEO for methylation). Fur-
thermore we restricted ourselves to external data sources for normal tissue expression
and methylation rather than use adjacent normal tissue samples from the TCGA.
This was mainly due to incomplete availability of methylation and expression of
normal adjacent to tumor samples for many cancer types and the presence of stro-
mal and immune cell contamination in these tissues [9, 98]. Secondly, identification
of existing and potentially new cancer type specific oncogenes and tumor suppres-
sors was previously done by combining evidence from multi-omic sources into one
prediction score using supervised machine learning [15]. However, this list is still
incomplete and the mechanism of action of many of these genes in different can-
cer types is not completely understood. Thirdly, since we are exploring correlation
patterns across different tissue and cancer types, it is likely that more significant
associations would be observed in arms with specific, high-intensity trends of either
gain or loss compared to arms that are less frequently altered. In sum, our data
analysis suggests that chromosome aneuploidies could be potentially involved in the
maintenance of gene expression levels characteristic of the normal tissue of origin of
cancers, in addition to targeting cancer type specific driver genes (Figure 4.6).
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Figure 4.6: Genes on the red chromosomes are on average, expressed at slightly higher
levels compared to other chromosomes in normal tissue A, whereas in normal tissue B,
the yellow chromosomes shows increased tissue-specific expression on average and genes
on the green chromosome are expressed at lower levels on average. The acquisition of
chromosomal aneuploidies in the respective cancer-types (gain of the red chromosome in
cancer-type A and the yellow chromosome in cancer-type B, accompanied by the loss of
the green chromosome in cancer-type B amplifies this effect and provides the genetic basis
of “hard-wiring” tissue-specific chromosome arm-wide gene expression levels. The dots
on the green chromosome reflects the presence of a tumor suppressor gene, which can be
targeted by the loss of the green chromosome in tumor evolution.
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Chapter 5
Algorithms for dissecting cellular heterogeneity in the TME (Tumor
Micro Environment)
?? This work was done in collaboration with Dr. Kun Wang. A bioarxiv
pre-print is available [240].
5.1 Overview
The importance of the tumor microenvironment (TME) in cancer has been
recognized since the late 1800s [169]. The recent success of immune checkpoint
blockade has further sparked interest in studying TME interactions that shape clin-
ical outcomes following immunotherapy, aiming to find biomarkers of treatment
response and new treatment opportunities [216]. One key step in studying these
interactions is the characterization of the molecular profiles of different cell types
in a patient’s tumor sample. Fluorescence-activated cell sorting (FACS) and single-
cell RNA sequencing have emerged as effective tools to address this challenge [238].
However, due to the cost of these procedures and scarcity of fresh tumor biopsies,
the application of these approaches has remained limited. Given that bulk tumor
gene expression from preserved biopsies is far more abundant, computational meth-
ods that can effectively extract cell-type-specific expression from such data, termed
deconvolution algorithms, could be very helpful. If successful, such deconvolution
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methods can markedly advance our knowledge of the TME across many tumor types
and different contexts, and beyond that, they may be readily applied to interrogate
other large bulk expression datasets.
Several previous studies have developed a variety of expression deconvolution
algorithms. DeMixT [3] was designed to estimate individual-specific expression for
three cell components provided prior reference samples of two of these cell com-
ponents. ISOpure [181] has aimed to derive sample-specific cancer cell expression
with the assumption that the observed bulk gene expression profile is a mixture of
predefined stromal and immune cell expression profiles that are shared across all the
samples. Building on this work, Fox et al extended ISOpure to predict individual-
specific non-tumor cell expression by subtracting cancer cell profiles from the bulk
mixtures in a two-cell type model [65]. More recently, Newman et al[163] developed
CIBERSORTx, the first approach that aims to predict the sample-specific gene ex-
pression of all cell types composing it by employing a set of novel deconvolution
heuristics. As a proof of concept, Newman et al showed that CIBERSORTx can
accurately reconstruct the cell-type-specific expression of genes in each input sample
under certain modelling assumptions. This groundbreaking work has, however, some
notable limitations: (1) The number of genes whose cell-type-specific expression can
be reconstructed in each sample is relatively small, especially for low-abundance cell
types, and (2) their approach does not provide confidence estimations of the predic-
tions made, while such estimations could be potentially useful in most deconvolution
applications in the absence of ground truth data.
Here, we introduce a new deconvolution algorithm and software, CODEFACS
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(COnfident DEconvolution For All Cell Subsets), which markedly advances the abil-
ity to successfully deconvolve bulk gene expression data. CODEFACS receives as
input bulk gene expression profiles of tumor samples and either pre-computed esti-
mates of abundance of expected tumor, immunological and stromal cell types in each
sample, or their prototypical molecular signatures, which serve as seeds for estimat-
ing the abundance of each cell type in each sample. CODEFACS then predicts the
cell type-specific gene expression profiles of each sample. It is a heuristic approach
aimed at maximizing the number of genes in each cell type whose expression across
the samples can be confidently predicted via a heuristic method to estimate con-
fidence. Using 15 benchmark datasets where the ground-truth is known, we show
that CODEFACS robustly improves over CIBERSORTx, both in terms of gene
coverage and the individual gene expression estimation accuracy. We additionally
developed LIRICS (LIgand Receptor Interactions between Cell Subsets), a pipeline
that integrates the output of CODEFACS with a database of prior immunological
knowledge that we curated to infer the active cell-cell interaction landscape in each
sample. These data can then be analyzed in conjunction with any sample-associated
clinical annotations (e.g., response to treatment) to infer the most important clini-
cally relevant immune interactions between the cell types in a given patient’s cancer
cohort.
Building on its enhanced coverage and accuracy, we next applied CODEFACS
to reconstruct the cell-type-specific transcriptomes of 8000 tumor samples from 21
cancer types in TCGA. Analyzing these fully deconvolved TCGA expression datasets
using LIRICS we find a shared repertoire of intercellular interactions enriched in the
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TME of mismatch repair deficient tumors of different tissues of origin, which is as-
sociated with improved overall patient survival and high response rates to anti-PD1
treatment, independently of their mutation burden levels. Finally, using machine
learning techniques, we identify a subset of intercellular TME interactions that are
predictive of response to immune checkpoint blockade treatment in melanoma pa-
tients.
In summary, CODEFACS and LIRICS present a new way to analyze large bulk
RNA-seq datasets to study cellular crosstalk in the TME of each patient, and to learn
more about the association of different tumor-immune interactions with different
clinical measures. The potential scope of applications of both CODEFACS and
LIRICS goes beyond studying the TME, as these tools can be applied to study any
disease of interest given bulk gene expression data and relevant reference signatures
of cell types involved.
5.2 Methods
5.2.1 Data curation
5.2.1.1 Single cell RNA-seq datasets
To benchmark the performance of CODEFACS, we first set out to obtain
publicly available single cell RNA-seq datasets where both tumor and non-tumor
cells were successfully isolated. This search led us to the identification of nine such
single cell RNA-seq datasets from the literature, each from a different cancer type.
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Collection of additional single cell datasets was frozen after Dec 2019. For each
dataset sequenced on the SmartSeq2 platform, the log normalized transcript counts
for each gene in each sequenced cell were made publicly available by the original
authors. For the application of deconvolution, these counts were transformed back
to the Transcripts Per Million (TPM) scale. For datasets sequenced on the 10x
platform, UMI counts for each gene were made publicly available and were scaled
by the library size of each cell and multiplied by a factor of 1 million to get expression
values in TPM scale. See Table 5.1
Table 5.1: Single cell RNASeq datsets collected and analyzed in this study





GSE115978 Melanoma SmartSeq2 32
GSE131928 GBM SmartSeq2 28
GSE103322 HNSCC SmartSeq2 18
CRA001160 PDAC 10x 35
GSE125449 LIHC SmartSeq2 12
GSE81861 CRC SmartSeq2 11
E-MTAB-6149 LUAD 10x 3
E-MTAB-6149 LUSC 10x 2
GSE118389 TNBC SmartSeq2 6
5.2.1.2 Bulk RNA-seq datasets
Gene expression and matching bulk tumor methylation data from fresh frozen
tumor biopsies in TCGA were downloaded from [77]. In addition, publicly avail-
able bulk expression data from formalin fixed paraffin embedded tumor biopsies
of melanoma patients receiving immune checkpoint blockade treatment were down-
loaded from [185, 75, 131]. All bulk RNA-seq datasets were collected such that they
102
have a sufficiently large sample size to reliably perform complete deconvolution of
expression profiles (¿ 4 times the number of cell-types involved) [163]. Collection
of datasets was frozen after Dec 2019. To maintain consistency with the pipeline
used for preprocessing TCGA data, bulk gene expression levels in immune check-
point blockade datasets were re-quantified using STAR v2.7.6a and RSEM v1.3.3
[30] with GENCODE v23 human genome annotation [91]. Furthermore, to mitigate
technical biases, between-sample scaling factors were estimated using TMM method
implemented in edgeR [195] and TPM values in each sample were further rescaled
by these scaling factors [196].
103
Table 5.2: bulk RNASeq datasets collected and analyzed in this study




21 distinct cancer types





Riaz et al, Cell,
2017 [185]
109 samples from 73
patients, 51 patients
had pre-treatment sam-




Gide et al, Can-
cer Cell 2019 [75]
91 samples from 75





Liu et al, Nature
Medicine 2019
[131]







5.2.1.3 Generation of simulated bulk RNA-seq datasets
To evaluate the performance of CODEFACS, we generated 14 different pseudo-
bulk RNA-seq datasets from mixing experiments with single cell data. Each sample
in each benchmark dataset has matching cell type specific gene expression profiles
derived from averaging single cell RNA-seq profiles of individual cells from the same
sample and same cell type. These profiles serve as the ground truth for the eval-
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uation of deconvolution performance. To avoid any circularity in our validations,
for each of the single cell datasets involved, single cell data from 4 randomly chosen
patients were separated from the rest. These data were used to derive reference
gene expression signatures for each cell type. The mixing experiments were then
performed on single cell data of the remaining patients that were hidden from the
reference signature derivation process. In addition, we simulated technical replicates
for each pseudo-bulk sample, wherein we injected noise in the pseudo-bulk expres-
sion of a few randomly chosen genes and then renormalized the expression data by
the sample library size. This procedure simulates mRNA composition noise that is
commonly observed in bulk RNA-seq datasets due to technical differences in sample
preparation [203, 64, 227, 194]. In addition, we obtained a FACS sorted lung can-
cer dataset which include purified RNA-seq for four cell types 10 and generated a
pseudo bulk correspondingly [72]. In total, 15 benchmark datasets were generated.
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Table 5.3: List of 14 artificially generated bulk expression datasets with matched cell-
type specific expression measurements for each sample (Used for performance evaluation




SKCM dataset 1 28 pseudo bulk melanoma samples generated by averaging
single cell RNASeq expression profiles (GSE115978) from
the same patient
SKCM dataset 2 28 pseudo bulk melanoma samples generated by aver-
aging imputed single cell RNASeq expression profiles
(GSE115978) from the same patient. Imputation of single
cell RNASeq data was performed using scImpute v0.0.9
SKCM dataset 3 First noisy technical replicate of SKCM dataset 2 generated
by injecting noise in each of the 28 mixes
SKCM dataset 4 Second noisy technical replicate of SKCM dataset 2 gener-
ated by injecting noise in each of the 28 mixes
SKCM dataset 5 100 pseudo bulk melanoma samples generated by sampling
single cell RNASeq expression profiles (GSE115978) from
different patients in varying cell type specific proportions
and averaging them.
SKCM dataset 6 First noisy technical replicate of SKCM dataset 5 generated
by injecting noise in each of the 100 mixes
SKCM dataset 7 Second noisy technical replicate of SKCM dataset 5 gener-
ated by injecting noise in each of the 100 mixes
GBM dataset 1 24 pseudo bulk GBM samples generated by averaging sin-
gle cell RNASeq expression profiles (GSE131928) from the
same patient
GBM dataset 2 24 pseudo bulk GBM samples generated by averaging im-
puted single cell RNASeq expression profiles (GSE131928)
from the same patient. Imputation of single cell RNASeq
data was performed using scImpute v0.0.9
GBM dataset 3 First noisy technical replicate of GBM dataset 2 generated
by injecting noise in each of the 24 mixes
GBM dataset 4 Second noisy technical replicate of GBM dataset 2 gener-
ated by injecting noise in each of the 24 mixes
GBM dataset 5 100 pseudo bulk GBM samples generated by sampling sin-
gle cell RNASeq expression profiles (GSE131928) from dif-
ferent patients in varying cell type specific proportions and
averaging them.
GBM dataset 6 First noisy technical replicate of GBM dataset 5 generated
by injecting noise in each of the 100 mixes
GBM dataset 7 Second noisy technical replicate of GBM dataset 5 gener-
ated by injecting noise in each of the 100 mixes
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5.2.1.4 Curation of reference signatures of cell types
For the application of CODEFACS, molecular profiles of signature genes of
each cell type of interest are needed to estimate the relative cell fractions in the
bulk. We used single cell expression derived signatures as priors to deconvolve the
melanoma ICB datasets. To derive these signatures from single cell data, we first
start out by obtaining the class labels of each cell type of interest. These data
are publicly available for each single cell dataset we collected. Hence, we primarily
use these labels in our study (unless further refinement of labels into specific cell
subtypes of interest is needed for a specific usage). With a collection of single cell
expression profiles and matching cell type labels as input, we used CIBERSORT
online tool to derive a cell-type-specific signature matrix. Thereafter, we applied
CODEFACS to ICB datasets with default parameters settings and batch correction
requirement specified. For TCGA deconvolution, we first estimated cell fractions
based on bulk methylation and then applied CODEFACS to corresponding bulk gene
expression for the 21 cancer types which have both types of data available. We chose
methylation signatures over expression-based signatures for TCGA analysis for two
reasons. First, single cell expression data with consistent cell types across 21 cancer
types are not available. Second, DNA methylation-based signatures are considered
to be more stable marks of cellular identity compared to dynamic RNA expression
derived signatures [24]. The methylation-based cell type signatures were obtained
from MethylCIBERSORT [39]. We applied CODEFACS to TCGA datasets with
default parameters settings and without batch correction requirement specified.
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Table 5.4: list of all cell types with reference methylation signatures available from
MethylCIBERSORT











cancer cell types with methylation
signatures









head and neck TCGA-HNSC
prostate TCGA-PRAD
liver TCGA-LIHC
lung NSCLC adenocarcinoma TCGA-LUAD






acute myeloid leukaemia TCGA-AML
B cell lymphoma TCGA-DLBC
5.2.2 Full in-silico deconvolution of bulk mixtures
CODEFACS is designed to do the following:
Input. (i) Bulk gene expression of a collection of samples (required) (ii) Cell fraction
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estimates of expected tumor, immune and stromal cell types in each sample; OR
Cell-type-specific signature profile (required if cell fractions are not provided)
Goal. (i) Predict the expression of each gene in each sample in each cell type in
the mixture (ii) Estimate confidence scores [0-1] for each gene-cell-type pair, which
denote the confidence level in the predicted expression of a gene in a cell type across
samples (≈1 High confidence, ≈0 Low confidence)
In this section, we provide a formal description of the computational prob-





∥∥(Bi,. − diag(Gi,.,. × F T )∥∥
s. t.
∑c
k=1 fjk = 1 ∀j
gijk ≥ 0 ∀i, j, k
fjk ≥ 0 ∀j, k (1)
where B represents the given bulk RNA-seq expression matrix (m genes × n
samples), in which each entry bij is the observed bulk expression for i
th gene and jth
sample; G is a three-dimensional deconvolved gene expression matrix (m genes × n
samples× c cell types), in which gijk denotes the unknown expression for gene i in the
jth sample and kth cell type; F is the cell fraction matrix (n samples × c cell types),
in which fjk denotes the unknown cell fraction of k
th cell type in jth sample. F
varies across samples and cell types but is constant across genes. ‖.‖, represents the
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L2-norm (which measures the reconstruction error) and diag() represents a function
that gives a vector by extracting the diagonal entries of a matrix. The objective is
to find an optimal solution for G and F with the constraint that the cell fractions (of
c cell types) in any sample j sum up to 1 and all the gene expression values gijk are
non-negative real values. In this study, we assume the gene expression is quantified
as TMM normalized TPM values. More specially, we employed a strategy introduced
by Monaco et al. [155], which first estimates between-sample scaling factors upon
raw TPM values using TMM method [196] and further scale TPM values in each
sample using these scaling factors.
Problem (1) has no unique optimal solution without additional constraints and
regularizations since there are more parameters to be estimated than observations
[181, 163]. However, problem (1) can be separated into two independent problems:
cell fraction estimation and cell-type-specific gene expression prediction for each




∥∥B′i,. − (Si,. × F T )∥∥
s. t.
∑c
k=1 fjk = 1 ∀j
fjk ≥ 0 ∀j, k (2)
Where S denotes the cell-type-specific signature matrix (l genes x c cell types)
and the l genes are a subset of all the m genes in G or B matrix that are pref-
erentially over-expressed in at least one of the c cell types and their expression is
assumed to be constant across the population to arrive at an approximate solu-
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tion of cell fractions in each sample. F is the same as that in equation (1), while
B′ is a submatrix of the bulk expression matrix B in equation (1) correspond-
ing to the l genes in cell-type-specific signature matrix S. Numerous effective cell
fraction estimation tools have been developed and reported to solve problem (2)
[211, 69, 179, 257, 79, 2, 162, 241, 166, 129, 154, 16, 175, 61, 104, 8, 255]. The ex-
perimental analog to these methods is the cell gating procedure described in FACS.
We solve this problem using a well-known reference-based approach: CIBERSORT
[162]. If needed, CODEFACS also provides a batch correction approach introduced
by CIBERSORTx that could be applied to minimize cross-platform technical batch
effects between bulk mixture profile and cell type signature profile generated from
different technical platforms (e.g. bulk RNA sequencing, SmartSeq2-based single
cell sequencing, 10x-based single cell sequencing and microarray expression profil-
ing) [163]. In addition, we provide the option to input prior known cell fractions
instead of performing cell-fraction estimation de novo. Either known cell fractions
or cell type signature profiles are required as input. Newman et al. [162, 163] found
that cell fractions determined by the CIBERSORT algorithm, which we reimplement
in CODEFACS, mostly exhibit strong concordance with ground truth.
Once F is estimated or provided, the full deconvolution problem formulated
in (1) can be reduced to solving for G, given B and F . One can additionally reduce
problem (1) to a simpler problem where one solves for the expected cell-type-specific
expression for a specific gene across a group of individual samples, given the cell





∥∥Bi,. − (Ēi,. × F T )∥∥
s. t. ēik = 1 ∀i, k (3)
where B is the same as in equation (1) and represents the input bulk expression
matrix; F is also the same as that in equation (1) and denotes cell fractions; Ē is
the expected cell-type-specific expression matrix (m genes × c cell types) across
the population, in which ēik denotes the expected expression of gene i in cell type
k. For a fixed F , a unique optimal solution for this problem exists and can be
found using non-negative least squares (NNLS) [163, 32, 168]. The key difference
between problem (3) and problem (1) is that the former aims to predict expected
cell-type-specific expression for each gene in the population, while the latter predicts
the expected cell-type-specific expression for each gene in each sample.
One can aim to solve problem (1) approximately by making use of a greedy
divide and conquer strategy that breaks down problem (1) into simpler problems
(2) and (3). Newman et al, in their groundbreaking work CIBERSORTx, were
the first to propose such an algorithm. In CODEFACS, we introduce the concept
of confidence scores and additional algorithmic improvements to extend this ap-
proach. We show that CODEFACS yields a much more accurate solution compared
to CIBERSORTx in 15 benchmark datasets with ground truth data.
The CODEFACS algorithm consists of three modules that are executed se-
quentially and a confidence ranking system that is invoked after the execution of
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each module. In module 1 we refined and extended the high-resolution deconvolu-
tion module introduced by CIBERSORTx. First, we generalized their two-freedom
estimation method into a recursive splitting method, which we call ”p-freedom esti-
mation” (The degrees of freedom represent the distinct latent sources of variability
in gene expression across individuals). We found that p-freedom estimation could
capture tumor heterogeneity better than the 2-freedom estimation. Second, we gen-
eralized their sliding window method by employing an ensemble of window sizes.
Using an ensemble of window sizes seeks to reduce the dependence of downstream
biological analyses on arbitrary choices of the window size parameter. In addition,
we developed modules 2 and 3 (hierarchical deconvolution and imputation-based
deconvolution) to further increase the number of highly predictable genes. The con-
fidence ranking system uses a series of heuristics to decide where the solution can
be improved by subsequent modules. See Figure 5.7 for the schematic diagram with
the inputs and outputs.
5.2.3 The notion of confidence
Before we formally describe the algorithm, we introduce the concept of confi-
dence, which is a central part of the algorithm. Each of the three prediction modules
operates under specific modeling assumptions that are, in theory, uniformly applica-
ble to all genes. However, in practice, certain genes might violate these assumptions.
Therefore, for such genes, one cannot confidently say whether their predicted cell-
type specific expression levels closely reflect the ground truth. To quantify this
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uncertainty, we designed a confidence ranking system, which can decide whether
a specific prediction requires further refinement in subsequent modules by defining
a ranking Φ over genes for each cell type using confidence relevant features (more
details are provided in following subsections). Additionally, the confidence ranking
system also re-evaluates the confidence level of each final prediction (gene-cell type
pair) and provides in the end report a confidence score between 0 and 1.
5.2.4 The CODEFACS Algorithm
5.2.4.1 Cell fraction estimation (optional)
Cell type signatures are derived based on prior reference datasets using the
signature derivation module from CIBERSORTx. Thereafter, we implemented a
support vector machine (SVM)-regression-based method to predict cell fraction
given bulk expression/methylation and prior cell-type-signature profiles following
the CIBERSORT algorithm21. Given the bulk mixture and cell type signature pro-
file, the SVM regression model outputs predicted cell fraction for each cell type
and sample (Figure 5.1). If the user provides prior known cell fractions as input,
CODEFACS will skip this optional step.
5.2.4.2 Batch Correction to refine cell-fractions (optional)
To account for any systematic batch effects between bulk expression and in-
dependently generated cell-type-specific signature expression data, which could bias
cell-fraction estimates, we re-implemented the batch correction method introduced
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Figure 5.1: Given the bulk mixture matrix B (m genes × n samples) and cell type
signature profile S (l genes × c cell types), we use SVM regression to predict the cell
fraction matrix F (c cell types × n samples).
by CIBERSORTx [163]. The rationale for this method is that any batch effect be-
tween the given bulk expression and independently generated cell-type-specific sig-
nature expression must also be reflected in the reconstructed bulk expression S×F .
Thus, one can further refine cell-fraction estimates of each cell type in each sample
after reducing the batch effect between the given bulk matrix and reconstructed
bulk matrix S × F , using the function ComBat() from the SVA package [125] in R
(Figure 5.2). The final output of this step is a refined cell-fraction matrix. Currently
our implementation focuses on correcting biases among bulk RNA sequencing and
SmartSeq2-based single cell sequencing datasets. This step is optional and will be
skipped if the user does not specify that it should be done. For more details on
the batch correction procedure, please refer to section “Cross-platform normaliza-
tion schemes for deconvolution” in the supplementary information of CIBERSORTx
[163].
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Figure 5.2: Given initial estimates of cell fractions F (c cell types × n samples) and cell
type signature profile S (m genes × c cell types), one can reconstruct the bulk expression
matrix via the matrix multiplication S × F . Batch effects are then reduced between the
given bulk subset B′ and reconstructed bulk S × F .
5.2.4.3 Module 1 - High resolution deconvolution
In this module, the observed bulk expression of a gene in a sample is modeled
as the weighted sum of cell-type-specific expression of that gene from that sample
(See problem 1 above).
Determine cell types in which a specific gene is weakly expressed (Step
1.1): To determine if a gene i is weakly expressed in a cell type, we first conduct
the following statistical analysis: individuals are randomly chosen without replace-
ment to generate 100 random subsets of individual samples and then problem (3)
is solved to estimate expected cell-type-specific expression for each random subset.
This bootstrapping procedure generates a distribution of expected cell-type-specific
expression values ēik in the population. We then derive two p-values for each cell
type k: first, an empirical p-value that is estimated by checking the percentage of
solutions where ēik > 0, and second, a p-value derived from a parametric t-test. The
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two p-values are then combined using Fisher’s method28 to obtain a final p-value
for each cell type. If a gene is weakly expressed in a cell type (FDR > 0.2), we force
the cell fractions of that cell type in the corresponding mixture model to be 0 to
improve the deconvolution of gene expression in other cell types.
Recursively splitting samples into finite sub-groups (Step 1.2): With
an appropriate cell-type-mixture model defined for each gene, we now try to find
an approximate solution to problem (1). For a gene i, one can divide problem (1)
into a finite number of simpler problems by assuming that individuals with similar
bulk expression levels of gene i must have similar cell-type-specific expression levels
of gene i. Hence, we first sort all samples in increasing order according to the bulk
expression of gene i. In the two-freedom deconvolution in CIBERSORTx algorithm,
one can then find a position t to partition all the sorted samples into two sorted
subsets: h1 = 1, 2, . . . , t− 1 and h2 = t, t+ 1, . . . , n, such that the expected cell-
type-specific expression in each of the sub-sets (obtained from solving problem 3
using NNLS) best reconstructs the observed bulk expression (For more details, see
section “Cell type expression coefficients that best explain the bulk GEP” in the
supplementary information of CIBERSORTx [163]). Either of these two subsets
can now be recursively partitioned further into smaller subsets in a similar fashion
if the re-construction error keeps dropping and the subsets sample size stays above
1.9 times the number of cell types. This is referred to as p-freedom approach which
extends the two-freedom approach of CIBERSORTx (Figure 5.3). The recursive
splitting pseudo-code is shown below:
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Figure 5.3: Given the estimated cell fractions F (c cell types × n samples) and sorted
bulk expression of gene i, we check whether we have an adequate sample size for NNLS
first: if not, it will exit; if yes, two-freedom splitting will be performed. Subsequently,
we will check whether the two-freedom splitting improves the bulk reconstruction. If yes,
both the low-expressed and high-expressed groups will recursively enter another round of
two-freedom splitting; if no, the two-freedom splitting based predictions will be ignored
and the function exits.
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Algorithm 1 Recursive Splitting
Input:
F= cell fraction matrix
B = bulk expression matrix
size = the number of samples required for NNLS
i = gene index
st = start position in the sorted list of samples
ed = end position in the sorted list of samples
Ēi,. = expected cell-type-specific expression of gene i over all sorted samples in the
range st,. . . ,ed (Obtained from solving problem 3)
Output:
Gpi,.,. = cell-type-specific expression over samples (1, 2, . . . , n) from recursive
splitting deconvolution
1: procedure recursive splitting
2: if ed− st+ 1 < 2× size then





6: t ← 2-freedom index that splits sorted samples in the range st, . . . , ed,
into two subsets: st, . . . , st+ t and st+ t+ 1, . . . , ed (See CIBERSORTx algo-
rithm for more details)
7:
8: L̄i,. ← expected cell-type-specific expression of gene i over all sorted sam-
ples in the range st, . . . , st+ t (Obtained from solving problem 3)
9:
10: H̄i,. ← expected cell-type-specific expression of gene i over all sorted
samples in the range st+ t+ 1, . . . , ed (Obtained from solving problem 3)
11:
12: Err1 =
∥∥Bi,st,...,ed − (Ēi,. × F Tst,...,ed,.)∥∥
13: Err2 =
∥∥Bi,st,...,ed − [(L̄i,. × F Tst,...,st+t,.) , (H̄i,. × F Tst+t+1,...,ed,.)]∥∥
14: if Err2 < Err1 then
15: save L̄i,. and H̄i,. to G
p
i,.,.
16: call recursive splitting(F,B, size, i, st, st+ t, L̄i,.)
17: call recursive splitting(F,B, size, i, st+ 1 + 1, ed, H̄i,.)
18: exit
Ensemble sliding window deconvolution (Step 1.3): For gene i, a sliding
window is defined over the sorted list of samples with a specific window size s.
For each window of sorted samples, problem (3) is solved using NNLS to estimate
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the expected cell-type-specific expression across samples within that window. Cell-
type-specific expression for each individual is then approximated by redistributing
population-level estimates of cell-type-specific expression within each sliding win-
dow (This is again based on the assumption that subsets of individuals with very
similar bulk expression profiles have a shared cell-type-specific expression profile.
For more details on how this is done, please refer to the CIBERSORTx algorithm
[163]). Thereafter, the initial approximate predictions from the sliding window de-
convolution of window size s are refined using a linear-regression-based smoothing
procedure such that the distribution of expression values is statistically consistent
with population level estimates over each subset of patients from the p-freedom es-
timation step. This is based on the assumption that the estimated distribution of
cell-type-specific expression in each subset is robust to outliers.
Given that this solution is a function of the window size, which is an artificially
defined parameter, we suspect that a consensus solution obtained from averaging an
ensemble of solutions from different window sizes would be more robust and closer
to the ground truth. Hence, in our ensemble sliding window deconvolution, we set
up window sizes ranging from s1 =
1.5×number of cell types
0.8
× number of cell types to
st = max
(
4× number of cell types, sample size
2
)
and then perform the above sliding
window deconvolution for each of these window sizes. Given multiple solutions for
the cell-type-specific expression profile of each sample derived from multiple choices
of sliding-window sizes (s1 to st), their average is computed to obtain a single initial
approximate solution to problem (1) (we refer to this as ensemble of window sizes).
The above steps are repeated for the next gene until all the genes are done. Given
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a re-implementation of the CIBERSORTx sliding window algorithm (as function
sliding window()), the ensemble sliding window pseudo code is provided below:
Algorithm 2 Ensemble Sliding Window
Input:
F= cell fraction matrix
B = bulk expression matrix
n = number of samples
i = gene index
Gp = expected cell-type-specific expression distribution over samples obtained from
recursive splitting step
c = number of cell types
m = number of genes
Output:
Cell-type-specific (3-dimensional) expression matrix for all samples: G
1: procedure ensemble sliding window
2: s1 ← 1.9× c





4: G← Zeros(m× n× c)
5: for w = s1 to st do





5.2.4.4 Confidence ranking of predictions from module 1
We expect that genes that follow the modeling assumptions of module 1 are
more likely to have their cell-type-specific expression levels predicted confidently.
Hence, while executing module 1, we collect a series of features that could be use-
ful in determining confidence level of expression predictions for each gene-cell-type
pair. These are: p-value of t-test determining if a gene is weakly expressed in a
cell type (obtained from completion of step 1.1), ratio of mean predicted expression
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levels and p-value of differential expression between subsets of samples h1 and h2
(obtained from completion of steps 1.2 and 1.3), Spearman correlation between pre-
dicted cell-type-specific expression and bulk gene expression across samples, Spear-
man correlation between bulk expression and the cell fraction across samples, etc.
We then define a ranking Φ using this feature space such that genes achieving a high
rank are on average ranked highly by each feature as follows:
Φ(gene i, cell type k) =
∑
feature∈set rank(feature(gene i, cell type k)
|set|
where Φ(gene i, cell type k) represents the prediction rank of gene i in cell type
k, feature represents each feature we collected in the feature set, |set| represents the
number of features and feature(gene i, cell type k) denotes each feature of gene i
in cell type k. The values taken by each feature are arranged so that for features
representing p-values, lower the value higher the rank, but for features representing
Spearman correlations, higher the value higher the rank.
Additionally, it is well known that (the proteins encoded by) genes may interact
with each other and behave collaboratively as complexes [100]; also, gene regulation
is highly dependent on numerous regulatory elements including transcription factors
[124, 120]. When looking at single cell expression data from three independent
single cell datasets, we indeed find that expression profiles of 1000 randomly selected
genes within the same cell type are much more strongly correlated than expected by
random chance (Figure 5.4). Hence, we reason that genes with correlated expression
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Figure 5.4: (A-C) boxplots depicting the gene-gene expression correlation distributions
among cell types in SKCM dataset 1, GBM dataset 1 and LUAD dataset respectively
for 1000 randomly selected genes. In each of the three plots, corresponding random-
permutation-based background controls are provided. The yellow box represents the cor-
relation derived from the original datasets as the foreground (fg), while the green box
represents that derived from the randomly permuted background control (bg). The y-axis
denotes the Spearman correlation value and the x-axis denotes the cell type.
predictions for a given a cell type will have similar confidence levels. Therefore,
ranking Φ is updated to Φ1 by accounting for these correlations as follows:
Φ1(gene i, cell type k) = rankk(max Φ(gene j, cell type k) : j ∈ Q)
Here, Q represents the set of genes whose predicted expression in cell type k is
strongly correlated with the predicted expression of gene i in cell type k (Spearman
correlation ≥ 0.4).
For each cell type k, we define two disjoint but non-exhaustive subsets: Hk
and Lk, which we call the “high” and “low”-confidence sets of cell type k. Genes
belonging to the set Lk will be passed on to module 2. Let mk be the number of
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genes whose predicted expression distribution in the population is at least bimodal
(i.e., fold change in expression between the subsets h1 and h2 > 1). Genes are then
assigned to the high, low confidence set of each cell type by the confidence ranking
system using the following rule:
Add gene i to set:














The results of the assignment are stored in a confidence matrix C (m genes × c cell
types) encoding the high vs low confidence memberships of each gene in each cell
type.
Figure 5.5: Given the estimated cell fractions F (c cell types × n samples), bulk and
confidence levels estimated from module 1, for each cell type k we merge all the other
cell types as a pseudo component to construct a two-component model. Thereafter for
each low-confidence gene i in cell type k, we run module 1 to predict the expression in the
pseudo component and finally remove the estimated expression of the pseudo component
from the bulk to estimate the expression of the low-confidence gene i in cell type k.
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5.2.4.5 Module 2 - Hierarchical deconvolution for low-confidence genes
emerging from previous step
In this module, we simplify the general cell-type-mixture model described in
module 1 to a 2-component mixture model (Figure 5.5). Specifically, for a gene
i in the low-confidence set of cell type k, its observed bulk expression level in a
sample is modeled as a mixture of 2 components: the first component represents
the cell type k and the second component represents a pseudo-cell-type that is a
composite of all the cell types except kth cell type. We then re-run module 1 to
predict individual specific expression of gene i for the pseudo cell-type. Finally, the
prediction for the pseudo cell-type is subtracted from the bulk to approximately
re-estimate the individual specific expression of gene i in cell type k. This is based
on the assumption that the expression of the pseudo component might be better
predicted than the expression of cell type k using module 1, especially if cell type
k is not abundant or gene i is weakly expressed in cell type k. The above steps are
repeated for all the remaining genes in the low-confidence set of each cell type. The
hierarchical deconvolution pseudo code is provided below:
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Algorithm 3 Hierarchical Deconvolution
Input:
F= cell fraction matrix
B = bulk expression matrix
C = confidence level matrix (records low confidence genes in each cell type that
need to be re-evaluated by module 2)
G = predicted gene expression in each cell type and sample (Output of module 1)
c = number of cell types
m = number of genes
Output:
Updated predictions of gene expression in each cell type and sample in G
1: procedure hierarchical deconvolution
2: for k = 1 to c do
3: F ′′ ← [F [k, ], 1− F [k, ]]]
4: for i = 1 to m do
5: if C[i, k] = 0 then
6: Gpseudo ← High resolution deconvolution(B,F ′′, i)
7: G[i, , k]← B[i,]−F
′′[2,]×Gpseudo[i,,2]
F ′′[1,]
5.2.4.6 Confidence ranking of predictions emerging from module 2
Following module 2, we re-rank all genes in the low confidence set Lk of each
cell type by re-defining the ranking Φ2 as follows:
For gene i ∈ Lk,








Where ρ(gene i,gene j) represents the Spearman correlation between new pre-
dictions of gene i and old predictions of gene j, and |Hk| represents the number
of genes in high confidence set Hk. This is again based on observations of single
cell expression data described above from which we deduce that genes with similar
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confidence levels are expected to have correlated predictions (Figure 5.4). We now
describe how the confidence ranking system takes this new ranking of genes in the
low confidence set of each cell type and decides which genes need to be upgraded to
the high confidence set.
Let |Lk| be the number of genes in the low confidence set of cell type k, m
be the total number of genes and CFMk be the mean cell fraction of cell type
k. The confidence ranking system upgrades the membership of genes from the low
confidence set Lk to the high confidence set Hk using the following rule:
For gene i ∈ Lk










The results of the assignment are stored in the confidence matrix C (m genes × c
cell types) encoding the high vs low confidence memberships of each gene in each
cell type.
5.2.4.7 Module 3 – Imputation-based deconvolution for low-confidence
genes emerging from previous step
Module 3 operates on the assumption that the expression levels of two genes are
supposed to be correlated in some cell types if we observe that their bulk expression
is significantly correlated 16. For a gene i still in the low-confidence set of cell type
k, the Spearman correlations between the bulk expression profile of gene i and bulk
expression profiles of genes in the high confidence set of cell-type k are estimated.
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If the bulk expression profile of gene i is highly correlated (Spearman correlation
0.5) with the bulk expression profiles of more than two genes in the high-confidence
set of cell type k, then a lasso regression-based machine learning model is trained
using bulk expression to impute individual specific expression of gene i in cell type k
based on predicted expression profiles of high-confidence genes in cell type k (Figure
5.6). The above steps are repeated for all the remaining genes in the low-confidence
set of each cell type.
Figure 5.6: Given the predicted cell-type-specific expression G (m genes × n samples
× c cell types ), bulk and confidence levels estimated from module 1, in each cell type k
and for each low-confidence gene i, we compute the correlation between gene i and each
of other genes in bulk. If the number of genes which are highly correlated with gene i is
more than 2, we build up a machine learning model to predict the expression of gene i
in cell type k based on the expression of other high-confidence genes which are correlated
with gene i. After imputation, both the predicted expression matrix G and confidence
matrix C will be updated to record the final low/high confidence memberships of genes in
each cell type.
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Algorithm 4 Imputation Based Deconvolution
Input:
F= cell fraction matrix
B = bulk expression matrix
C = confidence level matrix (records low confidence genes in each cell type that
need to be re-evaluated by module 3)
G = predicted gene expression in each cell type and sample (Output of module 2)
c = number of cell types
Output:
Updated predictions of gene expression in each cell type and sample in G
1: procedure imputation based deconvolution
2: for k = 1 to c do
3: Hk ← gene j : C[j, k] = 1
4: Lk ← gene j : C[j, k] = 0
5: Confhigh ← all genes ∈ Hk
6: Conflow ← all genes ∈ Lk
7: Corrs← Spearman correlation matrix(B[Conflow, ], B[Confhigh, ])
8: F ′′ = [F [k, ], 1− F [k, ]]]
9: for each gene i ∈ Lk do
10: if
(∑
j∈Hk Corrs[i, j] ≥ 0.5
)
≥ 2 then
11: train imputation model: B[i, ] fimp (B[Confhigh, ])
12: impute G[i, , k]← fimp (G[Confhigh, , k])
5.2.4.8 Confidence ranking for predictions emerging from module 3
Following module 3, we collect the following confidence ranking features for
each gene i in the low confidence set of cell type k: the correlations of predicted
gene expression with bulk expression, the correlation between cell fractions and bulk
expression, number of genes as features in the imputation model, average Spearman
correlation between new predictions of gene i and predictions of genes in the high
confidence set of cell type k. We re-define a ranking Φ3 over all genes in the low
confidence set of each cell type using this feature space such that genes achieving
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a high rank are on average ranked highly by each feature. Genes that are ranked
among top 80% (an artificial cutoff) of all genes in the low confidence set of a cell
type k are now upgraded to the high confidence set of cell type k by the confidence
ranking system.
5.2.4.9 Final output – confidence scores and cell-type-specific gene
expression profiles of each sample
To transform high- vs low-confidence set memberships of genes in each cell
type (which were based on artificially defined rules/cut-offs for easy implementation
of the greedy algorithm), into scores that are continuous in the range [0, 1], the
following final steps were taken: (a) The pair-wise correlations between the predicted
expression profile of a gene i in cell type k and predicted expression profiles of genes
belonging to the high-confidence set of cell type k are averaged to generate a score for
gene i; (b) the cell-type-specific expression predictions across the samples (columns)
are randomly shuffled to generate a background and step (a) is repeated to estimate
a background distribution of scores for each gene; (c) for each gene and each cell
type, one can now determine an empirical p-value pv based on this background
distribution of scores. These p-values quantify the probability of a gene having
high confidence predictions by random chance if its predictions are correlated with
predictions of any other genes belonging to the high-confidence set of a cell type. The
p-values are low for genes that are part of the high confidence set and high for genes
part of low confidence set and intermediate for genes belonging to neither. Hence,
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we record 1− pv as the final confidence score for each gene-cell-type pair. The final
outputs of CODEFACS are the approximate solution for 3-dimensional matrix G
after execution of module 3 (imputation-based deconvolution) and confidence scores
for each gene-cell-type pair.
5.2.5 Inference of clinically relevant cellular crosstalk in the TME
In this section we describe the database of putative ligand receptor interac-
tions between various immune cell types: LIRICS (LIgand Receptor Interactions
between Cell Subsets) and its application to discover clinically relevant cellular im-
mune crosstalk.
5.2.5.1 Curation of established ligand-receptor protein-protein inter-
actions between cell types in the tissue microenvironment
Known protein-protein interactions between tumor, epithelial, immune and
stromal cell types in the tissue microenvironment were manually curated from var-
ious resources. Specifically, interactions corresponding to cytokine/chemokine - cy-
tokine/chemokine receptor interactions, ligand-receptor interactions involved in cell
adhesion/leukocyte trans-endothelial migration, ligand-receptor interactions involv-
ing the TNF receptor superfamily and lastly, ligand receptor interactions involved in
regulation of NK and T cell cytotoxicity were all merged into one Excel spreadsheet
[35, 41, 110, 111, 159, 174, 242]. In total, 369 putative ligand-receptor interactions
were collected. This list primarily covers proteins that have well characterized im-
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munological functions. Certain receptors are complexes encoded by more than one
gene, such as TGF beta family receptors. They are documented as a list of genes
separated by a ”;”. Furthermore, certain proteins serve as both ligands on some cell
types and receptors on other cell types, such as HVEM (TNFRSF14).
5.2.5.2 Expected distribution of ligands and receptors across different
cell types from prior knowledge
The database assigns a binary indicator (1/0), for each ligand/receptor, across
the compendium of cell types indicating with 1 if the ligand/receptor can be pro-
duced by a cell type based on prior evidence of cell-surface protein expression or
secretion (0 otherwise). This knowledge was extracted from Appendix II-IV of
Janeway’s Immunobiology 9th Edition Textbook [159]. The appendix, in addition,
records ligands/receptors whose expected cell type specific distribution is less pre-
cisely defined. For instance, certain cytokines/chemokines are reported to be broadly
produced by lymphocytes. Hence, without additional evidence, it is reasonable to
expect that such ligands/receptors can also be produced in specific contexts by all
cell types that are lymphocytes. We formalize this notion by defining a functional
equivalence class for each cell type. For instance, the functional equivalence class
for B cells is defined as: lymphocytes, lymphoid cells, leukocytes, antigen presenting
cells, nucleated cells, all cells. A schema representing such relationships is stored in
the database. We then describe in a subsequent section how this prior knowledge
can be used to systematically enumerate all ligands/receptors that can potentially
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be produced by a specific cell type of interest.
5.2.5.3 Annotation of functional effects of ligand-receptor interac-
tions on participating cell types
Certain ligand-receptor interactions between immune cell types have an acti-
vating or inhibitory effect on the cell type expressing the receptor (also known as the
target cell type) or in some cases both the ligand and receptor expressing cell types
(regarded in literature as costimulatory). Discovery of such interactions resulted
in the development of immune checkpoint blockade therapy such as anti-PD1 and
anti-CTLA4 which has revolutionized cancer treatment. We systematically curated
literature on all such interactions from [35, 41, 174, 242, 23, 219, 80, 235, 220, 40]
and classified them into two ontologies as follows:
• Activating/costimulatory encapsulates interactions with the following func-
tional characteristics reported in literature: increased cytotoxicity, increased
cytokine production, increased cell proliferation, increased cell survival, ex-
istence of immunoreceptor tyrosine-based activation motifs (ITAMs) in the
cytoplasmic tail of the receptor.
• Inhibitory/checkpoint encapsulates the following functional characteristics
reported in literature: decreased cytotoxicity, exhaustion, reduced cytokine
production, decreased TCR signaling activity (for T cells), reduced cell pro-
liferation, reduced cell survival, existence of Immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) in the cytoplasmic tail of the receptor.
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In the database, interactions with conflicting effects reported on target cell
types or for cases where the effect of the interaction depends on other factors were
left un-annotated. In addition to activating/inhibitory interactions, the database
also annotates other interactions based on prior knowledge from Janeway’s immuno-
biology 9th Edition Textbook [159].
• Pro-inflammatory interactions involving inflammation mediator cytokines
such Interferon Gamma, TNF-alpha, IL1, IL12 and IL18
• Chemotaxis cytokine/chemokine interactions involved in cell chemotaxis in
regular or inflammatory conditions (responsible for lymphocyte infiltration)
• Cell-adhesion interactions involved in cell adhesion/leukocyte trans-endothelial
migration (responsible for extravasation from blood vessels to tissue)
5.2.5.4 LIRICS STEP 1: Querying all plausible ligand receptor inter-
actions between any two cell types based on prior knowledge
In this step, we query all ligand receptor interactions that could potentially
take place between two cell types A and B. The user can plug in the names of any
two cell types whose names match with the names of cell types in the database
and then LIRICS lists all ligand-receptor interactions that could potentially take
place between cell types A and B. This list is determined by first finding which
ligands/receptors can potentially be produced by each cell type (cell type A and B)
based on prior knowledge of the expected distribution of ligands and receptors on
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cell types. It then adds to this list any ligands/receptors that are expected to be
found in the functional equivalent cell types. Given a set of all potential ligands
and receptors on each cell type, LIRICS returns all known physical protein-protein
interactions involving these ligands and receptors.
5.2.5.5 LIRICS STEP 2: Identifying which plausible interactions are
likely to occur (or “active”) in each sample given deconvolved
gene expression data from CODEFACS
Given a queried set of all plausible ligand receptor interactions between cell
types (A,B,C, ...): {(LA1 , RB1 ), (LA2 , RC2 ), . . . , (LC1 , RB1 ), . . . , }, one can integrate this
prior knowledge with deconvolved expression data from CODEFACS to infer which
interactions are likely to occur in each sample as follows:
For any two cell types A and B with a plausible ligand-receptor interaction
(LAz , R
B
z ), we define a binary indicator ZLAz ,RBz ∈ {0, 1}, such that ILAz ,RBz = 1 if a
physical interaction between (LAz , R
B
z ) is likely to take place in a sample, and has
the value 0 otherwise. An interaction is considered likely to take place (synonym:
“active”) in a sample if the ligand LAz is overexpressed in cell type A and receptor
RBz is over expressed in cell type B, in that sample. To determine if ligand L
A
z and
receptor RBz are over-expressed in cell types A and B in a given sample, we use the
median deconvolved expression of the ligand LAz in cell type A over all input samples
and likewise the median deconvolved expression of receptor RBz in cell type B over
all input samples as controls. Ligands such as cytokines and chemokines, can be
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secreted by cells and hence are not surface bound. However, we expect the levels
of secreted cytokines/chemokines by a cell type to be proportional to their cell-
type-specific gene expression. Furthermore, multiple genes are required to encode
certain ligands/receptors, each gene being part of a specific subunit in the protein
complex. For such ligands/receptors to be expressed, all genes required to build the
ligand or receptor need to be expressed. Hence, we assume the expression of such
receptors or ligands in a cell type is the minimum of the expression of individual
genes constituting the ligand or receptor.
This approach has two key advantages, besides being biologically intuitive.
First, the binary indicator is expected to be robust to noise in gene expression despite
the varying levels of confidence in the predicted cell-type-specific gene expression
from different datasets. This follows from the statistical properties of median-based
filters in signal processing [251]. Second, it enables comparison of individual profiles
independent of the dataset source due to their shared biological representation if the
datasets being compared have expression measurements of the same genes. Thus,
one can seamlessly pool multiple datasets together, augment sample size and increase
statistical power.
5.2.5.6 LIRICS STEP 3: Downstream enrichment analysis and visu-
alization
Given this binarized representation, one can perform a Fisher’s exact test to
assess if any specific cell-cell interaction is more likely to occur in samples with a
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specific phenotype compared to a control group. This is quantified by computing
the enrichment score, expressed as an odds ratio of the interaction in each pheno-
type of interest. A score around 1 indicates a neutral trend, a score >1 indicates
enrichment of the interaction in the phenotype of interest and a score close to 0
indicates enrichment in the control group. Furthermore, the associated p-values of
each test can be inspected post multiple hypothesis testing correction to identify
any significant trends in the data. One can also plot the most significant trends
occurring in a network where each edge represents a ligand-receptor interaction be-
tween two cell types and the thickness of the edge is proportional to the enrichment
score of the interaction in a phenotype of interest. The circlize package in R is used
to make these plots [84].
5.2.6 Feature selection and machine learning
We used a genetic algorithm, which is a randomized heuristic search algorithm
designed to select optimal features for a prediction task given some user-defined
fitness function for training [146]. In this setting, the features are ligand-receptor
interactions between cell-types, the prediction task is predicting response to ICB
treatment and the fitness function is defined as the accuracy of predicting a user
defined phenotype based on the total number of interactions from those selected
occurring in a given sample; accuracy is quantified by the AUC. To reduce the
risk of over-fitting and aid in faster convergence of the genetic algorithm during
training, the size of the search space is reduced by first removing any ligand-receptor
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interactions with multi-gene receptors or ligands. These features are expected to be
noisy because the relationship between expression of genes encoding the protein
complex and the cell surface expression of the protein complexes is less well defined.
Second we assess the fold change of each feature between the two classes specified
in the training dataset (e.g., hypermutated vs non-hypermutated) and only select
those with a fold change >1. These features are then passed to the genetic algorithm
for further optimization.
The algorithm starts out by randomly generating sets of features. This is de-
fined as the seed population. These sets iteratively evolve via the phenomenon of
natural selection enforced by the user defined fitness function. Specifically, for each
subsequent iteration, features from the best performing sets, as determined by the
user defined fitness function, in the current iteration are mixed at random followed
by random new feature additions or dropouts (referred to as mutations) to build a
new generation of feature sets and the process repeats. Eventually, after a number
of epochs, which we set to 100, the fitness function converges to an optimum and
the best set of features for the prediction task is returned to the user. Since the
fitness function landscape is often non-convex and the training process is stochastic,
we repeat the training process 500 times, each with a randomly chosen seed popula-
tion, and eventually choose frequently selected features over all solutions to reach a
solution we suspect is close to the global optimum solution. For our plots, we set the
threshold to frequency > 100 times. The probability of any feature being selected
more than 100 times by random chance based on this approach is estimated to be
< 0.01. Results are qualitatively similar for more stringent thresholds. The genetic
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algorithm was implemented in R using the genalg package [246].
5.3 Results
5.3.1 Overview of CODEFACS and LIRICS
CODEFACS is designed to characterize the tumor microenvironment by recon-
structing the cell-type-specific transcriptomes of each sample from bulk expression.
It takes as input the bulk RNA-seq expression values of a cohort of tumor samples
and either the estimations of the cell fractions of a pre-defined set of cell types in
each sample or their cell-type-specific molecular signature profiles, derived based on
reference datasets or from the literature [163].
CODEFACS then employs a heuristic approach that sequentially executes
three modules: (module 1) high resolution deconvolution, (module 2) hierarchi-
cal deconvolution and (module 3) imputation. Each module is designed to predict
the cell-type-specific expression of genes in each sample; the second and third mod-
ules aim to overcome the shortcomings of the previous modules. A key component
of CODEFACS is its confidence ranking system, which receives cell-type-specific
expression predictions from the different modules and labels them as high or low-
confidence estimations. Genes whose expression is determined with high confidence
in a given module are added to the output set, while low confidence predictions
are continued to be processed in subsequent modules (See Figure 5.7 panel A). The
final output of CODEFACS consists of two items: (a) a three-dimensional gene ex-
pression matrix, where each entry represents the predicted gene expression a gene
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in a given cell-type in a specific sample, and (b) a two-dimensional matrix of con-
fidence scores ranging from [0,1] representing which gene-cell-type pairs have most
confident predictions (1) and which pairs have least confident predictions (≈0; See
Figure 5.7 A, Output). These scores can be further investigated to assess the quality
of predictions for a given dataset.
Given fully deconvolved gene expression data from CODEFACS, one can use
LIRICS (LIgand Receptor Interactions between Cell Subsets) (Figure 5.7, panel
B) to transform this data into a biologically interpretable feature space of active
ligand-receptor interactions between cell types in each sample. Specifically, LIRICS
takes the output of CODEFACS and processes it in three steps: (step 1) the first
step queries a database of all plausible ligand-receptor interactions between any two
cell types A and B, that we have systematically assembled and curated from the
literature. This database is publicly available as part of LIRICS. (step 2) In the
second step, given the deconvolved expression profiles of cell type A and cell type
B in a given bulk tumor sample, LIRICS denotes as ‘active’ or ‘likely to occur’
(‘1’) the interactions where both the ligand and receptor are over-expressed in the
relevant cell-types in that sample, or otherwise ‘inactive’ (‘0’). A ligand or receptor
is considered to be over-expressed in a given cell type if its expression exceeds
the median expression in that cell type (Supplementary Note). (step 3) Finally, a
Fisher’s enrichment analysis is performed to test the association of the activity of
specific ligand-receptor interactions with any relevant phenotypes of interest (e.g.,
treatment response, mutational subtype, etc.) (Figure 5.7, panel B). Furthermore,
if required, one can collectively analyze the binary profiles returned by LIRICS
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from multiple independent datasets to augment sample size and increase statistical
power. Finally, one can apply a false discovery rate (FDR) cut-off post multiple
hypothesis correction and visualize significantly enriched interactions in a volcano
plot as shown at the bottom of Figure 5.7, panel B, or, alternatively, display their
network structure as shown in subsequent biological applications.
5.3.2 Benchmarking CODEFACS performance
To assess the accuracy of CODEFACS, we generated 15 benchmark datasets
(see Methods) by merging publicly available single cell RNA-seq [103, 74] and FACS
sorted purified RNA-seq [72]. Thereafter, we applied CODEFACS to deconvolve
these generated bulk datasets and define the accuracy of its predictions by com-
puting the Kendall correlation between the predicted and ground truth expression
in each cell type across individual samples (the Kendall correlation provides a less
inflated measure of accuracy by accounting for ties in the data). In the main text,
we show the results obtained on three benchmark bulk datasets: one derived form a
FACS-sorted lung cancer data, one from a single cell melanoma RNA-seq data and
from a single cell glioblastoma RNA-seq dataset, respectively. Each bulk sample
from these datasets represents a real biopsy from a patient. We show that CODE-
FACS can predict the cell-type-specific expression of more genes than CIBERSORTx
(with Kendal’s correlation ≥ 0.3) (Figure 5.8 panels A,B,C), and its predictions are
overall more accurate (Figure 5.8, panels D,E,F). The results for all the remaining
12 benchmark datasets, created via artificial mixing of single cell profiles and single
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Figure 5.7: CODEFACS takes bulk gene expression profiles and prior knowledge of the
cellular composition of each sample and executes a heuristic three step procedure to infer
the deconvolved gene expression in each sample. In module 1, we perform a high-resolution
deconvolution, which extends the CIBERSORTx algorithm. In module 2 (hierarchical de-
convolution), bulk expression is modeled as a mixture of two components: a specific cell
type of interest and all the remaining cell types. The expression for the cell type of
interest is predicted by removing the estimated expression in the second component (us-
ing high-resolution deconvolution from module 1) from the bulk mixture. In module 3 –
imputation-based deconvolution, we impute the cell-type-specific expression of a specific
gene based on the predicted cell-type-specific expression of other high-confidence genes
that are co-expressed with that gene in the bulk. Each module is designed to overcome
the shortcomings of its predecessor based on their respective modeling assumptions. The
confidence ranking system is responsible for classifying all the predictions at the end of
each module into high-confidence or low-confidence predictions. Genes classified into the
low-confidence class at the end of one module (e.g. module 1) are passed to the next mod-
ule (e.g. module 2) for refinement. Finally, after all the three modules are executed, the
prediction confidence levels are re-evaluated. The final output of CODEFACS consists of
a 3-dimensional matrix with cell-type-specific gene expression predictions for each sample,
along with estimated confidence scores of predictions for each gene in each cell type. For
more details, see Supplementary note. (B) LIRICS takes the output of CODEFACS and
processes it in three steps. In step 1, for each possible permutation of cell type pairs, LIR-
ICS queries a literature-curated repository for enumerating all plausible ligand-receptor
interactions between specified cell types. In step 2 this prior knowledge is integrated with
the output from CODEFACS to infer which of the plausible cell-cell interactions are likely
to occur or be “active” in each individual sample. The result is a binary matrix with rows
representing each plausible cell-cell interaction and columns representing each patient’s
tumor sample. Finally, in step 3, given any clinically relevant phenotype (e.g. response
to therapy, driver mutation status, etc..), one can perform a Fisher’s enrichment analysis
(shown at the bottom) to discover cell-grounded receptor-ligand interactions in the TME
that are associated with the phenotype of interest.
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cell RNA-Seq imputation, also show the superiority of CODEFACS (supplementary
Figure 5.9 and 5.10). Overall, we observe that the more abundant the cell type
is, the better CODEFACS can predict its cell-type-specific gene expression (Figure
5.11).
Next, we quantified how well the confidence scores it returns align with the
Kendall scores that measure the true prediction accuracy with the ground truth for
each (gene, cell-type) pair to validate the claim that our confidence scores can help
the user filter out potentially noisy predictions in real bulk datasets. We quantified
this using two metrics: Spearman correlation and a classification AUC (Area Un-
der the ROC Curve). Across all the benchmark datasets analyzed, the Spearman
correlation between confidence scores of genes in each cell-type and their correspond-
ing Kendall scores (quantifying the true prediction accuracy) is strong and positive
(Figure 5.8, panel G depicts the results for the FACS sorted lung cancer benchmark
dataset, and Figure 5.12 depicts the results for the remaining benchmark datasets);
To perform a classification-based quantification, we grouped the genes in each cell-
type into two classes based on the correlation between their predicted and actual
expression, informative (prediction accuracy ≥ 0.1 and p-value ≤ 0.05) and unin-
formative (prediction accuracy < 0.1 or p-value > 0.05). We then tested whether
the confidence scores could be used to classify genes into these two classes for each
cell type. We find that the confidence score could effectively filter out uninformative
predictions (Figure 5.8, panel H depicts the results for the FACS sorted lung can-
cer benchmark dataset, and supplementary Figure 5.13, depicts for the remaining
benchmark datasets).
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Finally, to further evaluate CODEFACS on real bulk tumor data (where the
ground truth is unavailable), we applied it to deconvolve bulk expression data from
21 cancer types ( 8000 RNA-seq samples) in TCGA. To infer the cellular abundance
of each cell type in each sample which is required as input for CODEFACS, we made
use of matched bulk methylation data available for these samples and methylation-
based reference signature profiles of distinct cell types. These include 11 cell type sig-
natures (macrophages/dendritic cell:CD14+, B cells: CD19+, CD4+T cells, CD8+
T cells, T reg cells, NK cells: CD56+, endothelial cells, fibroblasts, neutrophils,
basophils, eosinophils and tissue-specific tumor cells) obtained from MethylCIBER-
SORT [39]. Reassuringly, we found strong Spearman correlations between the re-
sulting predicted tumor cell fraction and the tumor purity estimates derived from
matched mutation and copy number data (based on ABSOLUTE) for the same sam-
ples across 10 cancer types (Spearman correlation: min=0.72, max=0.88, avg=0.8).
This testifies that methylation-based cell fraction estimates indeed form a reliable
basis for running CODEFACS to deconvolve TCGA samples.
We then asked if CODEFACS can recover the expected cell-type-specific gene
expression signature of different cell types in a given cancer type. To this end, we
computed the Spearman correlation between (a) the mean deconvolved gene expres-
sion of the top confidently deconvolved genes in a given cell type (confidence score ≥
0.95) and (b) the mean expression of these genes, which we derived from completely
independent single cell expression data of the same cancer type (Methods). We find
that (a) and (b) are substantially correlated (Figure 5.8, panel I depicts results for
the TCGA-LUAD (lung adenocarcinoma) dataset as an example and supplementary
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Figure 5.14 for the remaining cancer types that have publicly available scRNA-seq
data). The concordance level is higher for cell types that are abundant (e.g., tumor
cells and fibroblasts) and decreases for less abundant cell types. Additionally, we
observed that tumor cells have the largest fraction of genes whose expression is pre-
dicted with high confidence, with the highest in thyroid cancer (THCA, 67.4% of all
genes). Furthermore, 7 KEGG pathways are significantly enriched (adjusted p-value
< 0.01) with highly confident genes in tumor cells (confidence score ≥0.95) across
the 21 cancer types. Those pathways mostly involve RNA transport, spliceosome,
DNA replication, and mismatch repair.
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Figure 5.8: (A-C) bar plots depicting the number of genes with a prediction accuracy
(Kendall correlation) ≥ 0.3 with the ground truth for each cell type, estimated from
bulk-generated samples of lung cancer (LUAD dataset; sample size = 26) [72], melanoma
(SKCM dataset 1; sample size = 28) [103] and glioblastoma (GBM dataset 1; sample size
= 24) [74] benchmark datasets, as estimated by CODEFACS (yellow bars) and CIBER-
SORTx (blue bars). (D-F) boxplots depicting prediction accuracy distributions of all
genes across different cell types in the lung cancer (LUAD with sample size 26) [72],
melanoma (SKCM with sample size 28) [103] and glioblastoma (GBM with sample size
24) [74] benchmark datasets, using CODEFACS (yellow) and CIBERSORTx (blue). A
two-sided Wilcoxon signed rank test was performed to compare the prediction accuracies of
CODEFACS and that of CIBERSORTx for each cell type in each dataset. ??? denotes p-
values < 2e-16. (G) Spearman correlations between prediction accuracies and confidence
scores among cell types in the lung cancer benchmark dataset (LUAD dataset; sample
size = 26) [72]. The y-axis indicates the spearman correlation coefficient value, while the
x-axis indicates the cell type. (H) AUCs obtained in classifying informative and uninfor-
mative predictions among cell types in lung cancer benchmark dataset (LUAD dataset;
sample size = 26) [72]. (I) bar plots depicting the Spearman correlations between mean
deconvolved cell-type-specific expression in TCGA-LUAD and mean cell-type-specific ex-
pression derived from publicly available single cell datasets of LUAD. The y-axis indicates
the Spearman correlation coefficient value, while the x-axis indicates the cell type.
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Figure 5.9: (A-L) bar plots depicting the number of highly predictable genes (Kendall
correlation ≥ 0.3) among 12 validation datasets (SKCM dataset 2, SKCM dataset 3,
SKCM dataset 4, SKCM dataset 5, SKCM dataset 6, SKCM dataset 7, GBM dataset 2,
GBM dataset 3, GBM dataset 4, GBM dataset 5, GBM dataset 6, GBM dataset 7).The
yellow bar represents the performance of CODEFACS, while the gray bar represents that
of CIBERSORTx.
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Figure 5.10: (A-L) boxplots depicting the accuracy distributions among the 12 bench-
mark dataset (SKCM dataset 2, SKCM dataset 3, SKCM dataset 4, SKCM dataset 5,
SKCM dataset 6, SKCM dataset 7, GBM dataset 2, GBM dataset 3, GBM dataset 4,
GBM dataset 5, GBM dataset 6, GBM dataset 7). The yellow boxes represents the perfor-
mance of CODEFACS, while the gray boxes represents that of CIBERSORTx. Wilcoxon
signed rank test was performed to compare the prediction accuracies of CODEAFCS and
that of CIBERSORTx for each cell type in each dataset. ? ? ? denotes p-values < 2e-16.
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Figure 5.11: For each cell type of each dataset, the average prediction accuracy was
computed by taking the average of prediction accuracies (Kendall correlation) across all
genes. The y-axis indicates the average prediction accuracy among genes and the x-axis
indicates the cell fraction. The Spearman correlation coefficient is 0.81 (p-value < 2e-16).
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Figure 5.12: (A-N) bar plots depicting the Spearman correlation between prediction
accuracies and confidence scores in each cell type for all 14 benchmark datasets (SKCM
dataset 1, SKCM dataset 2, SKCM dataset 3, SKCM dataset 4, SKCM dataset 5, SKCM
dataset 6, SKCM dataset 7, GBM dataset 1, GBM dataset 2, GBM dataset 3, GBM
dataset 4, GBM dataset 5, GBM dataset 6, GBM dataset 7). The y-axis indicates the
Spearman correlation value, while the x-axis indicates the cell types.
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Figure 5.13: (A-N) bar plots depicting the AUC in each cell type for all 14 benchmark
datasets (SKCM dataset 1, SKCM dataset 2, SKCM dataset 3, SKCM dataset 4, SKCM
dataset 5, SKCM dataset 6, SKCM dataset 7, GBM dataset 1, GBM dataset 2, GBM
dataset 3, GBM dataset 4, GBM dataset 5, GBM dataset 6, GBM dataset 7). Genes in
each cell-type are grouped into two classes based on the correlation between their predicted
and actual expression, informative (prediction accuracy ≥ 0.1 and p-value ≤ 0.05) and
uninformative (prediction accuracy < 0.1 or p-value > 0.05). The y-axis indicates the
AUC, while the x-axis indicates the cell types.
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Figure 5.14: (A-H) bar plots depicting the result for SKCM, HNSCC, GBM, PAAD,
LIHC, LUSC, COAD and TNBC respectively. The y-axis indicates the Spearman corre-
lation coefficient value, and the x-axis indicates the cell type.
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5.3.3 Tumors with DNA mismatch repair deficiency have heightened
T-cell co-stimulation that is independent of their tumor muta-
tion burden levels
In normal cells, DNA is constantly repaired in response to DNA damage or
DNA replication errors [63]. However, defects in specific DNA repair pathways in
cancer cells may result in the accumulation of many somatic mutations resulting
in hypermutated tumors (TMB ≥ 10-20 mutation/Mb) [133, 4, 160]. One of the
sources of hypermutability is a mismatch repair deficiency (MMRD), which leads
to the accumulation of insertions and deletion mutations in microsatellite regions of
the genome due to uncorrected DNA replication polymerase slippage events. This is
known as microsatellite instability (MSI) [67, 52]. Solid tumors with mismatch repair
deficiency were shown to be sensitive to immune checkpoint blockade (ICB) therapy
irrespective of tumor type, leading the FDA to approve MSI as the first cancer
type agnostic biomarker for patients receiving anti-PD1 treatment [28]. The reason
behind this general sensitivity to anti-PD1 treatment is not completely understood.
Prior work has led to the prevailing hypothesis that elevated tumor mutation burden
in mismatch repair deficient tumors leads to more neoantigens, and thus is more
likely to activate a host immune response against tumor cells [67, 68, 132, 122].
However, not all tumor types with elevated tumor mutation burden have similar
response rates to anti-PD1 [252, 89], and recent studies have revealed that T cells
recognize and respond to only a few neoantigens per tumor [193, 20, 197, 108].
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More generally, when looking at non-synonymous tumor mutation burden, MSI and
survival data across the TCGA collection (Figure ??, panels A and B, borrowed from
[226, 26]. See Methods), we see a significant association between hypermutability
and survival benefit of patients in solid tumor types with a frequent underlying
mismatch repair deficiency (Figure 5.15, panel C. log-rank test p-value = 0.00084),
in contrast to other tumor types (Figure 5.15, panel D, log-rank test p-value = 0.4).
These survival differences can be partially explained by the mutual exclusivity of
microsatellite instability and chromosomal instability, which has been previously
linked with a worse prognosis[226, 56, 13]. Taken together, these findings motivated
us to further study cellular immune crosstalk in the tumor microenvironment of
mismatch repair deficient tumors to gain additional cell-type-specific insights into
their sensitivity to anti-PD1.
We hence aimed to identify cell-cell interactions that are differentially active
between microsatellite instable tumors (highlighted as red dots in Figure 5.15, panel
A) and microsatellite stable tumors (highlighted as black dots in Figure 5.15, panel
A). To this end, we applied CODEFACS to deconvolve the bulk gene expression of
all solid tumors from TCGA and integrated their predicted cell-type-specific gene
expression levels with LIRICS. The top 50 interactions from this differential analy-
sis (ordered by FDR adjusted p-value) are shown in a network in Figure 5.16 panel
A. These interactions are frequently active in mismatch repair deficient tumors of
distinct tumor types (Figure 5.17) and importantly, they are more frequently ac-
tive in hypermutated tumors with DNA mismatch repair deficiency compared to
other hypermutated tumors (Figure 5.16, panel B, Figure 5.15, panel A), testifying
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Figure 5.15: (A) This panel plots the distribution of non-synonymous tumor mutation
burden on a logarithmic scale (Y-axis). All points above the horizontal line are typically
regarded as hyper-mutated tumors (> 10 mutations/Mb). All red points represent tumors
with a DNA mismatch repair deficiency detected via microsatellite instability (MSI). (B)
This panel depicts the percentage of all tumor samples per cancer type with microsatellite
instability (Y-axis). Tumor types marked with a ? represent those where MSI is prevalent.
(C-D) Comparison of overall survival of patients with tumors that are hypermutated vs
not hypermutated. Left panel (C) In Gastro-Intestinal+Endometrial tumor types where
MSI is prevalent (marked with a ? in panel B). Right panel (D) In other solid tumor types
where tumors rarely have an underlying mismatch repair deficiency. Statistical significance
of differences in survival was calculated using the log-rank test.
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to their MSI specificity. The top 50 MSI-specific interactions include the PDL1-
PD1 checkpoint interaction between tumor cells and CD8+ T-cells, but notably,
T-cell activating/co-stimulatory interactions such as the 41BBL-41BB interaction
between Tumor cells and CD8+ T cells, ULBP2-NKG2D between tumor cells and
CD4+T cells, and chemotaxis interactions involved in trafficking of lymphocytes in
and around the tumor mass, such as the CXCL9-CXCR3 chemokine interaction be-
tween macrophages and CD4+ T cells and CCL3/4/5 – CCR5 interactions between
various immune and stromal cell-types.
This shared heightened cellular crosstalk unique to the TME of mismatch
repair deficient tumors suggests that tumor infiltrating T cells can be activated by
co-stimulatory signals in the TME independent of overall tumor mutation burden,
only to be kept in balance by other immunoregulatory mechanisms such as the
PD1-PDL1 checkpoint interaction between CD8+ T cells and tumor cells. Our
results indicate that when this interaction is blocked by anti-PD1 treatment, the
presence of other co-stimulatory interactions can lead to the observed enhanced
response of MMRD tumors to immune checkpoint blockade therapy. This in turn
raises the possibility that switching on specific T cell co-stimulation signals in the
TME may lead to better responses to anti-PD1 treatment independent of tumor
mutation burden. Notably, recent pre-clinical studies have shown that combination
therapies aimed at enhancing such T-cell co-stimulating interactions improve anti-
tumor immune responses even in low TMB and highly immuno-suppressive settings
[42, 135, 18, 147, 43, 177]. Currently, several clinical trials to assess the safety and
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Figure 5.16: (A) Interaction network consisting of the top 50 interactions. Interactions
highlighted in green represent co-stimulatory interactions/having an activating effect on
the target cell. Interactions highlighted in red represent checkpoint interactions/having
an inhibitory effect on the target cell. Interactions highlighted in black represent pro-
inflammatory/chemotaxis interactions involved in inflammatory response and immune cell
trafficking to tumor sites. Eos: Eosinophils, CAF: Cancer associated fibroblasts. (B) A
volcano plot depicting on the x-axis the log2 fold change in the frequency of occurrence
of each cell-cell interaction in the TME of hypermutated tumors with an underlying DNA
mismatch repair deficiency vs other hypermutated tumors. The y-axis indicates the -log10
FDR adjusted p-value of the observed enrichment. Highlighted in red in the scatter plot
are the top 50 interactions that are most differentially active between all MSI vs non-MSI
tumors (shown in panel A)
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Figure 5.17: (A-F) Tumors are grouped into four different groups by tissue of origin:
STAD (stomach), COAD (colon), UCEC (endometrium) and other (all other solid tumor
types) in order to have sufficient numbers of mismatch repair deficient vs mismatch repair
proficient samples per group. The axes measure the enrichment scores of all plausible
ligand-receptor interactions between cell types in their respective group. A fold change
> 1 implies the interaction occurs more frequently in mismatch repair deficient tumors.
Interactions highlighted in red represent the shared core set of interactions from Figure
5.16 A that are universally enriched in mismatch repair deficient solid tumors.
5.3.4 Machine learning guided discovery of cellular crosstalk predic-
tive of response to immune checkpoint blockade therapy
Given the shortage of large publicly available transcriptomics datasets of pa-
tients receiving immune checkpoint blockade therapy, we asked if we can effectively
utilize this large resource of deconvolved TCGA data we generated to transfer-learn
cell-cell interactions robustly predictive of response to immune checkpoint block-
ade therapy. Specifically, since some mutations during tumor evolution can be im-
munogenic, we hypothesized that one could potentially discover cell-type-specific
ligand-receptor interactions predictive of response to ICB therapy by a joint anal-
ysis of mutation and deconvolved expression data from the TCGA. We focus on
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melanoma, currently the tumor type best responding to ICB, where there are many
independent publicly available bulk expression datasets of patient’s receiving anti-
PD1 treatment and single-cell derived cell-type-specific signatures, which serve as
priors for the deconvolution of these bulk datasets. Starting from the deconvolved
TCGA-SKCM dataset as our training set (N=469), we employed a genetic algo-
rithm to find cell-type specific ligand-receptor interactions, whose activation state
best separates hypermutated melanoma tumors from non-hypermutated tumors (Fig
5.15, panel A), assuming that the former group captures more samples with some
immunogenic mutations than the latter (Figure 5.18, panel A). We term the inter-
actions identified in this process melanoma mutation specific functional interactions
(MSFI), and the network formed by these interactions is displayed in Figure 5.18
panel B.
Having identified the MSFI interactions, we applied CODEFACS to deconvolve
the bulk expression data of pre-treatment samples from the three largest publicly
available melanoma datasets where patients received anti-PD1 treatment (either
monotherapy or in combination with anti-CTLA4; Methods) 42–44. We then em-
ployed LIRICS to the respective deconvolved expression of each of these checkpoint
datasets, without any additional training, and simply quantified the number of
MSFI interactions that are active in each of these patients’ tumor samples, which
we denote as the tumor’s MSFI score. Remarkably, we find that the MSFI score of
each sample can robustly stratify patients into those that are likely to respond to
ICB vs those that are unlikely to respond (Figure 5.18, panel C, progression free
survival log rank test p-value: 0.00057, Figure 5.18, panel D, overall survival log
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rank test p-value: 0.0031). Figure 5.19 depicts the survival differences for the two
treatment groups separately (anti-PD1 monotherapy and anti-CTLA4 + anti-PD1
combination). Additionally, Figures 5.20 and 5.21 depict the survival differences
for each ICB dataset separately. As evident, our results improve over recent bulk
gene expression based predictors of melanoma ICB therapy response (IMPRES [14],
TIDE [105] and the melanocytic plasticity signature (MPS) scores [176]). We note
that the performance levels of the latter on bulk expression datasets, where their
original RNAseq reads have been uniformly aligned and normalized as described in
the Methods, is lower than that reported in the original publications, pointing to
the potential sensitivity of expression-based predictors to the processing used and
the need to do that in a uniform, generally accepted manner (see Discussion).
To further evaluate the predictive performance of the MSFI score, we tested
its ability to predict partial or complete responders vs stable or progressive disease
patients in these datasets. To this end we plotted the receiver operator area under
the curve (AUC) obtained using it for classifying the patients to partial or complete
responders vs stable or progressive disease, and compared its performance to that
obtained with the three other published predictors for the different treatment groups
(Figure 5.18, panel E). On average, the MSFI score achieves an AUC of 0.63 (for
anti-PD1 monotherapy the AUCs obtained are 0.6, 0.77 and 0.52 for the three
individual ICB datasets, and for the combination ICB treatment its 0.77, 0.49 and
0.63). A similar performance could not be achieved if the placement of the ligand and
receptor between interacting cell-types in the MSFI network was swapped (average
AUC 0.58) or by randomly shuffling the interaction activity profiles (average AUC ≈
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0.5), testifying that the selected cell-cell interactions are best predictive of response
to ICB. Comparing MSFI predictive performance in this response classification task
to that of the recent melanoma bulk expression-based predictors, TIDE achieves an
average AUC of 0.6 (for anti-PD1 monotherapy the AUCS are 0.46, 0.66 and 0.45
for the three ICB datasets and 0.89, 0.55 and 0.61 for the combination), IMPRES
achieves an average AUC of 0.55 (for anti-PD1 monotherapy the AUCS are 0.59,
0.64 and 0.6 respectively for the three ICB datasets and 0.61, 0.44 and 0.42 for the
combination) and MPS achieves an average AUC of 0.51 (for anti-PD1 monotherapy
the AUCS are 0.61, 0.49 and 0.63 respectively for the three ICB datasets and 0.41,
0.59 and 0.38 for the combination).
Examining the MSFI network leads to interesting insights (Figure 5.18, panel
B). First, we find an over-representation of cell-type-specific co-stimulatory/immune
cell activating interactions known from prior immunological literature (hypergeomet-
ric test p-value < 0.05) [23, 219, 159, 41, 35, 174, 242, 80, 220, 40, 235]. Second,
the MSFI network additionally includes cytokine/chemokine interactions involved
in pro-inflammatory response and the trafficking of NK, T and B cells to the tumor
site (responsible for better lymphocyte infiltration into the tumor mass). Impor-
tantly, on fitting a multivariate Cox-proportional hazards model with MSFI scores
and TMB of each patient receiving anti-PD1 (wherever TMB data was available),
we see that a high MSFI score is significantly associated with improved progres-
sion free survival (p-value: 0.013) and overall survival (p-value: 0.0258), whereas
high TMB is not (PFS p-value: 0.224, OS p-value: 0.477). These results further
support the findings from the TCGA analysis that heightened co-stimulatory and
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pro-inflammatory signals in the TME can mobilize tumor infiltrating lymphocytes
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Figure 5.18: (Continued on next page)
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Figure 5.18: (A) Overview of the machine learning analysis employed to identify cell
type specific interactions that are predictive of response to immune checkpoint blockade
therapy. (B) A chord diagram of the resulting MSFI network. Each individual interaction
is represented by a link from the source cell type (ligand expressing cell type) to the
target cell type (receptor expressing cell type) and the color of the link represents the
color of the source cell type. For interactions that are activating/co-stimulatory, the sector
in the corresponding target cell type is highlighted in green. For inhibitory/checkpoint
interactions, the sector in the target cell type is in highlighted red. Interactions involved in
chemotaxis are highlighted in black and those I mediating a pro-inflammatory response are
highlighted in blue, cell-adhesion interactions are highlighted in grey. (C) Kaplan-Meier
plot depicting the progression free survival of the combined set of melanoma patients
receiving immune checkpoint blockade (N= 244). On the top, the patients are stratified
into low-risk/high-risk groups based on the median value of MSFI score from LIRICS.
Second from top, patients stratified into low/high risk groups based on median IMPRES
score[14]. Third from top, patients stratified into low/high risk groups based on median
TIDE score[105], Bottom, patients stratified into low/high risk groups based on median
MPS score [176]. (D) Kaplan-Meier plots depicting the overall survival of all melanoma
patients receiving immune checkpoint blockade (N= 244). On the top, the patients are
stratified into low-risk/high-risk groups based on the median value of MSFI score from
LIRICS. Second from top, patients stratified into low/high risk groups based on median
IMPRES score[14]. Third from top, patients stratified into low/high risk groups based
on median TIDE score[105], Bottom, patients stratified into low/high risk groups based
on median MPS score [176]. Survival differences among patients that received anti-PD1
monotherapy vs anti-CTLA4 + anti-PD1 combination are shown in supplementary figure
10 (E) Area under the ROC curves in predicting Complete/Partial-response (based on
RECIST v1.1) to immune checkpoint blockade therapy for the different scores. X-axis
marks patients grouped by dataset source and treatment regimen. PD1 mono represents
patients that received anti-PD1 monotherapy. PD1 + CTLA4 represents patients that
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Figure 5.19: (Continued on next page)
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Figure 5.19: All patients receiving anti-PD1 treatment are classified into low-risk group
if their LIRICS based cellular crosstalk score (MSFI score) exceeds the population median.
The Likewise, when using the IMPRES score [14]. For TIDE [105] and MPS scores
[176], all patients receiving anti-PD1 treatment are classified into low-risk group if their
values fall below the population median (as these scores were shown to be associated with
immune resistance1,2) (A,B) depict the survival differences for patients receiving anti-PD1
monotherapy only. (C,D) depict the survival differences for patients receiving anti-CTLA4
+ anti-PD1 combination. Significance in the difference of survival trends of the two groups
is calculated using the log-rank test. Time on the x-axis is measured in days.
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Figure 5.20: (A, E, I, M) Patients are classified into low-risk group if their LIRICS
based cellular crosstalk score exceeds the population median. (B, F, J, N) Patients are
classified into low-risk group if their IMPRES score [14] exceeds the population median.
(C, G, K, O) Patients are classified into low-risk group if their TIDE score [105] is less
than the population median. (D, H, L, P) Patients are classified into low-risk group if
their MPS score [176] is less than the population median. Significance in the difference of
survival trends of the two groups is calculated using the log-rank test. Time on the x-axis
is measured in days.
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Figure 5.21: (A, E, I, M) Patients are classified into low-risk group if their LIRICS based
cellular crosstalk score exceeds the population median. (B, F, J, N) Patients are classified
into low-risk group if their IMPRES score [14] exceeds the population median. (C, G,
K, O) Patients are classified into low-risk group if their TIDE score [105] is less than the
population median. (D, H, L, P) Patients are classified into low-risk group if their MPS
score [176] is less than the population median. Significance in the difference of survival




This study presents a computational tool, CODEFACS and a pipeline, LIR-
ICS, that enables an (averaged) ‘virtual single cell’ characterization of the TME
from bulk tumor expression data. Applying these tools, we identify cell type spe-
cific ligand-receptors interactions that are active and functionally important within
individual tumor microenvironments, in modifying patients’ survival and response
to ICB. Applying CODEFACS to 8000 tumors from TCGA, we estimate the cell-
type-specific gene expression profiles of each individual tumor sample thus enabling
the analysis of the TCGA at a cell-type-specific resolution. Integrating these data
with LIRICS, we systematically characterized the immune cellular crosstalk of the
tumor microenvironments of different tumor types. We identified a shared core of
intercellular TME interactions in DNA mismatch repair deficient tumors, which are
associated with improved patient survival and high sensitivity to immune check-
point blockade therapy. One potentially interesting implication of these findings is
that immunomodulators enhancing T-cell co-stimulation (e.g, via the 41BB recep-
tor) might improve patients’ response to ICB irrespective of their tumor mutation
burden. Finally, focusing on melanoma, we show that one can bootstrap on the
large deconvolved data resource from TCGA using machine learning techniques to
discover cell-cell interactions within the TME that successfully predict patients’
response to immune checkpoint blockade.
Now, while we have provided a toolkit to discover clinically relevant cell-cell
interactions from bulk tumor expression, there are some important limitations that
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should be noted and potentially further improved upon in the future. First, it
requires prior information about the cell type composition of the input tumors, or
alternatively, knowledge of the pertaining cell-types’ gene expression or methylation
signatures that can be used to infer their abundances, and its accuracy depends on
the accuracy of the latter. Second, its prediction power is limited to subsets of the
whole exome genes, and its performance deteriorates for lowly-abundant cell types.
However, the confidence scores provided partially alleviate this limitation, allowing
the user to rank genes in each cell-type by the quality of predictions of the expression
of each gene in a given cell-type. Third, regarding LIRICS, it is currently restricted
to well defined immune related ligand-receptor interactions between tumor, immune,
stromal and epithelial cell types and does not consider the spatial localization of
cells in the TME. The inclusion of the latter with the advent of forthcoming spatial
transcriptomics data is likely to lead to considerably more informative interaction
inference approaches.
(The source code related to this work is currently under review for a patent.




Tumor heterogeneity is a significant hurdle to developing cures for cancer.
Hence, to keep up with this constantly evolving enemy, it is important to develop
computational methods that parse these high dimensional genomic datasets and
unearth underlying patterns that can help us make sense of this heterogeneity. In
this work, we present some concrete examples.
6.0.1 Contributions to our understanding of epigenetic heterogeneity
in cancer
In chapter 2, we developed a computational framework to explore how epi-
genetic heterogeneity in cancer cells may lead to functional rewiring of genes via
dynamic changes in the protein-protein interaction network. With the help of breast
cancer and adjacent normal breast tissue gene expression data from TCGA, we show
how functional re-wiring events that are frequently selected in cancer modulate pa-
tient survival in general and lead to an improved clustering of clinically relevant
breast cancer subtypes. Such functional heterogeneity explains why many genetic
interactions are context specific, making their translation to clinically effective tar-
geted therapies a challenge. Currently, the exception to these trends are synthetic
lethal interactions between single strand and double strand break DNA repair path-
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ways, which are highly conserved in all eukaryotic cells [11]. However, there has
been renewed interest in the identification of additional robust genetic interactions
in tumor cells with the emergence of high throughput CRISPR screening technolo-
gies [59, 78, 10, 183, 165, 210]. Another aspect fundamental to characterization
of epigenetic heterogeneity is our ability to model how cells respond to different
genetic or environmental perturbations. A pre-requisite to building such models
is having good functional annotations of biological networks. However, such an-
notations are currently sparse [213]. To make some progress in this direction, we
developed and validated new mixed integer linear programming formulations that
utilize high-throughput genetic screening data and the network topology to anno-
tate biological networks of cells with directions of signal flow and signs representing
different functional activation or inhibitory effects. Overall, we demonstrated that
our method markedly outperforms the state of the art for this task.
6.0.2 Contributions to our understanding of genetic heterogeneity in
cancer
In chapter 3 we shifted gears to understand how intra-tumor genetic hetero-
geneity impacts anti-tumor host immune responses in melanoma. From the com-
putational side, we developed an unbiased approach to estimate the number of
genetically distinct cancer cell clones in any given tumor sample by utilising both
point mutation and copy number alteration information on each sample. Our results
from patient and mice data suggest that increased intra-tumor genetic heterogene-
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ity leads to reduced overall immunogenicity of the tumor sample despite similar or
higher levels of tumor mutation burden thereby impairing host anti-tumor immune
responses. These findings are clinically relevant as the FDA recently approved tumor
mutation burden as a biomarker for responses to anti-PD1 treatment in metastatic
solid tumors [224]. Our results indicate that an elevated mutation burden may
lead to poorer responses to immune checkpoint blockade therapies in melanoma
if accompanied by an increased intra-tumor genetic heterogeneity. Hence, moving
ahead, it is going to be important to account for the intra-tumor genetic heterogene-
ity of the sample when using the tumor mutation burden as a biomarker to decide
which patient should receive immune checkpoint blockade treatments. In addition,
in chapter 4, we came up with statistical machine learning techniques to uncover
novel factors explaining the observed heterogeneity of recurrent chromosome arm
gains and losses in cancer. Overall, our analysis of the GTEx and TCGA databases
revealed that the normal transcriptional state of different chromosome arms in a
tissue can influence which arm is recurrently gained or lost in emerging cancer types
from that tissue.
6.0.3 Contributions to our understanding of micro-environmental het-
erogeneity in cancer
In chapter 5, we developed a new computational tool CODEFACS that markedly
improves over the state of the art method, CIBERSORTx, in reconstruction of cell
type specific transcriptomes from bulk gene expression profiles of each tumor sam-
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ple. With this tool we are not only able to infer the abundance of different cell
types in each sample, but also the transcriptional states they exist in. This informa-
tion is key for deciphering which cell types are likely to interact with each other in
each patient’s tumor micro-environment and which of these interactions are likely to
modulate responses to immunotherapy. Using our tool we deconvolved the TCGA
collection to provide a cell type specific molecular atlas of ≈ 8000 tumor samples.
This resource can serve as a valuable test bed for the immuno-oncological research
community to test specific hypotheses about specific cell types and the effect of their
interactions with other cell types on clinical outcomes of patients.
Overall, our analysis of the TCGA and immune checkpoint blockade treated
datasets using CODEFACS + LIRICS reveals that while tumor neo-antigens are
a necessary ”ignition switch” to activate T cells, additional co-stimulatory signals
in the TME (for eg: 41BB-41BBL, ULBP2-NKG2D) might be required to sus-
tain effective anti-tumor immune responses upon releasing the brakes using immune
checkpoint blockade treatments. In the future, finding the right balance is going to
be key to maximizing clinical benefit of patients while minimising immune related
adverse events.
Although this work focuses on studying the tumor microenvironment, these
methods can be applied to discover important cell-cell interactions in noncancerous
tissues under a variety of normal and disease states. One interesting application
that we envision is the characterization of clinically relevant intercellular interactions
occurring at the maternal-fetal interface using corresponding bulk gene expression
data and pregnancy outcome information, whose elucidation may help treat and
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mitigate preeclampsia and other pregnancy related complications. One can also use
our tools to study bulk gene expression data from pre-malignant tissue samples and
compare them against malignant samples to elucidate cell-cell interaction dynamics
on the way malignancy. Finally, one can use our tools to deconvolve expression data
from autoimmune disorders to learn more about the underlying immune interactions.
6.0.4 The challenges and road ahead
The rate at which genomic datasets are being generated is gradually increasing.
Furthermore, with the emergence of self-supervised deep learning [106], in principle
we should be able to directly extract features associated with specific patterns of
genomic alterations in patients and overlay them on top of clinical data to identify
new biomarkers. However, there are two fundamental challenges unique to this
domain that need to be addressed. First, is the lack of standardized data pre-
processing methodologies and second, is the curse of high dimensionality, which can
lead to model overfitting. For instance, several recent publications have reported
discrepancies between different RNA-seq expression quantification methods based
on the sample preservation protocol, reference transcriptome version used and choice
of method (alignment based vs alignment free) [250, 203, 64, 227, 194]. This can
dramatically affect reproducibility of the learned predictive models. While in fields
like computer vision and natural language processing, such issues are addressed by
feeding the models with more data from other related domains or data augmentation,
such a strategy is still not scalable to genomics datasets given their incredible high
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dimensionality. To address this challenge, injecting prior mechanistic or expert
knowledge into the feature representations would be key [12].
With the emergence of methods that integrate genomic knowledge with non-
invasive imaging or liquid biopsy technologies [47, 141, 94], accessing specific features
of each patient’s tumor and the surrounding micro-environment will only get easier.
This will enable real-time monitoring of patient responses from diverse perspec-
tives and hence provide a much more pragmatic and scalable framework for guiding
precision medicine-based treatment combinations.
Although development of methods discussed above will make management of
tumor heterogeneity easier in clinics, it will still not solve the problem. Additional
effort should also be invested in basic science; understanding the mechanisms fueling
tumor heterogeneity. For example, it is important to study the mechanisms of gen-
eration and re-integration of extrachromosomal DNA elements into cancer genomes,
which is a major driver of intra-tumor genetic heterogeneity and treatment resis-
tance [114]. This could reveal novel ways to uniquely target cancer cells so that they
don’t diversify and bounce back in response to standard of care treatments.
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Bejnood, Erna Forgó, Sushama Varma, Yue Xu, Amanda Kuong, Viswam S.
Nair, Rob West, Matt Van De Rijn, Chuong D. Hoang, Maximilian Diehn,
and Sylvia K. Plevritis. A human lung tumor microenvironment interactome
identifies clinically relevant cell-type cross-talk. Genome Biology, 21(1), 2020.
[73] G. Germano, S. Lamba, G. Rospo, L. Barault, A. Magri, F. Maione, M. Russo,
G. Crisafulli, A. Bartolini, and G. Lerda. Inactivation of dna repair triggers
neoantigen generation and impairs tumour growth. Nature, 552:116–120.
[74] Umesh Ghoshdastider, Marjan Mojtabavi Naeini, Neha Rohatgi, Egor Revkov,
Angeline Wong, Sundar Solai, Tin Trung Nguyen, Joe Yeong, Jabed Iqbal,
Puay Hoon Tan, Balram Chowbay, Ramanuj DasGupta, and Anders Jacobsen
Skanderup. Data-driven inference of crosstalk in the tumor microenvironment.
bioRxiv, page 835512, jan 2019.
[75] Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping
Shang, Jeff Holst, Jason Madore, Su Yin Lim, Rebecca Velickovic, Matthew
Wongchenko, Yibing Yan, Serigne Lo, Matteo S. Carlino, Alexander Gumin-
ski, Robyn P.M. Saw, Angel Pang, Helen M. McGuire, Umaimainthan Pal-
endira, John F. Thompson, Helen Rizos, Ines Pires da Silva, Marcel Bat-
ten, Richard A. Scolyer, Georgina V. Long, and James S. Wilmott. Distinct
Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and
183
Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 35(2):238–255.e6,
2019.
[76] Jesse Gillis and Paul Pavlidis. ”Guilt by association” is the exception rather
than the rule in gene networks. PLoS Computational Biology, 8(3), 2012.
[77] Mary J. Goldman, Brian Craft, Mim Hastie, Kristupas Repečka, Fran Mc-
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